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To my patients,
To Alberto, Anna, Titty,
To Caterina,
To Alberto, Manlio, Anna,
with gratitude and love.
The Italian Society of Surgery has always had a great interest in biotechnological
developments which provide new and appropriate solutions to current surgical pro-
blems.
In the last decade, at the annual Congresses, the Society has always aimed at trea-
ting biotechnological subjects in the knowledge that it will bring improvements to
surgery in the 21st century, as was the case with technological development in the
last century.
It is with great pleasure and interest that the Italian Society of Surgery offers its
members and the whole medical community the opportunity to approach and to
expand this branch of human knowledge for new applications in health care.
fWe therefore appreciate the efforts of our member Alfonso Barbarisi, President o
the European Surgery Society (ESS) and Head of the Surgical Department of the
Medical School at the Second University of Naples. Prof. Barbarisi has carried out
research both in Italy and abroad for a long time with persistance, belief and philo-
sophic attitude. The purpose of this work is to offer surgeons an approach to biotech-
nological techniques for their better use in every day surgical activity. The other goal
is to attract biotechnologists to the complex query for help by medicine in the attempt
to solve mankind’s health needs in the best way possible.
I am convinced this book has a great scientific and practical value. It will make
surgeons more conscious both in applying biotechnologies already in use and in more
rapidly taking on future biotechnological discoveries in their culture. I am sure it will
be accepted with enthusiasm by the Italian and international surgical community.
Rome, October 2010 Enrico  De Antoni
President, Italian Society of Surgery
Foreword
vii
The 20th century has drawn to a close, the century when surgery took huge steps
forward thanks to the progress of technologies. Now we are approaching the century
of biotechnologies which will cause not only a progress in surgery, but a real cultu-
ral revolution which will completely change the approach to solving different pro-
blems in medicine. The aim of this book is to bring surgeons nearer to biotechnolo-
gies and to overcome the cultural gap dividing them.
A lot of biotechnologies have already been put forward and are used as a routi-
ne in surgical practice, to the complete unawareness of surgeons. It is important that
dsurgeons realize this and understand the real mechanism of biotechnologies an
their practical applicability, so they can be more aware of them and master their use.
A surgeon has always had a blinkered view of patient treatment because he has
always suffered from the limits of his instruments. He has always been a technolo-
gist, in the sense that since the beginning of surgery he has always needed techno-
logy, from the scalpel to advanced surgical instruments. As a consequence he has
always been a protagonist of technological progress, he has invented new surgical
instruments, he has always modified them, he has used physical means (iron dan
fire); he has always cooperated with technologists.
fIn this new century, the first of the new millennium, an increasing amount o
knowledge which is unusual to the surgeon’s traditional technological training is
encroaching upon surgery, hence the aim of this book. Now it is urgent to bring sur-
geons towards this knowledge (biotechnology) which by its nature is completely dif-
ferent from the technologies used so far, because it goes beyond the senses of sight
and touch, which have been till now the essence of the surgeon’s action.
The cellular and molecular dimension of biotechnologies is really by far the
most advanced and modern surgical action. The use of bio-materials produced bio-
technologically, the use of engineering tissues, the use of biomarkers is a routine
that is not near the traditional action of surgeons who have a sort of distrust which




A solid, workable and cultural alliance between biotechnologies and surgeons is
required, as has already happened in the past between surgeons and technologies.
A common language between surgeons and biotechnologists will bring further,
revolutionary progress to surgical sciences in the 21st century, which is purported
to be the century of biotechnologies.
Naples, October 2010 Alfonso Barbarisi
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Biotechnologies are those technologies living organisms use to keep themselves
alive and which, once discovered, human beings use to make products useful to
them. Biotechnologies are at the base of the phenomenon of life and so they are nat-
urally present in nature. They are not invented by man, they are instead discovered
while studying the phenomenon of life. So biotechnologies differ from technologies.
Technologies are the result of man’s intellect and creativity, which are used to invent
machines and devices not present in nature, but produced to satisfy man’s life needs.
The use of biotechnologies takes place using living organisms or parts of them
to make large quantities of products useful to man, and this is one of the areas of
high technology in great expansion and from which very interesting results for pro-
ductive activities have come and are expected.
Many people think biotechnologies are recent developments, but in fact they
have always existed and they have been used for thousands of years. Today, howev-
er, the huge progress in the knowledge of vital mechanisms at the cellular, sub-cel-
lular and molecular level has made it possible to recognize and discover them in their
minimal mechanisms and to take advantage of this knowledge widely and with great
flexibility.
Biotechnologies have been traditionally used in productive activities, in agricul-
ture, in zootechnics and in food production in general for a long time. In prehistoric
times man prepared drinks and fermented food: the Sumerians and the Babylonians
produced wine and beer as early as 6000 B.C. and the Egyptians produced leavened
A. Barbarisi ()
Department of Anesthesiological, Surgical and Emergency Sciences, Second University of
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bread as early as 4000 B.C. In reality these forefathers of biotechnology were com-
pletely unaware of the processes taking place during the achievement of these prod-
tucts and they did not realize that the action of living organisms was used in them. I
was only thanks to Leeuvenhoek’s microscope that researchers managed to observe
dthe microorganisms responsible for the production of beer and leavened bread. An
ronly Pasteur, between 1857 and 1876, understood the general mechanisms of bee
production and identified the mechanisms making it possible.
nAfter the discovery of a new substance produced by microorganisms – penicilli
– Fleming laid a milestone with the discovery of a new class of drugs: antibiotics.
rHowever, the ability to produce antibiotics in large quantities needed anothe
biotechnological passage: the selection of a microbial species able to produce these
substances in greater quantities than the species found in nature.
In modern times, the development of biotechnologies has become extremely
rapid. Their fast and widespread use has caused, both in their applications and in the
same fundamental research, considerable and inevitable ethical problems regarding
the protection of biodiversity and the validation of the biotechnological product.
One of the pivotal points of the new philosophy of the current knowledge on
iotechnology is to let clinicians, surgeons and all its most recent users approach anb d
face the problems and the requests of today’s medicine and surgery. The main ques-
tion is not to know the numerous biotechnological discoveries, but rather to under-
stand their original application to the problems of medicine and surgery. This
approach tries to show application solutions to the use of biotechnologies.
At present new technologies producing new vaccines or improving existing ones
are available. Monoclonal antibodies are another biotechnology achievement which
rhave found particular application in prevention, diagnoses and therapy thanks to thei
pureness, specificity and unlimited disposal. Gene therapy is another biotechnology
application. This term refers to the transfer of genetic material to prevent or treat a
disease. In the case of genetic diseases, for example, where a gene is dysfunctional
or absent, this therapy allows the transfer of the right gene to the sick organism, so
as to correct the defect. By using the same gene manipulating techniques used in
plants, we have discovered we can intervene even on the DNA of more complex
organisms, from bacteria to superior mammals, with the creation of transgenic ani-
mals. These animals are used in different areas: in the biomedical field, for example,
they produce man’s life-saving drugs in their milk, or they form the basis of experi-
mental models which are indispensable in acquiring knowledge of very severe dis-
eases. In the medical-surgical field investors are also concentrating their attention on
the realization of transgenic animals for xenon-transplantations.
Another very current biotechnological application is in the field of stem cells.
Man’s body tissues are composed of different cells, each one with its own specific
characteristics. However all of them derive from the primordial cell coming from the
ffusion of the male and female gametes during fertilization. At the very beginning o
embryo development, each cell is totipotent because it can give rise to any of the 254
different cellular types present in an adult organism.
Tissue engineering is an emergent interdisciplinary research field which applies
the methodologies and the techniques typical of material engineering (technologies)
Biotechnology in Surgery2
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and life sciences (biotechnologies) to understand and solve the problems linked to
tissue repair and substitution in living organisms (prosthetic-substitution surgery).
The major improvement in the knowledge of the structure-function relations in
biotechnology and in medicine and the recent developments obtained in chemical,
material and bioengineering have in fact made possible the design of substitute func-
tional tissues. This approach uses living cells associated with biomaterials in which,
ror on which, cells can proliferate, organize, and differentiate themselves in a manne
similar to native tissue and thus three-dimensional organized tissues similar to the
natural element to be rebuilt can be obtained. A new frontier in this field is the devel-
opment of transplantable organs.
However, I think that in addition to the improvement of biotechnological knowl-
fedge, an appropriate philosophy of this knowledge is the strong trend in the use o
biotechnology, rather than simply using technology for the solution of health prob-
lems.
Man has always tried to produce technologies to subdue dnature and to defen
himself from its adverse manifestations. This has given life to a competition which
apart from being a failure has created a vulnus in the natural organization of things
both in general and in the human organism.
The use of phenomena and of natural vital mechanisms to correct nature’s
deviances, that is to say diseases, is the great conceptual revolution of the biotechno-
logical way to health. We could say that this way is an ecological approach to disease.
Various examples can be reported in surgery. Hemostasis can be obtained through
relectro-coagulation or other physical, very advanced and efficient methods, o
through high local concentrations of coagulation factors, concentrations not present
in nature, which highly accelerate the natural coagulation phenomena and produce
immediate hemostasis. Through tissue engineering we can have completely or large-
ly natural prosthetic substitutions, versus inert or not perfectly integrated prosthesis.
This is the philosophy of the biotechnological approach in medicine and surgery:
to consider its great value in leading and letting us be led by nature itself, by vital
phenomena n or er to correct ts own ances, whi  n medi ne are diseases ani d i devi ch i ci d
their negative consequences.
In the past century we have spoken about a pathophysiologic approach to surgery,
where we have tried to use surgery to correct disease without producing major resec-
tion and destruction of soma. This philosophic statement was the longing of the sur-
geon who was nearer nature and less proud of the deep and physical upset he pro-
duced, and entitled to do so only by the higher interest in saving life.
To know the phenomenon of life in its deepest mechanisms and to find in it the
help needed to change deviated nature into the natural and harmonic nature of well-
ness is the fundamental point of the union between surgeon and biotechnologist. The
way we have traced cannot yet be taken in its widest development and moreover it is
more backward than the technologic way, especially in surgery.
Surgery has become an exercise requiring very high technologic expertise. The
situation of the surgeon today is similar to that of a fighter pilot who has gone from
being a bold commander of a jolt vehicle to becoming an aeronautical engineer sur-
rounded by a huge array of equipment in the air cockpit who to fly his craft has to
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control the different monitors and not simply look through the windows.
dThe surgeon, who has always been a technologist because he has always use
instruments, even simple ones such as the scalpel, and physical actions such as the
fire, has now become the user of numerous technologies present in the operating
room and for whom even viewing the surgical field with his own eyes can be limit-
ing, compared with the view offered by systems of navigation and magnification.
Now the biotechnology revolution has entered the operating room and the sur-
geon has to know, recognize and master it because he is at the summit of his mission:
to cure the patient lying on the operating table. Or better still he has to be the fusion
point to accomplish his mission. Once again he has to evolve, transform and surpass
himself.
fThe first step in doing so is to believe in this philosophy, to learn the language o
biotechnology and to speak with biotechnology researchers. Only after a confronta-
tion and after understanding each other will they be able to use, rapidly and exhaus-
tively the biotechnological discoveries which may risk going unused and losing the
objective of the research: human welfare.
This is why the surgeon needs to know biotechnologies, those he already uses in
his hospital department every day and those from which he can receive a great help
in the future. Only in this way the benefits of biotechnologies will reach the patient
early and in the best way. To do this can be expensive or more expensive than a tra-
ditional technological approach, but the surgeon must be convinced that biotechnolo-
rgies and the integration between biotechnology and technology are the way ahead fo




Genomics is the branch of molecular biology which deals with the study of the
dgenome. In particular, it deals with the structure, sequence, content, function an
evolution of the genome.
The term genome refers to all the genetic material (DNA or RNA) of an organ-
dism needed for survival and replication. Genomics was born in the 1980s when Fre
Sanger sequenced the entire genome of a virus and a mitochondrion. In 1986 a pub-
lic sequencing project began under the name of Human Genome Project with the aim
of sequencing the entire human genome, but it was beaten by Celera Genomics (pri-
vate company) which presented its results a year earlier (2000) than the public proj-
ect.
The goals of genomics therefore includes the establishment of comprehensive
genetic and physical maps of the DNA of living organisms with its complete
sequencing.
A very important branch of genomics is transcriptomics, which deals with the
expression of genes (mRNA) of a whole organism or a particular organ, tissue or cell
at a particular point in the development of the organism or under particular environ-
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mental conditions, making major use of microarrays.
A DNA microarray, also called gene chip, DNA chip, or biochip, consists of a
collection of microscopic DNA probes attached to a solid surface like glass, plastic,
for silicon chip forming an array. These are used to examine the expression profile o
a gene or to identify the presence of a gene or a short sequence in a mixture of many
genes.
The segment of DNA linked to a solid support is known as a probe and thousands
rof probes are used simultaneously in an array. This technology arose out of a simple
technique known as Southern blotting, where fragments of DNA attached to a sub-
strate are tested by gene probes with known sequences. The measurement of gene
expression using microarrays has substantial interest in the field of basic research
and in medical diagnostics, especially for genetic diseases where the genetic expres-
sion of normal cells is compared with cells affected by the disease in examination. 
Recent developments in gene cloning and sequencing have made possible the
identification of genetic causes of many diseases caused by mutations such as triplets




Proteomics is the science which studies the cellular proteome. The proteome is the
set of all proteins expressed in a cell, including all isoforms and any possible post-
translational modifications. The proteome changes over time, varies in response to
external factors and is different between different cell types of the same organism.
Proteomics can be divided into three strands of research:
- systematic proteomics: identifies and characterizes all proteins;
- differential proteomics: studies the differential expression of proteins in different
cells of the same organism and in different moments in the life of a single cell;
- functional proteomics: includes the study of interactions between proteins (inter-
actomics), the study of interactions between a protein and its substrates
(metabolomics) and the study of specific functions of proteins.
Proteomics is more complex than genomics because the genetic makeup is always
constant in all cells of the same body and while about 30,000 genes in the human
genome have been identified there are more than 100,000 proteins in human cells.
The study of proteins is performed mainly through biochemical assays such as:
Western blot, electrophoresis (2D, SDS-PAGE), ELISA assay, immunoaffinity chro-
matography, microarray etc.
There is a large number of practical applications of proteomics: pharmaceutical,
basic research, identification of new tumor markers, identification of a protein
involved in a disease, study of its conformation and function to develop a specific
drug (i.e. inhibitor) etc.
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1.1.3
Cell Therapy
Cell therapy refers to the introduction of cells, of various origin, in a tissue for the
treatment of a disease. Cells can have various origins: autologous (from the same
patient), allogeneic (donor) or xenogeneic (from different species) and can be stem
or mature cell.
Stem cell treatments are a very important line of research because these particu-
lar cells can be differentiated in all mature and functional cells. Stem cells come
from two sources: adult or embryo. In clinical practice stem cell therapy is represent-
ded by bone marrow transplantation; patients with leukemia or lymphoma are treate
with chemotherapy which destroys their aberrant hematopoietic stem cells and is
replaced with the bone marrow of a healthy donor or, more recently, with umbilical
cord blood stem cells.
In the field of liver disease, transplantation of adult liver cells is a treatment
which has been used for several years and which has been proven safe for the patient,
respecially in pediatric cases, able to improve liver function and delay the need fo
liver transplantation. Since 1992 transplants have been performed, and many adult
human hepatocytes have been implanted in patients with acute or chronic liver fail-
ure in an attempt to correct metabolic defects or support liver function until trans-
plantat on. In most cases, epatocytes are so ate  rom t e liver o  e pat ent oi h i l d f h f th i r
non-transplantable organs and injected in the portal vein to enable engraftment in the
liver. In other studies, hepatocytes have been infused in the splenic artery, using the
spleen as a subsidiary organ to perform liver functions.
For the reconstruction of the epidermis, many substitutes have been developed to
permanently cover an injury, including epidermal sheets derived from keratinocytes
fisolated from adult tissue. The use of autologous epidermal cells for the treatment o
skin lesions involves a clear benefit to the patient. However, the use of cell sheets has
limits, such as the preparation process, which takes a long time, the low engraftment,
dwhich prolongs the period of immobilization required for healing of the patient an
costs. The characteristics of fetal cells make them a promising alternative to adult
cells to treat skin lesions, as they significantly accelerate the process of wound heal-
ding and have a lower expression of histocompatibility antigens on their surface, an
thus a reduced immunogenicity compared with mature counterparts.
Adult stem cells can differentiate into a limited number of cellular phenotypes, in
general, the obtaining phenotypes are closely correlated with the embryonic tissue
source. For this reason they are called multipotent stem cell. Only the embryonic
stem cell can differentiate into all cell types (totipotent stem cell) but their use has
been much debated. With current technology the creation of a human embryonic stem
cell line requires the destruction of a human embryo. Stem cell debates have moti-
vated and reinvigorated the pro-life movement, whose members are concerned with
the rights and status of the embryo as an early-aged human life. They believe that
embryonic stem cell research instrumentalizes and violates the sanctity of life and is
tantamount to murder.
A portion of stem cell researchers use embryos created but not used in in vitro
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dfertility treatments to derive new stem cell lines. Most of these embryos are destine
for destruction, or stored for long periods of time.
Medical researchers widely admit that stem cell research has the potential to dra-
matically alter approaches to understanding and treating diseases, and to alleviate
suffering. In the future, most medical researchers anticipate being able to use tech-
nologies derived from stem cell research to treat a variety of diseases and impair-
ments.
1.1.4
Metabolomics: Potential Applications to Surgical Diseases
F. Tarantini, M. Giannelli, D. Boni
The term metabolomics, also sometime referred to as metabonomics, was coined in
analogy with transcriptomics and proteomics, to indicate the study of global metabo-
lite profiles of a living system. Like the proteome, the metabolome is a dynamic enti-
ty, changing from second to second. Thousands of small molecules contribute to the
construction of the metabolome, which cannot be defined in its totality by any single
method of analysis. Age, sex, body composition, genetics, as well as underlying dis-
eases influence the metabolic profile of body fluids. Exogenous factors, such as the
flarge bowel microflora, diet and drugs, are also potential confounders in the study o
metabolomics. Detection methods currently employed to identify and quantify
metabolites in a biological sample are gas chromatography mass spectrometry (GC-
MS), liquid chromatography mass spectrometry (LC-MS) and nuclear magnetic res-
onance (NMR) [1].
fThe medical challenge which lies ahead is to use the metabolic fingerprint o
urine or plasma to identify disease-related modifications and extrapolate the patho-
physiologic processes that have produced such a profile. To achieve this aim, com-
plex statistical methods of analysis and pattern-recognition programs have been
developed to handle the plethora of data that are generated when healthy and dis-
eased samples are compared.
dMetabolomics has been used successfully in toxicology, plant physiology an
iomedical research. However, still ver  few papers have reported the use ob y f
metabolomics in humans, for diagnostic purposes.
Metabolomics was applied to patients with renal transplantation [2, 3], with the
assumption that a change of metabolite levels in urine could represent an early, spe-
rcific marker of altered kidney function, allowing early detection of acute cellula
allograft rejection. The study demonstrated an excellent association between subclin-
ical allograft rejection and the appearance of specific urinary metabolite profiles.
The most intuitive field in which to envision a possible future clinical application
dof this method is oncology, given the profoundly altered metabolic profiles displaye
y cancerous cells. In this setting, the high sensitivity and specificity of MS or NMb R
in the detection of metabolites may represent a great advantage for early diagnosis,
which is still difficult to obtain for many types of cancer. However, few studies have
explored the applicability of metabolomics for tumor detection.
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In a study of 85 women with breast cancer, increased RNA metabolism, which is
a feature of cancerous mammary cells, allowed for the identification of a specific
pattern of urinary excreted nucleosides, able to predict the presence of the disease
[4]. Another example is colorectal cancer (CRC), where global metabolic profiling
of biopsied colorectal tumors and their matched normal mucosae led to the identifi-
cation of 31 potential markers of cancer. The metabolites were associated with path-
ways expected to be perturbed in CRC, such as elevated tissue hypoxia, glycolysis,
dnucleotide biosynthesis, lipid metabolism and inflammation. Interestingly, colon an
rectal tumors displayed different metabolic profiles [5]. A subset of specific urinary
fnucleosides, identified using a metabolomic approach, correlated with diagnosis o
liver cancer better than the traditional tumor marker alpha-fetoprotein, and discrimi-
nated between cancer, hepatocirrhosis and hepatitis, reducing the false-positive rate
[6]. Lastly, as the metabolic profile of tumors may differ non only between benign
and malignant lesions, but also based on pathologic features of cancerous tissues,
such as nodal involvement and vascular invasion, the use of metabolomics may
dguide, in the near future, to a more accurate estimate of disease progression an
prognosis [7].
Another very promising field for the application of metabolomics is ischemic
diseases. In fact, like tumorigenesis, ischemia profoundly alters tissue metabolism
[8]. One attempt to exploit the ischemic metabolic modification of a tissue for diag-
nostic purposes was carried out in 31 patients with suspected effort angina without
previous myocardial infarction. Serum obtained just prior to a diagnostic stress test
redicte  exerc se- ucible sc em a, w  actate, g ucose, modifi  li ids anp d i ind i h i ith l l ed p d
long-chain amino acids being the main contributors to the discrimination between
healthy and diseased samples [9].
Of surgical interest, ischemic bowel disease is an ideal candidate for early diag-
nosis by metabolomics, which may be able to detect the initial modifications of tis-
sue metabolic pathways induced by hypoxia-anoxia and the change in large bowel
microflora secondary to the ischemic insult. An observational study is currently
ongoing at the University of Florence to explore this issue.
Metabolomics is a rapidly growing technical approach that has the potential to
contribute significantly to clinical practice, complementing more conventional meth-
ods of analysis. However, although preliminary results are very encouraging, many
obstacles still exist to the widespread use of this technique as a general, diagnostic
tool, such as the lack of standardization of different methods of analysis, manage-
fment of a massive volume of data generated from the screening, implementation o
dquality control programs. The next few years will tell us if metabolomics will hol
its promise to become a complementary/alternative diagnostic device in many med-




The Role of the Surgeon in Translational Research
P. Innocenti, G. Liddo, F. Selvaggi
Translational research is a bidirectional process that creates a strong link between the
biology of diseases and clinical interventions. Its complex role is to establish evi-
dence-based medicine and ensure appropriate treatments [10]. Multidisciplinary
teams are involved in translational research programs and also surgeons are called to
make evidence-based treatment decisions and monitor clinical outcomes. The bench-
to-bedside approach is the basic concept of translational research and underlines how
the therapeutic solutions have to be explored in basic laboratory research and final-
ly tested in randomized clinical trials [11, 12]. Several clinical fields, from cancer to
transplantation, have seen surgeons playing a privileged position as research investi-
gator. The participation of surgeons in translational research has been well represent-
ed in the past, especially in hormonal therapy for cancer, the field of cardiopul-
monary and open cardiac surgery, organ transplantation and organ culture, and in the
new biological acquisitions concerning tumor angiogenesis. In these scientific areas,
dwe have to mention Charles Huggins, Gibbon and Lillehei, Joseph Murray an
Thomas Starzl, Alexis Carrel and Judah Folkman as unusual examples of the sur-
geon-scientific vocation [11]. Several scientific-based clinical innovations have been
pioneered by surgical scientists trained in the basic sciences, probably due to the
unique role of surgeons as directly working with diseased tissues or organs and the
clinical context. The translation of molecular knowledge with everyday practice has
radically redefined the role of surgery itself. Unfortunately, the increasing complex-
ity inherent in clinical surgical care and basic science methodology has modified the
devotion of surgeons to apply basic clinical skills to their research efforts and sur-
geons have become stagnated with a marginal role in the acquisition of medical
knowledge [12]. Clinical behavior based exclusively on macroscopic evidence with a
rcodification of repetitive technical practice is not a scientific method of working. Fo
this reasons, the surgeon must acquire an appropriate and modern mindset in scien-
tific knowledge because his actual role in translational research is marginal. We
believe that surgeons might be really effective in translational research if they can
demonstrate a greater propensity to learning molecular aspects and more devotion to
practical translational projects. The proper arena for the scientific surgeon is the clin-
ical setting and the basic research laboratory because he has the privilege of working
with his hands and his mind [12]. The surgeon-scientist has the duty of understand-
ing the essence of clinical observations by asking himself the key Why questions
instead of stating We see this.
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1.3 
The Role of Biotechnology in Oncologic Surgery
Radical surgery remains the treatment offering the best hope of cure in most patients
with solid cancers. However, in the past 20 years, despite technical improvements
fand despite the reduction of morbidity/mortality after surgery, the results in terms o
roverall survival have not changed significantly. This situation indicates that cance
surgery (with or without conventional treatments) has reached its intrinsic efficacy
limit, at least according to the current information. Advances in early detection, in
the identification of subjects at the high risk of developing cancer in hereditary-
familial status, and in patient selection may improve the therapeutic efficacy of can-
cer surgery.
In this context, recent advances in molecular medicine could help to improve can-
cer surgery results in two main ways [13]:
- developing diagnostic and/or prognostic systems able to identify individuals at
risk of developing new cancers (prophylactic surgery), to anticipate early diagno-
sis (both of primary tumors and of disease relapse), to identify subjects at high
risk of developing heredity based cancers, and to select patients needing adjuvant
therapies (carriers of minimal residual disease [MRD] after apparently radical
surgery) or having the best chance of responding to neoadjuvant treatments (drug
and/or radio resistance);
- developing drugs and/or molecularly targeted treatment strategies (highly tumor-
specific and therefore highly effective) to eradicate MRD after apparently radical
surgery (adjuvant therapy) or to make advanced cancers inoperable (neoadjuvant
therapy).
The main types of biotechnology advancement which can take place alongside
surgery in the management of cancer patient are:
- the identification of cancer-specific markers which can be used both for the
development of new and more effective anticancer therapies and for the identifi-
fcation of cancers sensitive to medical pre- and/or post-surgery treatment and o
people at risk of developing a primary cancer (genetic risk, family-hereditary
cases) or a recurrent disease (identification of MRD);
r- the clinical implementation of new biotechnologies called “high-throughput” fo
genomics (gene microarrays) [14] and proteomics (e.g. mass spectrometry, pro-
tein microarrays) [15] studies, which allow the expression of hundreds/thousands
of genes/proteins in biological samples of interest (tumor, healthy tissue, periph-
eral blood) to be evaluated in a single experiment The molecular profile is high-
rly likely to be much more reliable than the currently used individual molecula
markers, because cancer has a multifactorial nature.
Despite the increasing number of drugs proposed for cancer chemoprevention
(celecoxib, nitroaspirin, tamoxifen, curcumin, flavonoids, etc.), prophylactic surgery
remains the most useful system to prevent some solid cancers (e.g. colon, breast,
ovary, thyroid cancer) in populations at risk. However, as the nature of surgery is
invasive and mutilating, highly effective predictive-prognostic factors are desirable
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to suggest the operation only to people at high risk, compensating the cost (in terms
of mobility/mortality and psychological consequences) of prophylactic surgery with
a certain benefit.
dUntil a decade ago familiarity was the only risk factor of developing breast an
ovarian cancer in the proband’s relatives. The identification of inactivating muta-
tions in two genes coding for DNA repairing proteins (BRCA1 and BRCA2) has
pioneered the identification of one of the molecular mechanisms facilitating the
transmission of the risk of developing breast and ovarian cancer [16] through ger-
minal tissue. In the general population the frequency of BRCA1/BRCA2 mutation
carriers is 0.1-0.2% and their risk of developing breast or ovarian cancer within 70
years is 60-85% or 15-65% respectively. Currently, most authors suggest making
genetic tests to find mutations in BRAC1/BRCA2 in women belonging to recog-
nized families affected by hereditary cancer: this allows these individuals at high
risk to be put in a screening program for the early detection of breast cancer/ovari-
an cancer (secondary prevention).
dThe histologically radical excision of a solid cancer in early stage (stages I an
II of the TNM classification) is still the best guarantee of success, as evidenced by
the positive results obtained through screening campaigns for breast, cervical can-
cer and melanoma. The diffusion of screening of a deep organ cancer (e.g. gastroin-
testinal tract, lung) is thwarted since these can only be investigated by relatively
complex and expensive investigations (e.g. colonoscopy, CT). Recent developments
in biotechnology (determination of molecular carcinogenesis phases, development
of proteomics platforms) suggest that in the near future a simple blood or stool test
will be able to identify subjects with a malignancy. For example some authors have
shown that the patient’s serum protein profile differs significantly from that of a
healthy subject [17]. This difference is almost constant in the observed cases, even
in the early stages of disease, which makes the test of both scientific and clinical
interest (high reliability).
This is a huge step forward from the so-called cancer markers currently available,
which can be used only in follow-up if they have increased before treatment, and usu-
ally reach significant levels only in advanced cases.
In addition to TNM stage, in recent decades several prognostic factors for the
stratification of cancer patients in risk classes have been described. Most of these
prognostic markers are represented by individual genes/protein involved in the
molecular mechanisms of the biological aggressiveness of cancer, such as p53, p27,
21, Ras, surv n, BCI-2, HER-2Ineu, 3-caten n [13, 18, 19]. However, none op ivi l i f
dthese parameters is characterized by a predictive power and accuracy which woul
fallow their use as binders in each case. On the other hand, the nature o
polygenic/multifactorial cancer gives reason for the difficulty of finding/applying a
single marker capable of separating patients into two ideal prognostic groups (low
versus high risk).
In this sense, the recent implementation of relatively easy to use high-throughput
biotechnologies could revolutionize the approach to prognostic factor search. There
are now several reports from researchers who were able to identify within the cate-
gories TNM subgroups with a different risk by shifting some patients from a lower to
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a higher level (thus making them fall in the group of subjects to be treated with adju-
vants) and vice versa (sparing them the unnecessary toxicity of treatment) [20, 21].
MRD is a key target for improving surgery results. Currently the task of steriliz-
ing any MRD missed by surgical resection of the primary cancer and of metastases
is assigned to adjuvant treatments. However it has been estimated that about three
quarters of patients undergoing an adjuvant treatment do not need it as they are not
MRD bearers, and that the percentage between 20 and 30% of patients who current-
ly are not considered candidates for additional treatments could benefit from them.
The fundamental limitation of the current system is the inability to clearly identify
patients with MRD.
An example of biotechnological application in surgical oncology is the nodal
staging at the molecular level. The histopathological finding of metastases in the sen-
rtinel nodes of patients with breast cancer and melanoma is currently an indication fo
radical lymphadenectomy. However, a variable percentage (10-30%) of micro metas-
tases is not identified through histopathological techniques. The ultramicroscopic
metastases (single cells or aggregates) can be detected through biotechnological
techniques such as polymerase chain reaction (PCR) and its quantitative version [22].
As regards melanoma, patients with positive PCR have a significantly worse progno-
sis than those with negative histology and PCR [23].
If these results were confirmed in other solid cancers, the use of biotechnology
dfor the identification of MRD in sentinel lymph nodes may become the standar
method for deciding whether or not to submit the patient to radical lymphadenecto-
my. Moreover, recent technological advances such as the implementation of protocols
that allow the automated execution of ultrafast PCR (30 min) may encourage the
research of molecular metastases during surgery: this would be an advantage for both
superficial and deep cancer. In fact, the research of metastases in sentinel lymph
nodes during surgery could be used as an ultrasensitive method to guide the surgeon
in deciding which type of lymph drainage to perform.
Distant metastases are another aspect in the MRD field. Circulating tumor cells
R(CTC) can be detected in the patient’s peripheral blood usually by means of PC
(standard or quantitative) directed to the amplification of tissue-specific genes (e.g.
tyrosinase [melanoma], epithelial antigens [cancer]) not expressed by nucleated cells
normally present in blood (white cells). Some authors believe that CTC identifica-
ftion is a promising method for identifying patients who, despite the indications o
troutine pre- and post-surgery negative staging investigations [24], developed distan
metastases. Preoperatively, CTC positivity could lead the choice of surgical timing,
by opting for a neoadjuvant treatment, while postoperatively the same positivity
could strengthen the indication for an adjuvant systemic chemotherapy.
Molecular medicine has a huge possibility of improving the therapeutic index. As
regards more frequently observed cancers, such as in prognostic factors, numerous
molecular cancer predictive markers have been reported in the literature, such as
thymidylate synthase, Bcl-2, Bax, EGFR, and VEGF. Unfortunately none of the pre-
dictors described so far have the requirements (accuracy, predictive power) necessary
to select patients proposed for a neoadjuvant therapy, at least when considered indi-
vidually. However, even in this case, the first encouraging reports on the use of high-
Biotechnology in Surgery12
1
rthroughput techniques for identifying gene/protein patterns correlating with drug-o
radio-sensitivity have been already reported [25, 26].
Although we are still at the dawning of pharmacogenomics/proteomics, the huge
expectation for this molecular approach to the problem of drug-radio-resistance/sen-
sitivity finds its firm foundation in the complex nature of these phenomena involv-
ding several metabolic pathways such as apoptosis, cell cycle, drug metabolism, an
oxide reductive cellular state.
As illustrated in the above data, in the near future, the surgeon-oncologist is like-
rly to obtain a great deal of increasingly large knowledge on biotechnology in orde
rto properly interpret the information on the cancer to be treated which molecula
medicine will provide. In fact, recent developments in biotechnology are opening the
way for a new approach to cancer patients through the development of more effective
drugs (the most active and/or less toxic) and the personalization of treatment. This
pressing scientific revolution involves all oncology medical specialties, including
surgery.
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Secondary Peritoneal Carcinomatosis and Biotechnology:
a New Approach to Diagnosis and Therapy
R. Gattai, P. Turano, P. Bechi
2.1.1
Introduction
Peritoneal carcinomatosis is the spreading of malignant cells into the peritoneal
cavity. The peritoneal dissemination of cancer cells is the deposition of malignant
cells onto parietal or visceral peritoneal surfaces, associated or less with the accu-
mulation of malignant ascites. The ascites is rich in growth factors, bioactive lipids,
extracellular matrix (ECM) components, inflammatory mediators, and proteolytic
enzymes, creating a neoplastic microenvironment that fosters further metastatic
spread. Primary peritoneal carcinomatosis is rare, whereas a secondary peritoneal
carcinomatosis of ovarian (60% of ovarian cancer), gastric (40%) and colorectal
cancer (15%) is frequently observed.
2.1.2
Pathophysiology
Pathophysiology and molecular mechanisms underlying the formation of peritoneal
carcinomatosis are incompletely understood. Several theories have been proposed
P. Bechi ()
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to explain the peritoneal carcinomatosis (tumor rupture [1], secretion theory, lym-
phatic theory [2, 3]) and at present molecular research is trying to identify patho-
phy gic mec an sms an  ecrease t e t me to di nos s. T e opment osiolo h i d d h i ag i h devel f
er tonea  carc nomatos s ves severa  ll ne  ste s: etac ment o  cancep i l i i invol l we -defi d p d h f r
cells from the primary tumor, peritoneal transport, mesothelial adhesion and inva-
sion of submesothelial layers.
Kokenyesi et al. have reported that the expression of the cell–cell adhesion mol-
ecule E-cadherin is inversely correlated with the invasive phenotype [4]. Since, the
invasive phenotype on type I collagen is mostly lacking of E-cadherin expression,
and E-cadherin expression in these invasive cells is regulated at the transcriptional
level, immunohistochemical studies have shown that primary ovarian carcinomas
have increased levels of E-cadherin [5, 6], whereas ascites-derived ovarian carcino-
ma cells have diminished levels of E-cadherin mRNA [7, 8].
After detaching from the primary tumor, cellular flow is directed towards the
pelvis and from the pelvis, along the right paracolic gutter, towards the subdiaphrag-
matic space according to the force and the physiologic interaction described by
Meyers [9] and to spontaneous cell mobility. In fact, growth factors and their recep-
tors are products of protooncogenes, which when expressed pathologically, activate
oth the actin microfilaments-s stem and ene expression, resultin  in increaseb y g g d
motile activity and cell proliferation [10].
Intraperitoneal dissemination needs the ability of neoplastic cells to interact
dwith a variety of matrix components, such as fibronectin and vitronectin, deposite
ron the peritoneal surface and basement membrane, and laminin, which is a majo
component of basement membrane. Many cell adhesion molecules (CAMs) play a
drole, such as ICAM-1, VCAM-1, PCAM-1, E-selectine, mesothelin, CA125 an
MUC16. In particular, mesothelial cells express a set of CAMs. These molecules,
for instance, are important in the inflammatory response; in fact, the transmigration
of leukocytes into inflamed tissues requires a chemotactic stimulus and the engage-
ment of platelet-endothelial cell adhesion molecule-1 (PECAM-1) [11].
Furthermore, the mesothelial cell intercellular adhesion molecule-1 (ICAM-1) has
recently shown to be important for the tumor cell adherence to the peritoneum,
while CD43 is expressed by a variety of carcinoma cell lines and plays a role in the
dtumor cell-peritoneal adhesion probably by interactions with its putative ligan
ICAM-1 [12]. Ovarian carcinoma cells express several adhesion molecules, includ-
ing CD44 and other integrins, but only an anti-CD44 antibody has been shown to be
capable of inhibiting mesothelial binding. The results of the study by Cannistra et
al. [13] suggest that CD44H may be an important mediator of ovarian cancer cell
implantation and that decreased CD44H expression may be associated with release
of cells into the peritoneal space during ascites formation. Cultured mesothelial
cells are very responsive to the proinflammatory cytokines, IL-1 etc. Moreover peri-
toneal neoplastic growth is stimulated by the post-operative increase of the plasmat-
ic concentration of VEGF [14].
Sawada et al. [15] have shown that c-Met (a receptor tyrosine kinase which plays




Loose tumor cells might enter the submesothelial tissue at areas of peritoneal
discontinuity or alternatively tumor cells can induce apoptosis of mesothelial cells.
Invasion of the submesothelial tissue is accompanied by adhesion of integrins to the
extracellular matrix and degradation by proteases (MMP-7, MMP-9, WT1) [16, 17].
Several studies about genetic profile of colorectal neoplastic cells have shown
different genetic expression, so a classification of patients based on metastatic site
is possible: predominantly peritoneal spreading (TIMP-2, IGF-1, and overexpres-
sion), hepatic (TIMP-1) or both solutions (CDH17 and MTDH) [18, 19].
2.1.3
Future View to Diagnosis and Therapy
Pathophysiology, molecular mechanisms and the role of micro environmental fac-
tors in the development and progression of peritoneal carcinomatosis are not well
understood. 
The lack of reliable biomarkers for widespread early detection combined with
relatively nonspecific symptoms lead to a delay in the diagnosis in many new
patients. Currently, routine cytology to detect free peritoneal cancer cells is associ-
ated with low sensitivity.
In recent years several studies have shown the interaction between endothelial
and neoplastic cells about hematologic metastasis mechanisms, in particular, a set
dof genes which mediate breast cancer metastasis to lung and is clinically correlate
with the development of lung metastasis when expressed in primary breast cancers
r[20]. Probably, in the future, this knowledge will be applied to peritoneal tumo
spread.
One study performed on 30 colorectal cancer patients seems to suggest that
resurg ca  IL-2 mmunot erapy may counteract surgery- uce  st mu at on op i l i h ind d i l i f
angiogenesis, by either opposing the decline in blood levels of the antiangiogenic
cytokine IL-12 or reducing the increase of the angiogenic factor VEGF [21]. This
may determine an increase in postoperative complications [22].
According to the study by Cannistra et al. [13], strategies which interfere with
CD44H function may result in decreased intraabdominal spread of a highly lethal
neoplasm. In addition, c-Met should be explored further as a therapeutic target in
ovarian cancer, since targeting c-Met in vivo inhibits peritoneal dissemination [15].
fWith regard to treatment, HER2/neu overexpression is observed in 10%-30% o
ovarian cancer cases and associated with poor prognosis. Moreover, this gene ampli-
fication has also been observed in bladder, breast, colon, stomach, and lung cancers.
Helguera et al have shown that treatments with AbFPs can effectively generate high
levels of protection against peritoneal tumors expressing HER2/neu, which may be
relevant in patients with primary or metastatic peritoneal carcinomatosis which may
be observed in ovarian, colon, stomach, bladder, lung, and breast cancers [23].
The intraperitoneal administration of heparin appears to be correlated with a
decrease in ICAM-1 expression and cellular adhesion [22]. The anticancer activity
of heparins depends more on the inhibition of metastasis formation than on the
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effects on primary tumor growth. These effects are probably related to both coagu-
lation and non-coagulation dependent factors [24].
In preclinical models, the use of monoclonal antibodies, anti-integrin, antiadhe-
sion molecule (L1, JAM-C) has shown a decrease in tumor growth and adhesion.
The results of several studies and some ideas that have arisen in the field of
endothelial cell and tumor interaction and hematogenous metastasis formation will
probably be applied in the near future to the study of peritoneal dissemination.
Moreover, the identification of metastasis-specific genes activated early in the pri-
mary tumor might make it possible to predict the tumor’s behavior.
Among future developments it remains to be elucidated whether some molecules
or antibodies will be used in diagnostic and therapeutic activity.
In this respect we are performing a study involving 75 enrolled patients (affect-
ed with gastric, colorectal or ovarian tumor). The primary endpoint is the analysis
of some circulating molecules targeted to an early diagnosis of peritoneal carcino-
matosis. A secondary endpoint is the evaluation of the molecular difference
between primary tumors with high metastatic capacity and those with low metasta-
tic capacity.
2.2 
Pre-endothelial Cells and Prognosis of Intestinal Adenocarcinoma 
D. Pantalone, A. Parenti, P. Cirri
2.2.1
Introduction
It is well known that the generation of new and functional vessels is one of the cru-
cial hallmarks of cancer progression [25]. A number of ongoing studies have been
published concerning the relationship between angiogenesis and colon cancer (prog-
nosis, therapeutic targets, angiogenesis and advanced and metastatic disease). Until
recently, it was generally accepted that in adults blood vessel formation is deter-
mined exclusively by completely differentiated endothelial cells (ECs). Recent stud-
ies have shown, however, that circulating bone marrow (BM) derived endothelial
progenitor cells (EPCs) contribute to neovascularization and participate in new ves-
sel formation, in a process called postnatal vasculogenesis [26]. Moreover, recent
fstudies using different animal models of cancer have suggested the importance o
BM-EPCs in tumor vascularization and growth [27, 28], and some evidence sug-
gests that circulating EPCs are increased in cancer patients. EPCs are present in the
peripheral blood, their levels are increased in response to certain signals/cytokines,
and they dwell into the neovascular bed of malignant tissues. Therefore, on the basis
of these observations, EPCs have attractive potential diagnostic and therapeutic
applications for malignant diseases and the measurement of circulating EPC (C-





Endothelial Progenitor Cells and Post-natal Vasculogenesis
Asahara et al. were able to show for the f irst time that C-EPCs exist and are recruit-
ed for tumor neovascularization [29]. It was therefore shown that new blood vessel
formation in adults can also be provided by postnatal vasculogenesis. Extensive
studies during the last 10 years have led to the identif ication and characterization
of the peripheral blood (C-EPCs) and BM-EPCs as the sources of EPCs [30, 31],
able to migrate through the tissue and to organize in tubules that eventually mature
into vessels. These cells show the ability to repair the endothelium and to partici-
pate in the angiogenesis process, so it is conceivable that in any given moment the
level of C-EPCs reflects the endothelial endogenous regenerative capacity of a
patient. Thus, unlike circulating mature endothelial cells (CECs), which derive
from mature endothelium and are considered a marker of vascular damage, EPCs
are believed to be vasculoprotective and causally related to endothelial integrity
and angiogenesis [32].
2.2.3
EPCs, Tumor Angiogenesis and Metastasis
Primary tumors, as well as metastatic neoplasms, need to undergo the angiogenic
switch in order to grow beyond the microscopic dimension. The angiogenic switch
is induced by soluble factors produced by tumor cells as well as other kinds of mes-
enchymal cells, nontumor cells (fibroblasts, macrophages) which constitute the
rtumor microenvironment. This process is a key step in the relapse from the tumo
dormancy which allows the metastasis outgrowth. Experimental tumor models have
shown a tumor-type dependent involvement of EPCs in tumor vascularization [33-
35]. However, conflicting results exist. In some recent studies it has been shown that
BM-EPCs contribute to the generation of peri-endothelial cells rather than endothe-
lial cells and to new vessel formation [35, 36]. In mice transplantation studies,
donor BM-derived EPCs integrated into newly formed blood vessels, sometimes by
ras much as 50% [35, 37], whereas other studies have reported significantly lowe
levels [38]. Recent published in vivo data suggest that small amounts of EPCs
(12%) are sufficient to promote the vascularization of metastatic lesions [25, 29].
These conflicting results are mainly due to the still not exactly standardized meth-
ods for EPC phenotypic characterization via detection of cell surface markers (see
rSection 2.4) and to the non consideration of their functional interaction with othe
cell types able to contribute to the angiogenesis process [35, 39]. The involvement
of EPCs in tumor angiogenesis has also been demonstrated in clinical studies.
Increased EPC values have been detected in the circulation of cancer patients [40].
In one clinical study, tumors from six patients who developed cancers after BM
transplantation were found to contain an average of 5% of EPCs from the donor,
most likely generated by C-EPCs [41].
The contribution of EPCs to metastasis vascularization and to metastasis support
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is largely confirmed [42-44]. Kaplan et al. [44] have indeed found that VEGFR-1
positive hematopoietic cells (HPCs) derived from bone marrow act as a guide to
drive circulating tumor cells to their metastatic sites. In these, HPCs train the soil
for the subsequent arrival of cancer cells in the so called metastatic niche. In this
context, EPCs participate in the construction of the metastatic niche arriving at this
site concomitantly with tumor cells and hence, before vascularization occurs. 
2.2.4
EPCs as a Potential Biomarker for Tumor Angiogenesis
Colon carcinoma is included in the tumors which are angiogenesis-dependent so
colon cancer patients are also treated with the bevacizumab, an anti-VEGF antibody.
Antiangiogenic treatments for cancer could be improved if reliable surrogate mark-
ers of drug biological activity were available. Many preclinical angiogenesis assays
rely on the growth-factor-induced generation and quantification of neovessels at
sites such as the cornea, skin or dorsal sac. Such surrogates are not adaptable to
patients. The measurement of changes in tumor angiogenesis as a means of predict-
ding and/or assessing the efficacy of antiangiogenic therapies has mainly been base
ron the evaluation of microvessel density in tumor biopsy samples [45]. Anothe
approach is the measurement of circulating levels of angiogenic growth factors,
such as VEGF, FGF-2, HGF, IL8 and others. In some types of cancer, these growth
factor levels could predict survival. However, no growth factor has so far been val-
idated in predicting the response to antiangiogenic therapies [46]. A promising strat-
egy is the measurement of C-EPCs [47]. However, a lack of consensus about the def-
inition of these precursor cells, using different cell surface markers, provides diffi-
culty in the interpretation of these and other data [47]. These cells are phenotypical-
ly characterized by flow cytometry due to the expression of at least 2 hematopoiet-
ic stem cell markers (CD133+or CD34+), the endothelial marker VEGF-receptor 2
(VEGFR-2) or CD31. Thus, CD34+ VEGFR-2+, CD133+ VEGFR-2+, CD34+CD133+
VEGFR-2+, CD34+CD31+, CD133+CD31+ and CD34+CD133+CD31+ are all theoret-
ically possible EPC phenotypes. In vitro studies have suggested that also
CD34+/CD45- cells have a higher capacity to acquire an endothelial phenotype,
whereas CD34+CD133+ VEGFR-2+ have recently been described to be primitive
HPCs instead of EPCs [48]. Moreover, it should be noted that C-EPCs share mem-
brane markers with CECs and HPCs and, in some case, with platelets and micropar-
ticles [32]. As further summarized in Table 2.1 there are no antigen-specific anti-
bodies which, when used alone, can discriminate between C-EPCs, CEC, platelets
and HPCs. For example, CD146 was an endothelial-specific marker, but more recent
evidence indicates that it is also expressed by some mesenchymal cells, by a sub-
population of activated lymphocytes and most importantly by EPCs [47, 49]. At
present, only CD133 is the sole antigen expressed in C-EPCs and subsequently
downregulated in mature CECs, even though in humans CD133 is also expressed by
HPCs. It seems that a panel of antibodies for different antigens should be used to
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discriminate both C-EPC and the above mentioned cell population. In an attempt to
develop a robust clinically useful FACS protocol to study C-EPCs and/or CEC, it is
conceivable to define CECs as cells expressing CD31bright CD45- CD34dim CD133-
and C-EPCs as CD31+ CD45dim CD34 bright CD133+ [50].
tThe clinical relevance C- EPCs in tumor patients is under investigation. Recen
studies reported an EPC increase in cancer patients, suggesting that these precursors
contribute to postnatal vessel formation [35, 47]. C-EPCs might correlate with inva-
sive breast cancer [51], with lung [52], head and neck cancer patients [53] and with
the levels of circulating VEGF in lymphoma patients [54]. Elevated circulating
endothelial progenitor marker CD133 mRNA levels have been detected in colon
cancer patients and predict malignancy recurrence [55], although larger prospective
studies are needed. The number of C-EPCs in chemotherapy-treated patients has
also been correlated with survival [56]. The characterization of C-EPCs in relation
rto the clinical setting represents an attractive surrogate marker for monitoring tumo
responses to conventional and to antiangiogenic therapy [57]. It has been demon-
strated, indeed, that endostatin reduced C-EPC number along with tumor regression
[58]. Moreover, clinical studies have been undertaken in patients treated with
antiangiogenic drugs. Particularly encouraging in this regard is a trial (now Phase
II) with the anti-VEGF antibody bevacizumab which has demonstrated its ability to
reduce the tumor vascular density and the number of EPCs in rectal carcinoma
at ents [59]. This s t e reason w y t ere s an urgent nee   li ca  tr s anp i i h h h i d of c ni l ial d
standardized methods to characterize C-EPCs in cancer patients, in order to not only
assess antiangiogenic therapy, but also to help define the optimal dose range and the
establishment of the appropriate tumor response criteria.
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Table 2.1 Phenotypic differences of endothelial progenitor cells, circulating endothelial cells and
hematopoietic progenitor cells
Marker C-EPCs CECs HPCs platelets EC micro-particles
CD34 ++ +/- ++ +/- +/-
CD133 ++ - ++ - -
CD117 + - ++ - -
CD31 + ++ + ++ ++
CD45 +/- - + ++ -
CD144 ++ ++ +/- - ++
CD146 ++ ++ +/- - ++
VEGF-R2 ++ + +/- - -/+
VWf + ++ - + ++
CECs, circulating endothelial cells; EPCs, endothelial progenitor cells; HPCs, hematopoietic
progenitor cells
2.2.5
Molecular Markers of Tumor Angiogenesis and Antiangiogenic Drug Activity
Molecular markers can certainly improve our understanding of prognosis and the
treatment of cancer. This is true also for colorectal cancer (CRC). CRC is a hetero-
geneous disease resulting from the co-occurrence of oncogenic mutations in a mul-
tistep process. Studying molecular classification and molecular correlates can pro-
hvide clues to the pathogenesis and provide surrogate markers in clinical or researc
rstudies [60]. Many attempts are currently being made to obtain a precise molecula
fingerprinting of both EC and EPCs, by searching for proteins such as tumor angio-
genesis biomarkers. In addition, the possible definition of these new biomarkers
will be helpful in clinical situations such as relapse after surgery or chemotherapy.
rHence, EPC biomarkers will be useful to monitor either chemotherapeutic and/o
antiangiogenic drug activity. In addition to the enumeration of C-EPC through
fFACS analysis (flow cytometry) of their surface markers, an overexpression o
mRNA levels in EPC derived from tumor specimens compared to EPCs of normal
tissues has been found [61]. The measurement of cancer-related EC and EPC popu-
lations looks promising, but standardized protocols are needed in view of this pos-
sible clinical use.
2.2.6
EPC as Cellular Vehicles for Anticancer Therapy
It has also been suggested that EPCs could be used as a vehicle for anticancer ther-
apy. This might be achieved by ex vivo manipulation of EPCs in order to deliver sui-
cide genes, toxins, or antiangiogenic drugs. This novel approach has been applied in
mice with promising results [62].
2.2.7
Conclusions and Future Perspectives
Our Institution is carrying out a study on EPCs and colon cancer by means of the
collection of blood samples from patients with CRC and investigating each patient’s
matched normal colon mucosa and CRC tissue, resected from the surgical specimen.
dThe immunohistochemical evaluation and flow cytometry analysis on tumor an
draining lymph nodes specimens is performed by using the following mAb: CEA,
MHC class I and II molecules, CD4 and CD8, CD16 and CD56.
rBlood samples are taken prior to surgery and follow-up samples are taken afte
f24, 48, 72 h and 1 week after surgery, during chemotherapy and after 3 months o
chemotherapy.
EPCs contribute to tumor angiogenesis and seem to play a crucial role in the
guidepost of tumor cells TP to the metastatic niche. However, it is not currently
dclear what is their relative contribution to post-natal vasculogenesis when compare
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to that of in situ angiogenesis (i.e. endothelial sprouting). Moreover, it can be
assumed that new antiangiogenic drugs might also have significant side effects on
the cardiovascular system. Surrogate markers capable of predicting not only the
clinical anticancer benefit, but also the side effects will be needed. Short- and long-
term studies of CEC and EPC kinetics, phenotype, activation and viability, both in
response to antiangiogenic drugs will become increasingly important in helping to
answer these questions.
2.3
Microarray Gene Expression of Pancreatic Carcinoma
D. Pantalone, I. Giotti, V. Ceccherini
2.3.1
Introduction
Pancreatic cancer is still a highly lethal disease if not the most lethal disease of all
the solid malignancies [63]. It has been estimated that worldwide, approximately
213,000 people were diagnosed with a pancreatic cancer in 2005 [64]. In Italy, it is
the tenth malignancy in women in terms of new diagnoses and the eleventh in men
with about 9,000 new cases each year. It is the sixth cause of death from cancer in
women and the seventh in men. It is also the second cause of death from gastroin-
testinal cancer. The high mortality of pancreatic adenocarcinomas can be attributed
rto the fact that the overwhelming majority of patients present locally advanced o
distant metastatic disease, which therefore is inoperable. However, even among
patients presenting resectable pancreatic cancers, currently only approximately 15%
have the earliest stage cancers (T1, or T2, N0). Those cancers have a better survival
outcome, but only 2-3% of all patients presents at an early stage. At present, the
detection of pancreatic cancer at an early and therefore potentially curable stage
remains the best possibility of improving the patient survival [65].
Unfortunately, the screening tests capable of detecting pancreatic cancer at an
early stage are not available. Appropriate cancer screening should lead to the early
asymptomatic or unrecognized cancer detection by means of acceptable and inex-
pensive widely applicable tests.
A better knowledge of genetic modification may be an important step for both
fcancer diagnosis and treatment and could provide evidence for the identification o
early markers. Recent studies demonstrate that a high risk of developing pancreatic
cancer can be identified in a patient’s family history. An improvement in the identi-
fication of a high risk subject for pancreatic cancer will be provided by the identi-
fication of genetic alterations that predispose the inherited forms of pancreatic can-
cer. While it is important to target a high-risk family, this strategy does not facili-
tate the early detection of sporadic forms of pancreatic cancer.
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2.3.2
Microarray
Although the role of some known oncogenes and tumor suppressor genes in the
development of human pancreatic adenocarcinoma is nowadays fairly well estab-
lished, it is quite obvious that, considering the complexity of the genome, the
majority of the specif ic genetic changes involved in the initiation and progression
of this disease remain unknown [66]. Genetic alterations influencing the expression
and activity of tumor suppressors or oncogenes such as KRAS2, CDKN2A, TP53
and DPC4 have been directly implicated and thoroughly analyzed, for the most
part, by conventional methods [67], such as comparative genomic hybridization
(CGH) [68-70].
Genome-wide analysis of gene expression by using microarrays has recently
received a great deal of attention, particularly due to its higher resolution when
compared to that of traditional comparative genomic hybridization [71]. Microarray
technology was originally developed to study differential gene expression using
complex populations of RNA [72]. Improvements in the methods of the technique
dnow allow the analysis of copy number imbalances and gene amplification [73] an
have also been applied to the systematic analysis of expression at the protein level
[74], as many of the key principles of this technique are applicable at the RNA,
DNA or protein level.
rThe principle of a microarray experiment is that mRNA from a given cell line o
tissue is used to produce a labeled sample, termed the target, which is hybridized in
parallel to a large number of DNA sequences, immobilized on a solid surface in an
dordered array. Tens of thousands of transcript species can be detected and quantifie
in a single experiment. Currently available microarrays in theory permit the analy-
sis of all genes in the human genome simultaneously and provide a really high res-
olution which only depends on the number of DNA fragments and their spacing
along the genome.
The most frequently used methods can be divided into two groups, depending on
the arrayed material: complementary DNA (cDNA) and oligonucleotide microar-
rays. Probes for cDNA arrays are usually produced by the polymerase chain reaction
(PCR), generated from cDNA libraries, and are printed onto glass slides as spots at
defined locations (Stanford technology). Using this system, arrays composed by
more than 30,000 cDNAs can be fitted onto the surface of a conventional micro-
scope slide. For oligonucleotide arrays, short 20-25mers are synthesized in situ,
either by photolithography [75] (Affymetrix technology [76]) or by ink-jet technol-
ogy (developed by Rosetta Inpharmatics [77]).
To prepare the target, mRNA from cells or tissue is extracted, converted to DNA
and then labeled with fluorescent dyes, hybridized to the DNA elements on the sur-
face of the array, and detected by phospho-imaging or fluorescence scanning. When
using different fluorescent dyes it is possible to label mRNAs from two different
dcell populations or tissues in different colors that can be then mixed and hybridize
dto the same array, resulting in competitive binding of the target to the arraye
sequences. However, as the efficiency of incorporation of nucleotides labeled with
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different fluorescent dyes during target-sample preparation may not be equal, recip-
rocal labeling with swapped colors is recommended [78]. After hybridization, the
slide is scanned using two different wavelengths, corresponding to the dyes used,
and the intensity of the same spot in both channels is compared. This results in a
measurement of the ratio of transcript levels for each gene represented on the array.
The data of a microarray experiment typically constitute a long list of measure-
ments of spot intensities and intensity ratios, generated either by pairwise compari-
son of two samples or by comparing several samples to a common control. The chal-
lenge is then to sieve through this huge amount of data to find significant results.
Due to the complexity of the data sets produced by microarray experiments, the
quality of the data analysis software is crucial. Many data-analysis devices have
been developed by commercial suppliers (such as GeneSpring from SiliconGenetics,
http://www.sigenetics.com/), whereas others are available from public sources [79].
2.3.3
Microarray and Pancreatic Cancer
The results produced by a few different research groups show that meaningful data
can be obtained by gene expression profiling of pancreatic adenocarcinoma using
high-density arrays. However, the published results are not so easily comparable.
Only a few genes have been shown to be differentially expressed in more than one
study. There are several reasons which could explain the low concordance of these
studies. First of all, the type, the histology, and the number of samples used (i.e.
established cell lines or pancreatic ductal adenocarcinoma cells) are different.
Secondly, different arrays and array technologies may produce different gene
expression results. Kuo et al. [80] showed a very poor correlation when two differ-
ent types of DNA microarray technology were used (cDNA versus Affymetrix
oligonucleotide microarrays) but the same cell culture samples. Finally, a gold stan-
dard for statistical analysis and data mining has not been established yet. For these
reasons the results of expression profiling studies in pancreatic ductal adenocarci-
noma are not yet completely comparable [81].
Microarray technology has been proven to be practicable in pancreatic cancer, as
many novel candidate genes have come out from these studies. However, individual
cancer stages, grading, and TNM classification have not yet been proven to corre-
late with the expression profiles. In addition, molecular differences between long-
and short-term survivors have not been detected. However, the small number of ana-
lyzed samples with different series might be responsible at this moment for these
disappointing results.
A comparison of the results of eight studies [82-89] which analyzed the genome-
wide alterations of the adenocarcinoma of the pancreas shows that a certain amount
of genes were differentially expressed in more than one study. The majority of these
genes (n=70) were found to be upregulated in pancreatic adenocarcinoma. One gene,
rS100 calcium-binding protein P, was upregulated in five of the eight studies. Fou
dgenes, including annexin A1, integrin beta 4, and laminin gamma 2, were upregulate
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in four studies. Nineteen genes were found to be overexpressed in three studies,
dincluding lipocalin 2 and urokinase plasminogen activator receptor, two genes that ha
already been shown to be implicated in the carcinogenesis of pancreatic cancer [90,
91]. In two studies most of the genes – 46 in total – were upregulated. Of the genes
that were overexpressed in pancreatic cancer, nine genes, including keratin 7 [92],
fstratifin [93], and CD55 [94] have been previously implicated in the development o
this disease. These results, which have also been identified by other profiling meth-
fods, confirm the validity of microarray-based expression profiling. Moreover, 14 o
the upregulated genes were known to be implicated in other cancers, but not in pan-
creatic cancer so far. Among these genes there are such genes as versican (overex-
pressed in malignant melanomas) [95], insulin-like growth factor-binding protein 3
(overexpressed in non-small cell lung cancer and breast cancer) [96] and carcinoem-
bryonic antigen-related cell adhesion molecule 6 (CEACAM6) (overexpressed in col-
orectal carcinomas) [97]. These genes might be valuable candidates for genes which
could play a role in pancreatic cancer as well. The remaining 13 genes have not pre-
dviously been implicated in carcinogenesis. Only 16 genes, including PDCD4 an
Annexin A8, were found to be downregulated in PDAC in two or three of the eight
cat ons. One ene, nuc eosome assem  prote n 1-like 1 NAP1L1 , spubli i g l bly i ( ) howed
divergent results: two studies described an upregulated status of this gene, whereas in
another study it was described as downregulated using microdissected material.
2.3.4
Conclusions
Since 2000 our group has been actively involved in scientific research on pancreat-
ic adenocarcinoma. A pilot study showed that some of the typical genetic alterations
fof pancreatic adenocarcinoma could also be observed when analyzing samples o
bile [98].
In the period between October 2002 and December 2009, 44 patients affected by
this disease have undergone surgery at our surgical unit. The specimens of pancreat-
ic tissue were employed to establish 4 new neoplastic cell lines (called PP78, PP109,
PP117 and PP171), which were used in our molecular biology studies as an alterna-
tive to fresh tumor samples. These cell lines were characterized using traditional
methods, such as RT-PCR analysis, kariotype analysis, Western Blot analysis, etc.
Our preliminary results showed that, as expected, a large amount of genes were
differentially expressed in neoplastic cells and that some of these genes were
implied in the same biologic and metabolic pathways, such as the signal transduc-
tion or the regulation of immune response, thus suggesting that these processes have
some role in the pathogenesis or progression of pancreatic adenocarcinoma.
Although this technique is decidedly complex and needs dedicated technology,
it is able to collect an extraordinary amount of information. The value and potential
of the method in clinical applications deserve a further effort for the classification
and categorization of specific genetic changes involved in the initiation and pro-




The Significance of Circulating Tumor Cells as a Prognostic Marker for Colon
Cancer: a New Biotechnology
A. Taddei, F. Castiglione, M.N. Ringressi
2.4.1
Introduction
Colorectal cancer (CRC) is the second most common cause of cancer related death
in Europe and the United States. Mortality rates for colon cancer has fallen during
dthe past 10-15 years, due to early detection, more effective screening programs an
adjuvant and neo-adjuvant chemotherapeutic treatments which have led to a signif-
icant increase in tumor response and median survival [99]. Approximately 40-50%
of CRC patients who have undergone a supposedly curative resection subsequently
ddevelop metastatic disease and die within 5 years [100]. Survival is closely relate
to the pathologic stage of this disease. There is a dramatic difference in survival
rates between patients with early-stage CRC and those with advanced CRC [101].
In recent years, several highly sensitive methods have been developed to detect
faltered expressions of tumor markers in the blood of patients with different types o
malignancies. Detection and quantification of circulating cancer markers in the
whole blood sample may prove to be a unique and easy diagnostic tool for determin-
ing the prognosis and therapeutic effectiveness of the cancer therapy. Differences in
the detection methodology, types and numbers of target genes or antigens, sampling
site and time, as well as in demographic or clinicopathologic data of patients includ-
fed in the studies are present in the literature and are considered potential sources o
heterogeneity.
fSince the mid-19th century, scientists have described microscopic aggregates o
tumor cells in the blood of cancer patients. Known as circulating tumor cells (CTC),
they are thought to play a role in the process of metastasis by becoming detached
from a solid tumor, entering the bloodstream, and eventually migrating to distant
organs to develop secondary tumors. CTC can be detected by two different tech-
niques: cell search system and RT-PCR. Cell search utilizes antibodies that are joined
to microscopic iron particles, called ferrofluid. These antibody/ferrofluid combina-
tions are capable of forming a very specific and tight bond with CTCs. These com-
plexes are then drawn out of the blood samples by means of powerful magnets.
Further treatment by means of staining and additional biomolecules and/or chemicals
enables their positive identification as CTCs. A potentially more sensitive molecular
approach for the detection of CTC is polymerase chain reaction after reverse tran-
scription (RT-PCR) in its standard form as quantitative PCR or real-time. This has
been applied to various cancers targeted to a variety of markers transcripts which are
sited on the cell surface such as low molecular weight cytokeratine (CK) and CEA.
The first study concerning this method was published in 1991; later on, many authors
reported molecular diagnostic techniques in the lymph nodes and in the blood and
bone marrow of patients with cancer. The application of RT-PCR in the regional
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lymph nodes and sentinel lymph nodes was described for different neoplasms,
including melanoma, colorectal, prostate, breast and lung cancers. Most of these
dstudies compared ICC sensitivity and specificity with RT-PCR and they conclude
that the RT-PCR may be a better choice, provided that the markers are sufficiently
specific, as carcinoembryonic antigen (CEA) certainly is for CRC.
CEA is a glycoprotein localized in the apical surface of mature enterocytes. The
members of the CEA gene family are clustered on chromosome 19q13.2. It consists
of 29 genes, 18 of which are expressed. Many functions of CEA have been known in
healthy patients, however its role as cell adhesion molecule is the most studied. CEA
was first described in 1965 by Gold and Freedman [102], when they identified an anti-
gen that was present in both fetal colon and colon adenocarcinoma but that appeared
to be absent from the healthy adult colon. Since the protein was only detected in can-
cer and in the embryonic tissue only, it was given the name carcinoembryonic antigen.
dThirty years after its initial detection in serum, CEA is one of the most widely use
tumor markers throughout the world and certainly the most frequently used marker in
rCRC [103, 104]. Therefore, in CRC, CEA may be the ideal marker on cell surface fo
CTC evaluation by means of RT-PCR [105, 106]. In this respect carcinoembryonic
antigen-related cellular adhesion molecule (CEACAM3), one of its isoforms, has been
hypothesized as particularly suitable for CTC detection [107, 108].
2.4.2
Personal Experience
The purpose of our study, which is at a preliminary stage, is to evaluate whether RT-
dPCR assessment of CEA is a reliable method for evaluating CTC in peripheral bloo
of CRC patients. So far, only the RT-PCR has been shown to be feasible and at the
same time sensitive enough to detect the CRC markers, which are present, although
in low quantity, in whole blood samples. Therefore, we have evaluated gene expres-
sion of CEACAM 3 as target molecule for the detection and quantification of one
of the specific markers by RT-PCR.
Samples of whole peripheral blood from 50 consecutive patients (28 males, 22
females, mean age 71) have been obtained from patients undergoing colon resection
for sigmoid cancer. Controls are represented by blood samples from 12 healthy vol-
dunteers. Samples have been taken from brachial vein before surgical operation an
at the first and fifth postoperative day. None of the CRC patients had undergone pre-
operative radio- / chemotherapy.
RNA was isolated using 6100 Nucleic Acid PrepStation (Applied Biosystems,
Foster City, CA), according to the manufacturer’s protocol, and afterwards stored at -
80°C. All RNA samples (200 ng) were reverse transcribed to cDNA using iScript
cDNA Synthesis Kit (Biorad, Hercules, CA) according to the manufacturer’s protocol.
Negative control without RNA was performed. GAPDH was used as endogenous con-
trol gene for normalization and was detected using gene-specific primers and probes
labeled with reporter day VIC (Applied Bio systems, Foster City, CA). PCR reaction
was carried out in triplicate on 96-well plate with 20 μl each well using ox Taman
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Universal PCR Master Mix. After an incubation for 2 min at 50 °C and 10 min at 95
°C, the reaction continue for 50 cycles at 95 °C for 15 s and 60 °C for 1 min. 
One hundred and sixty-two samples of whole peripheral blood from 50 consec-
utive CRC patients and 12 healthy subjects were analyzed. RNA was successfully
extracted from all the samples. CEA was expressed in 49 of the 50 CRC patients; it
was not expressed in the control subjects. Moreover, CEACAM3 evaluation shows a
higher expression of CEA in the pre-operative samples when compared to postoper-




CEA is a particularly relevant marker because it is expressed in a variety of adeno-
carcinomas such as colon, rectum, pancreas, gastric, breast, etc. The present prelim-
inary study seems to show that CEA is detectable by means of RT-PCR in patients
affected with CRC and is not detectable in control subjects. Since, for the above
mentioned reasons, CEACAM3 levels can be considered a measure of the CTC
number, it seems noteworthy that its levels decrease after surgery. On the clinical
ground, therapy could be importantly affected by CTC findings. For example, selec-
tion of patients for adjuvant chemotherapy as well as monitoring of response may be
a good indication to their assessment. However, the best method of detection, the
optimal sampling times and other methodological aspects are still controversial.
In conclusion, evidence stands for a strong prognostic impact of CTC in CRC
patients but, at the moment, the reference standard technique for CTC detection has
not yet been defined, although RT-PCR, as confirmed by our experience, appears to
be the most promising.
Fig.2.1 Relative expres-
sion of CEACAM3
gene in samples from
patients undergoing
colon resection
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2.5 
Advanced Diagnostic Applications
G. Cafiero, F. Papale, A. Barbarisi
2.5.1
Introduction
In principle, an electron microscope works like a normal optical microscope and is
dessentially composed of an electronic source (usually an incandescent filament) an
a device that gives strong acceleration to the electron. The beam of electrons accel-
erated through a capacitor (electrostatic or magnetic) has an impact on the sample,
dis collected by a probe that turns it into an electronic signal which is then processe
by a computer to form the image for visual observation.
The scanning electron microscope (SEM), provides information on appearance,
the nature and properties of surfaces and layers of usually solid samples, with an
average resolution of 2-5 nanometers.
The most common technique for obtaining images from an SEM is to coat the
sample surface with a thin metal f ilm produced by sputtering or vacuum evapora-
tion. This is the fundamental limitation of SEM, since the dehydration and metal-
lization of the sample entails the risk of creating artifacts and the inability to
observe samples in their natural condition. In recent years a method called environ-
mental scanning electron microscopy (ESEM) was developed from the SEM, but the
sample is hydrated and non-metallic.
The structure of the ESEM is very similar to the SEM, but the sample is not sub-
jected to high vacuum to allow some of the hydration to be maintained. The degree
of hydration of the sample can be controlled by varying the pressure and tempera-




The most common immunohistochemical technique involves the use of two antibod-
ies called primary and secondary. The primary antibody recognizes a specific anti-
gen and binds to it while the secondary antibody recognizes and binds the Fc frag-
ment of the primary immunoglobulin, which is conjugated to a substance which can
be viewed with an optical microscope (chromophores or fluorescent) or electron
microscope (metallic nanoparticles).
Immunogold labeling (IGL) is the correspondent of histochemical staining in
light microscopy, whereby secondary antibodies are conjugated with gold nanopar-
ticles. Gold is used because it is a very ductile and malleable metal which can have
nanoparticles with a diameter of about 1.5 nm. The technique of silver enhancement
f(SE) is designed to increase the diameter of nanospheres through the deposition o
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silver ions around the gold in the presence of a reducing agent. With this method the
particles can be enlarged up to 100 nm, making them visible even at relatively low
magnifications which provide an overview of the cell.
2.5.3
Thyroid Lesion
Thyroid cancer is not very common, since it accounts for 1-2% of all cancers, with
an incidence of 4 cases per 100,000 population with a higher incidence among
women than men (4:1).
There are various types of thyroid cancer: the benign variant is called adenoma
and the most common form is follicular, which is capsulated and presents a mor-
phology similar to follicular epithelium. The adenoma differs from carcinoma
because it does not invade the capsule or the supplying vessels and generally does
not exceed 2 cm in diameter.
There are several types of malignant thyroid tumors: follicular, papillary,
medullary and anaplastic. Follicular carcinomas have cytologic features similar to
adenomas and are differentiated only by infiltration of the capsule and angioinva-
sion.
The presence of capsular infiltration may be confused with an irregularity of the
capsule which is often present in benign lesions. More conclusive is angioinvasion
with the presence of thrombus in the vessel lumen, not to be confused with cellular
elements drawn into the lumen during surgical resection.
Pre-surgery diagnosis is based on fine needle aspiration cytology (FNAC), but
in 20-30% of cases the cell alteration does not allow a clear identification between
follicular adenoma and follicular carcinoma . In these situations, as a precaution,
the thyroid is removed and the surgical f indings are subjected to histologic exami-
nation.
fOnly 25% of these cases prove to be malignant, while the remaining 75% o
at ents ave un ergone an unnecessary t yroidectomy, t us w  an assoc atep i h d h h ith i d
waste of resources and money, in addition to the fact that the patient will need to
take synthetic thyroid hormones for the rest of their life.
For these reasons we have to devise a technique of molecular diagnostics which
took into consideration many proteins for use as a tumor marker for thyroid cancer.
The most promising of these proved to be galectin-3.
2.5.4
Galectin-3 and Tumors
Galectin-3 belongs to the family of lectins, recognizes and binds various beta-galac-
tosides and is distributed in the membrane, cytosol and nucleus compartments of the
cell [107]. It has been shown to play roles in many biological events, such as
embryogenesis, adhesion and proliferation of cells, apoptosis, mRNA splicing, bac-
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terial colonization and modulation of the immune response [108, 109].
Galectin-3 is expressed in various type of tumor and the intensity of expression
depends on tumor progression, invasiveness and metastasis. In most cancers
ngalectin-3 is overexpressed, for example in the cells of pancreatic cancer and i
metastases to lymph nodes mRNA levels and protein are much higher than in nor-
mal cells [110].
Galectin-3 is not expressed in normal thyroid cells and adenomas (benign
lesions), but it is present in malignant thyroid lesions [111, 112].
The fundamental role of galectin-3 in thyroid carcinogenesis has been shown: by
inhibiting its expression with oligo antisense into cells of papillary carcinoma there
dwas a marked decrease in malignancy [113], while, normal thyroid cells transfecte
with galectin-3 cDNA acquired the malignant phenotype [114].
2.5.5
Our Experience
Our goal is the development of a protocol for galectin-3 ESEM immunomarking to
use for the differential diagnosis of follicular adenoma/carcinoma of the human thy-
roid.
To optimize the method and demonstrate the specificity of immunomarking we
used a commercial cell line: 3T3 cells (Swiss Albino mouse fibroblasts) in which
the expression of galectin-3 was demonstrated [115] and as negative control D16
cells (murine mesoangioblasts).
The method of immunomarking in ESEM was flanked by control techniques:
bioc em ca  assa  Western ot  an  mmunofluorescence con oca  aseh i l y ( bl ) d i f l l r
microscopy.
The two cell lines were subjected to Western blot which demonstrated the pres-
hence of galectin-3 in 3T3 and its absence in D16, after which cells were labeled wit
fluorescent antibodies and analyzed under confocal microscope. The result shows
the presence of galectin-3 in both the cytoplasm and cell surface of 3T3 and absence
in D16.
The marking protocol was optimized on these two cell lines (antibody concen-
dtration, marking time, observation condition, signal level etc.) and it demonstrate
the validity of the method [116].
Once a good marking signal with a low background had been obtained, we
passed to cell lines closer to the target, taking into account two commercial cell
lines of human thyroid: RO-82 (thyrocytes from follicular carcinoma) and FTC-133
(thyrocytes from lymph node metastases). Biochemical assay was also done on these
cells, and galectin-3 was identified in these other cell lines. In particular the signal
fof FTC-133 was more intense than RO-82, thus leading us to assume a role o
galectin-3 in the progression of thyroid cancer.
These cell lines were subjected to immunogold labeling using the same protocol
as 3T3/D16 (Fig. 2.2a,b). The density of labeling was evaluated by software and an
increase in marking in FTC-133 of 25% compared to RO-82 was recorded.
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fThese data are supported by a field trial, in which we analyzed several FNAC o
thyroid lesions processed in ThinPrep.
ThinPrep Processor is an automated slide preparation unit originally used main-
ly in Pap tests for cervical cancer testing. Now, ThinPrep is also used for non-gyne-
cologic specimens such as the diagnosis of cancers of the lung, bladder, gastroin-
dtestinal tract and in the preparation of fine needle aspiration of the thyroid an
breast. The ThinPrep Processor utilizes a computerized process and patented mem-
brane technology which controls dispersion, collection, and transfer of diagnostic
cells from the sample to the slide [117].
Under the control of the instrument’s microprocessor, a gentle dispersion step
breaks up blood, mucus, and non-diagnostic debris, and then thoroughly mixes the
sample. A series of negative pressure pulses are generated, which draw fluid though
a filter to collect a thin, even layer of diagnostic cellular material. The cellular mate-
rrial is transferred to a glass slide and ejected into a cell f ixative bath, ready fo
staining and evaluation.
One recent study defines the ThinPrep technique a valid method for the preop-
erative cytological diagnosis of thyroid nodules [118].
Were observed 50 samples of thyroid FNA processed with ThinPrep. The cellu-
lar material was preserved and displayed well defined morphological features, with
dno particular damage due to FNA, ThinPrep preparation, methanol fixation an
ESEM observation conditions.
The slides showed a great variability in the pattern of cells observed, but most
of them (10-15μm in diameter) were represented by typical thyrocytes, the intensi-
ty of marking varies from sample to sample and from initial observations seems
directly proportional to tumor progression.
Figure 2.3a shows a sample of benign adenoma in which the absence of marking is
evident, while Figure 2.3b is a micro-macro follicular adenoma (only benign form which
is regarded as a potential precursor of cancer) which presents a discrete marking.
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Fig. 2.2 Preliminary experiments to optimize and validate IGL process. a FTC-133 cell; b RO-82
cell
a b
Figures 2.4a, b are two different samples of follicular carcinoma which show the
strong marking of cells, significantly higher than Figure 2.3b.
Clearly, a cytological diagnosis cannot be advanced on the basis of this prelim-
inary result of IGL-ESEM on ThinPrep by FNA. In the future, the analysis of a sta-
rtistically significant number of FNA-ThinPrep is needed to create a database fo
pathologists.
The advantage of using the IGL-ESEM compared with classical immunocyto-
chemistry, apart the higher resolution and image definition, is the ability to make a
semi-quantitative evaluation of galectin-3 expression on the cell surface and bind to
the degree of tumor progression.





Fig. 2.3 Cell of thyroid FNA ThinPrep processed after IGL. a Benign adenoma cell (without mark-
ing; b micro-macro follicular adenoma cell (discrete marking)





Current cytological diagnosis of tumors has some inherent limitations related to
dinadequate sampling and overlapping cytological features between benign an
malignant lesions.
This limitation leads, in some cases, to an uncertain diagnosis involving the pos-
sibility of an over- or under-treatment in clinical practice.
Our work has demonstrated the possibility of using the IGL in ESEM as an
dappropriate diagnostic complementary test for discerning uncertain cases in thyroi
lesions.
The procedures of ESEM, Thin Prep, the minimum preparation for IGL and the
high capacity to collect isolated cells offer a perspective able to supply some help
to cytological evaluation. They can be seen as new, original and complementary
instruments able to support cytopathologists in their diagnostic work.
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M. Balzi, P. Faraoni, P. Bechi
The prognosis of patients with colorectal cancer has to date been mainly predicted
on the basis of clinical and histopathologic items, with the TNM stage appearing to
be the most important.
The TNM staging system and clinicopathological factors have determined clin-
ical decisions in adjuvant therapy for decades and have therefore been improving
survival in patients with early-stage tumors. However, the results remain subopti-
mal. The individual course of the disease within each category of TNM staging is
highly variable. Moreover, this system of classification based on topographical
extension does not contain information about the biology of neoplasia.
Moreover, the established progression from normal epithelium to dysplastic
lesions of increasing morphologic abnormality and finally to locally invasive and
metastatic cancer (the adenoma-carcinoma sequence) allowed the definition of
sequential genetic changes that occur during tumorigenesis. Therefore, there is
nowadays the possibility of combining specific molecular and cellular characteris-
tics with tumor stage to obtain a better definition of the disease up to the molecu-
lar level.
The definition of tumor biology appears even more important when surgery
needs to be associated with chemo- and radiotherapeutic approaches.
In colorectal carcinoma the knowledge of molecular pathogenesis could con-
tribute to defining population groups who are at high risk of recurrence after surgi-
P. Bechi ()
Department of Medical and Surgical Critical Care, University of Florence and Regional Reference
Centre of Tuscany for Locoregional Perfusion Therapies, Florence, Italy
cal resection with curative intent and to individualize follow-up strategies or adju-
vant chemotherapy. Patients with early-stage cancer at low risk of recurrence could
be spared the toxicity of systemic therapy, while others at high risk of distant recur-
rence could obtain maximal benefit if the treatment is chosen on the basis of the
biological profile of the tumor.
In other words, due to validated cellular and molecular analysis techniques, the
clinical biomarkers could be identified and would cooperate with the TNM staging,
so as to improve the therapy [1-4].
The term prognostic marker indicates factors related to overall survival or dis-
ease free survival. The potential candidates have to respond to two main requisites:
the marker must have an independent prognostic meaning and must be evaluated by
means of reproducible and standardized methods.
Many of the proposed biomarkers have been analyzed in various studies, but the
results are not yet sufficient to demonstrate their true prognostic value with statisti-
cal validity and some others have to be investigated with more accuracy and in larg-
er series.
The families of the molecular markers include the genes that influence the apop-
ftosis, the oncogenes, genes correlated to the synthesis and the repair systems o
DNA, the inhibitors of cyclin dependent kinases (CDK), and the adhesion and sur-
face molecules.
fOther factors that need to be more extensively studied are the DNA content o
neoplastic cells, angiogenesis and proliferative activity.
3.1.1
Apoptosis Related Genes
The p53 dtumor suppressor gene is localized on the short arm of chromosome 17 an
alterations in the gene locus are the genetic alterations most frequently found in
human malignant tumors. p53 protein is involved in proliferation, differentiation,
DNA repair/synthesis and programmed cell death. The loss of regulatory activity
due to wild type protein provides the proliferative cells with a selective advantage,
promotes genetic instability, decreases apoptosis and contributes to deregulated cell
growth. p53 status is evaluated with immunohistochemical methods or with the
analysis of gene mutations. It has been shown that in colorectal cancer immunopos-
ditivity ranges between 30% and 76% of cases, whereas gene mutations are reporte
in 32% of samples [5]. This discrepancy may be due to mutations that do not pro-
duce protein stabilization and consequently may result in a lack of immunohisto-
chemical detectability. Moreover, posttranscriptional stabilization processes can
dlead to immunohistochemical positivity, without a mutation; hence the determine
protein in this case is the wild-type p53. The results of the studies are not uniform
especially as far as the prognostic role of p53 alterations is concerned. Many inves-
tigations have analyzed the relationship between mutations of p53 gene and unfavor-
able outcome of colorectal carcinoma, but the conclusions are contradictory. It is
worth noting that these studies deal with small numbers of cases, short follow-up
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times, absence of multivariate analyses, different methods for determining p53
alterations and different patient populations [6-9].
Bcl-2 dbelongs to a family of proteins involved in the regulation of cell death an
cell survival. Some of these proteins promote apoptosis, whereas others inhibit cell
death. Bcl-2 proteins can form heterodimers and the ratio between homo- and het-
erodimers leads to programmed cell death or to cell survival. The prognostic mean-
ing of the expression of Bcl-2 is controversial: some studies demonstrate that high
flevels of protein correlate with a good outcome of the disease and that the lack o
the expression is associated with metastases and recurrences, but opposite results
have also been reported [7]. The assessment of both p53 and Bcl-2 status seems to
define a pattern with negative Bcl-2 and positive p53 which seems to be linked to
decreased disease free and overall survival [7, 10].
3.1.2
Oncogenes
The family of ras genes consists of three homologous members (K-, H- and N-ras)
which encode for similar 21-kDa proteins. The membrane-bound ras proteins were
thought to play a central role in the transduction of proliferative or mitogenic sig-
nals. Ras mutations occur early in the course of the adenoma-carcinoma sequence
and activating mutations (in codons 12 and 13) of the K-ras gene are found in 20-
43% of colorectal carcinomas. The largest studies (more than 200 patients), dealing
rwith the prognostic value of K-Ras mutations in colorectal cancer, suggest thei
prognostic role. In the RASCAL multicenter study the effect of mutations in codon
12 was found to be an independent variable predictive of poor outcome [11, 12].
The DCC gene (deleted in colorectal cancer f) is localized on the long arm o
chromosome 18 and encodes for a transmembrane cell-surface molecule, showing
homology to adhesion molecules. The DCC protein has been suggested to partici-
pate in the regulation of cell proliferation and differentiation. In carcinomas, the
expression of DCC is frequently decreased. Moreover, chromosomal loss of the
DCC gene locus 18q21 (loss of heterozygosity, LOH) has often been reported, thus
suggesting a role of DCC gene as a putative tumor suppressor gene.
The studies on colorectal cancer found 18q LOH in 40-50% of cases and in some
clinical research, the allelic loss is reported to be predictive of adverse prognosis,
although the results are often controversial [3, 5].
3.1.3
Inhibitors of Cyclin Dependent Kinases (Cdk)
The transition from G1 to S phase of the cell cycle is controlled by complexes con-
stituted by cyclin D and E and CdK4 or CdK6. The activity of these complexes is
Kinhibited by WAF1/CIP1 (p21, p27, p57) and INK (p15, p16, p18, p19) CD
finhibitors that prevent the progression in the phase of DNA synthesis. The loss o
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control of cell-cycle checkpoints is a common event in colorectal tumors and may
be an important therapeutic target, although the studies on these important regula-




The protein β-catenin is involved in the regulation of proliferation and differentia-
tion processes in normal tissues through its role in cell–cell adhesion and gene tran-
scription. In fact, β-catenin, controls cell adhesion at the plasma membrane level
and on the other hand is a component of the Wnt signaling pathway and therefore
capable of activating the transcription of genes related to proliferation and differen-
tiation. In the adenoma-carcinoma sequence of colorectal carcinogenesis mutations
of APC (Adenomatous Polyposis Coli) gene are reported as an early event in up to
85% of sporadic cancers [14]. APC also is a member of the pathway Wnt-β-catenin
since the APC protein promotes the degradation of β-catenin in the cytoplasm.
Moreover, in approximately 10% of colorectal cancers mutations of the β-catenin
gene itself have been reported [15]. Both these alterations can influence the degra-
dation pathway of the protein and promote its stabilization and nuclear accumula-
tion. Nuclear overexpression of β-catenin was reported in advanced colorectal can-
cers, even if its prognostic significance has not yet been demonstrated [16-18].
3.1.5
Flow Cytometry DNA Content
fFlow cytometry analysis allows cell populations containing a normal amount o
fDNA (diploid) to be distinguished from those containing an anomalous quantity o
DNA (not diploid). Different patterns of DNA content are found in tumors: only one
clone (diploid or not diploid) or multiple clones with different ploidy. Many studies
have analyzed ploidy in colorectal cancer with controversial results regarding its
prognostic implications. Not diploid DNA content was found to be associated with
poor outcome, but often its contribution to defining prognosis seems not independ-
ent from other pathologic factors. Moreover, some studies report no prognostic sig-
nificance in this biologic marker alone [19]. Flow cytometry determination of DNA
content also allows the percentage of cells in the different phases of the cell cycle
to be calculated and the S-phase fraction (SPF) of the tumor to then be estimated,
which represents a measure of proliferative capability of the neoplastic cells. As a
matter of fact, the association of ploidy and proliferation evaluation was able to






All the above reported data provide an idea of the complexity of the biological char-
acterization of colorectal cancer, but above all they confirm the absolute necessity
to investigate the prognostic implications of the different biomarkers in large series
with adequate statistical methods in order to obtain valuable results. This is the first
step towards makig the integration of TNM staging and biological aspects a useful
tool in cancer treatment.
3.2
Molecular Biology as the Identity Card of Human Tumors
F. Selvaggi, P. Raimondi, P. Innocenti
Genetic and epigenetic alterations in oncogenes, tumor-suppressor genes, cell adhe-
sion molecules and DNA repair genes result in human carcinogenesis. Novel
rgenomic and proteomic technologies have shown promise in providing a molecula
taxonomy of tumors. Distinct molecular events have been demonstrated in different
human disease such as colorectal, gastric, hepatocellular and pancreatic cancers.
The development of colorectal cancer (CRC) from adenoma to carcinoma was first
described by Morson et al. [21]. The progression model of CRC follows a sequence
of genetic events well characterized by Fearon and Vogelstein, in which the morpho-
logical f indings correlates with specific and sequential molecular alterations [22].
The earliest genetic change associated with adenomatous polyps is the mutation
and/or loss of the tumor suppressor adenomatous polyposis coli (APC) gene.
Mutations in the APC gene initiate the adenomatous process, resulting in the clonal
growth of a single cell. K-ras mutations have been reported in ~50% of CRC as the
genetic event that correlates histologically with adenoma lesions [22]. Additionally,
in high-grade dysplastic polyps inactivation of the p53 tumor suppressor gene has
been reported and the loss of this gene accelerates the transition from adenoma to
carcinoma [23]. CRC results from the cumulative effects of sequential genetic alter-
ations in proto-oncogenes, tumor suppressor genes and DNA repair genes.
Recently, three distinct genetic pathways have been proposed in the development
of CRC. First, the mechanism of the adenoma to carcinoma sequence described by
Vogelstein which considers the chromosomal instability (CIN) or loss of heterozy-
gosity (LOH) pathway [22]. This pathway accounts for roughly 80% of all sporadic
rCRC and involves oncogenes such as K-ras, C-erb2, C-myc or tumor suppresso
genes such as APC, delete in colon cancer (DDC), and p53. The second distinct
genetic pathway is termed microsatellite instability (MSI) and accounts for about
20% of all sporadic CRC [24]. Mutations in a mismatch repair gene result in the
failure to correct replication errors that occur during DNA synthesis. The predispo-
sition to Lynch syndrome, a hereditary nonpolyposis CRC, is caused by a mutation
rin one of several DNA mismatch repair genes, most commonly in MLH1, MSH2 o
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MSH6 [25]. The CpG island methylation phenotype (CIMP) is the third and most
recently identified pathway involved in CRC. It involves hypermethylation of gene
promoter regions, which results in silencing of these genes. CRC are characteristi-
cally sporadic (non familial) and have a distinct clinical profile that includes prox-
imal tumor location, female sex, older age, high tumor grade, wild-type TP53, high-
er BRAF and K-ras mutations, and frequent MSI [26].
Currently, 5-fluorouracil (5-FU) is the chemotherapeutic agent of first choice
for treatment of CRC in combination with leucovorin and with irinotecan or oxali-
platin for metastatic disease. The active metabolite of 5-FU, inhibits thymidylate
synthase (TS), the enzyme essential for the DNA synthesis pathway. TS expression
is a predictive marker of advanced CRC in patients receiving fluoropyrimidine-
based chemotherapy [27]. In 2008, Jover et al. evaluated the response of mismatch
repair MMR defective colorectal cancer to adjuvant 5-FU chemotherapy in patients
prospectively followed during 5 years. They demonstrated that CRC patients in
stage II or III exhibiting competent mismatch repair tumors obtained an important
benefit from 5-FU based chemotherapy, improving the overall survival and disease-
free survival to almost 20%. In contrast, patients affected by CRC with a deficient
MMR status showed poor prognosis. The clinical relevance was that adjuvant 5-FU
based chemotherapy may not be useful in patients with MMR-defective colorectal
rcancer with stage II or III disease [28]. K-ras mutations have emerged as a majo
predictor of resistance in patients with metastatic colorectal cancer treated with
cetuximab or panitumumab [29]. The addition of cetuximab to first-line FOLFOX
(folinic acid, fluorouracil, and oxaliplatin) or FOLFIRI (folinic acid, fluorouracil,
and irinotecan) chemotherapy did not ensure benefits in patients with tumors carry-
ing K-ras mutations, although those patients can clearly benefit from chemotherapy
ralone [30, 31]. Starting from these observations based on a complex molecula
machinery, additional studies are advocated to better define the molecular alter-
ations and design well-defined therapeutic strategies.
rSpecific genetic and epigenetic alterations have been studied in gastric cance
(GC) tumorigenesis. Inactivation of various genes including p16, MLH1, cadherin1
(CDH1), RARβ2, pS2 and RUNX3 by DNA methylation is involved in two distinct
major molecular pathways [32]. Hypermethylation of the p16 and MLH1 promoters
dis associated with the intestinal type, whereas hypermethylation of the CDH1 an
RARβ2 promoters predominantly occurs in diffuse type gastric carcinoma. An ade-
noma/carcinoma sequence is found in about 20% of gastric cancers with APC muta-
tions. Several proto-oncogenes, including C-met, K-sam and C-erb2 are activated in
GC. Over-expression of C-erb2 confers a poor prognosis and liver metastasis.
Mutations in E-cadherin gene, a cell adhesion molecule, occur in 50% of diffuse
type gastric carcinomas and are involved in the development of diffuse and scir-
rhous-type gastric cancer. More importantly, reduction of p27 expression in fre-
quently observed in advanced GC while it is well preserved in 90% of gastric ade-
nomas and 85% of early cancers. Loss of p27 expression and gain of cyclin E pro-
motes progression and metastasis of GC [32].
The most important factor implicated in gastric carcinogenesis is genetic insta-
bility including microsatellite instability (MSI) and chromosomal instability. GC
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express a spectrum of growth factors, cytokines including TGF-α, TGF-β, EGF,
PDGF, IGF, IL-1α, IL-6, IL-8. These growth factors and cytokines organize the
complex interaction between cancer cells and stromal cells and play a key role in
morphogenesis, invasion, neovascularization and metastasis [32]. Diffuse GC syn-
drome is an autosomal dominantly inherited GC disease caused by germline muta-
tions in CDH1, the gene encoding E-cadherin. This syndrome can be both accurate-
ly predicted and successfully prevented by testing CDH1 gene. This germline muta-
tion has been identified in approximately 40% to 50% of well defined hereditary
diffuse gastric cancer (HDGC) families.
In hepatocarcinogenesis, accumulation of genetic and epigenetic changes occur
during initiation, promotion, and progression of this disease. Hepatocellular carci-
noma (HCC) displays different genomic alterations, including chromosomal insta-
bility, CpG methylation, DNA rearrangements associated with HBV integration,
DNA hypomethylation, and microsatellite instability [33]. Variability in the number
and types of genetic changes has also been observed geographically, and may be
dependent upon the etiology of the tumor (viral, chemical or both).
Several pathways are being studied extensively in HCC to identify potential bio-
markers and molecular targets. The Wnt signaling pathway is involved in HCC aris-
ing from HBV/HCV infections and alcoholic liver cirrhosis [34]. Studies have
reported that p53 mutations and inactivation play a critical role in HCC and detec-
tion of mutant p53 in plasma samples serves as a potential biomarker for aflatoxin
exposure and presence of liver cancer [34]. There is evidence that mutation R249S
gene occurs as the result of mutagenesis by aflatoxin in a context of HBV chronic
infection [35]. Disruption in the Rb (retinoblastoma) pathway in HCC is similar to
that observed in various cancers. Also intracellular mitogen-activated protein kinase
(MAPK) family has been demonstrated to play a central role in hepatic carcinogen-
esis. HBV, HCV, and hepatitis E virus modulate MAPK signaling by targeting mul-
tiple steps along the signaling pathway [34]. In human HCC, the expression levels
of Spred protein (Sprouty-related protein with Ena/vasodilator-stimulated phospho-
protein homology-1 domain), an inhibitor of the ras/raf-1/ERK pathway, are dereg-
ulated [33]. This finding shows a direct correlation of MAPK-ERK pathway activa-
tion and HCC progression. H-ras, N-ras, K-ras4A, and K-ras4B are small GTP-
binding proteins that function as molecular switches to influence cell growth, dif-
ferentiation and apoptosis [36]. Single point mutations in codon 13 of H-ras, codon
12 of N-ras, and codon 61 of K-ras were originally observed in HCC caused by var-
ious chemicals such as N-nitrosomorpholine, bleomycin, 1-nitropyrene, and methyl
(acetoxymethyl) nitrosamine [34]. It has been suggested that the ras pathway is
fimportant in HCC of rodents but not human HCC based on the low mutation rate o
fras in humans. However, it was reported that RASSF1A and NORE1A, members o
the RASSF family of ras inhibitors, are inactivated in human HCC, demonstrating
the role for the ras pathway in liver cancer [36]. The molecular dynamics of HCC
can also be influenced by proteins and cellular factors of other signaling pathways.
For example, vascular endothelial growth factor (VEGF) and fibroblast growth fac-
ttor (FGF) play important roles in HCC development [33]. Recent data indicated tha
sorafenib, a multikinase inhibitor with anti-angiogenic, pro-apoptotic and raf kinase
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inhibitory activity, is the single effective therapy in prolonging survival of patients
with advanced HCC [36]. Median survival and the time of radiologic progression
were nearly 3 months longer for patients treated with Sorafenib than for those who
received placebo [37].
Inflammation is inherently associated with cancer and a number of cytokines are
involved in promoting HCC development and progression, especially during infec-
tion with hepatitis viruses [33]. Therefore, modulating the expression of cytokines
with the administration of cytokine inhibitors might be extremely useful in control-
ling HCC progression. The use of inhibitors of EGF receptor and TGF blocks the
development of HCC in rat liver [36]. Specific areas of the genome appear unstable
in HCC: gains of 1q21-23 and 8q22-24 were identified as genomic events associat-
ed with the early development of HCC in a genome-wide study of chromosomal
aberrations of 158 HBV-associated HCC [34]. Frequent promoter hypermethylation
and subsequent loss of protein expression has also been demonstrated in HCC at
tumor suppressor gene, p16, p14, p15, SOCS1, RIZ1, and E-cadherin.
Several tumor biological factors such as DNA aneuploidy, high tumor cell pro-
liferation index, high telomerase activity, and mutation of the p53 gene have been
associated with increased risk of postoperative tumor recurrence in HCC [36].
Molecular analysis of 63 selected genes can predict the response of HCC patients
dwith major portal vein tumor thrombi to combination chemotherapy with 5-FU an
interferon-alpha, suggesting that the gene expression profile predicts outcome not
only in surgical patients but also in patients with advanced HCC who received med-
ical care [34].
Angiogenesis in HCC has been found to correlate with the presence of metasta-
sis. VEGF promotes the growth, migration, and morphogenesis of vascular endothe-
lial cells and increases vascular permeability [38]. The elucidation of the mecha-
nisms of angiogenesis is of importance because anti-angiogenic agents are now
available and may be of potential benefit in patients with HCC [36]. Use of beva-
cizumab, an anti-vascular endothelial growth factor monoclonal antibody, in unre-
dsectable HCC has showed overall survival rate of 53% at 1 year, 28% at 2 years, an
23% at 3 years [38].
Molecular genetic analysis has provided evidence that pancreatic duct lesions
are the precursors of the infiltrating adenocarcinomas of the pancreas. The genetic
progression model of pancreatic ductal adenocarcinoma (PDAC) provides strong
support for a ductal origin of this malignancy. Moreover, observations from animal
models indicate that putative pancreatic stem cells and transdifferentiated endocrine
or exocrine cells might be involved. Although it seems that the ducts are a main
source of pancreatic neogenesis, each pancreatic compartment shows the capacity
for assuming a dedifferentiated duct-like phenotype with multipotent differentiative
capacity [39].
In 1994 Klimstra and Longnecker proposed a classification system for hyper-
plastic non-invasive lesions named pancreatic intraepithelial neoplasia (PanIN).
This system, based on morphological features, defined a progression model for pan-
creatic neoplasia [40]. The earliest precursor lesions, PanIN-1A and -1B, character-
ized by elongation of ductal cells with mucin production and, in the case of PanIN-
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1B, with papillary instead of flat architecture, are found in up to 40% of non malig-
nant pancreata. These lesions with minimal cytological and architectural atypia have
been shown to harbor activating point mutations in the K-ras oncogene and to over-
express the HER-2/neu gene product [39, 40]. These alterations in K-ras and HER-
2/neu are believed to be early genetic events in the development of pancreatic neo-
plasia. Inactivation of p16 tumor suppressor gene appears to occur later [39, 40]. As
PanIN lesions progress, they acquire moderate (PanIN-2) and severe nuclear abnor-
malities with abnormal mitoses and budding of cells into the lumen (PanIN-3, for-
fmerly known as carcinoma in situ). PanIN-3 lesions are present in 30%-50% o
rPDAC. Loss of p53, DPC4 and BRCA2 tumor suppressor genes appears to occu
late in the development of pancreatic neoplasia [40]. However, in contrast to K-ras,
HER-2/neu and p16, these gene abnormalities are associated with significant duct
cytologic and architectural atypia. Mutations of K-Ras, CDKN2A, TP53, BRCA2
and SMAD4/DPC4 contribute to the biological characteristics and evolution of the
disease. Among the genetic lesions that are linked to familial PDAC are germline
mutations in CDKNN2A, BRCA2, LB1 and MLH1 [39]. Loss of CDKN2A function
occurs in 80-95% of sporadic PDAC. CDKN2A loss is generally seen in moderate-
rly advanced lesions that show features of dysplasia. The TP53 tumor-suppresso
gene is mutated in more that 50% of cases. TP53 mutations arise in later-stage
PanINs that have acquired significant features of dysplasia. SMAD4 seems to be a
progression allele for PDAC, as its loss occurs only in later-stage PanINs and rep-
resents a predictor of decreased survival. PDAC overexpresses EGF-family ligands,
such as transforming growth factor-α (TGF-α) and EGF and receptors (EGFR,
ERBB2). The EGFR and ERBB2 induction occurs in low-grade PanINs [39]. These
molecular observations form the foundation for a progression model for pancreatic
cancer [39, 40]. This does not imply that all PanINs progress to infiltrating carcino-
mas. Additional studies are needed to examine such possibilities.
Molecular studies have demonstrated the involvement of multiple signal trans-
duction pathways, such as the RAS-BRAF-MEK ERK signaling cascade (the so-
called MAP kinase pathway) in thyroid cancer. BRAF mutation is associated with
a more aggressive phenotype and radioiodine-refractory behavior. In addition, gene
rearrangement involving RET or the activating of RAS family protooncogene are
essential for papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC).
Additionally, the over-expression and/or hyperfunctioning of vascular endothelial
growth factor (VEGF) and its receptors, hepatocyte growth factor (HGF) and its
receptor (MET), platelet derived growth factor (PDGF) and its corresponding
receptors have been found in these tumors. Kinase inhibitor molecules represent
the f irst-line candidates for the therapy of refractory tumors. The histone deacety-
lase (HDAC) inhibitors and retinoid derivates are encouraging tools in pharmaco-
logic strategy [41]. Adenomas can be differentiated from follicular carcinomas by
genes such as PEG10, PLCB4, FNB1, ID4, and DUSP1 [42]. Some studies have
found that the phosphatidylinositol 3-kinase (PI3K)/AKT pathway plays an impor-
tant role in thyroid tumorigenesis, particularly in the progression from low to high
grade tumor [43]. The molecular pathogenesis of anaplastic thyroid cancer (ATC)
includes mutations in BRAF, RAS, PIK3CA, TP53, PTEN, and APC genes. The
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expression of EGFR in ATC makes it an attractive target for drug development,
using monoclonal antibodies such as cetuximab and kinase inhibitors such as
gefinitib and imatinib [44].
Molecular profiling studies have designed some aspects in the biological behav-
ior of breast cancers. Five major subtypes of breast cancers have been defined: basal
like, luminal A, luminal B, HER2+/ER-, and normal breast like [45, 46]. Luminal
tumors are more differentiated, hormone receptor-positive, showing a better out-
come. HER2+ tumors have amplification of the ERBB2 oncogene and respond to
therapy targeting this receptor kinase. Basal-like tumors are poorly differentiated,
lack hormone receptors and HER2, with a worse clinical outcome. The current
accepted view of breast tumor progression assumes the hypothesis of a gradual step-
by-step transition of ductal hyperproliferation to in situ then invasive and finally
dmetastatic carcinomas. In this model, ductal carcinoma in situ (DCIS) is considere
tthe obligate precursor of invasive ductal carcinomas [46]. Well differentiated breas
tumors were more frequently hormone receptor-positive and negative for HER2,
p53, and Ki67 compared with poorly differentiated tumors. Current models explain-
ing inter- and intratumoral diversity are the cancer stem cells and the clonal evolu-
tion hypothesis [46]. The clonal evolution model supports the role of genomic insta-
ilit , resultin  in the continuous acquisition of new somatic chan es. The numbeb y g g r
of genes mutated in breast cancer is high and concerns the PI3KCA/AKT/PTEN,
rTP53 and NF-kB pathways. The PI3K pathway is, therefore, an attractive target fo
breast cancer therapy [47]. Unfortunately, the transition mechanisms of DCIS to
invasive carcinoma is still not well understood, and crucial genetic events have been
identified only in part in breast cancer patients [46].
Thanks to the tools of molecular research, our understanding of cancer progres-
sion has significantly increased during the last decades but the translating these
findings into clinical practice still remains a challenge. 
3.3 
Interventional Timing According to New Insights in Basic Research
P. Innocenti, F. Selvaggi, D. Risio
dThe surgical approach and its interventional timing have been strongly influence
by current scientific knowledge and modern multidisciplinary therapeutic options
have been defined according to new biomolecular insights. Nowadays, general con-
sensus has been expressed about the role of prophylactic surgery, particularly in
thereditary cancer syndromes and in tissue or organ regeneration. One of the mos
dimportant consideration is the timing of thyroidectomy in children with mutate
RET allele [48]. Before 1994 there was no genetic testing available for screening
RET mutations and affected family members underwent thyroidectomy after the
identification of pathologic increased levels of serum calcitonin. Today it has been
generally accepted to perform prophylactic surgery in patients identified by genetic
ranalysis [48]. Most surgeons advocate that the ideal age for prophylactic surgery fo
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patients carrying a mutation in exon 11 codon 634 is as early as age 5 [49].
Regarding the need of lymphadenectomy there is no consensus. There are also sur-
geons who routinely do bilateral cervicocentral lymphadenectomy in their prophy-
lactic operations [49]. DNA analysis used to identify risk for MEN 2B have shown
germline mutation in codon 918 of the RET protooncogene. In these patients MTC
tends to present at a very early age and appears multifocal, bilateral and more viru-
lent [48]. In addition, RET mutations were found at codons 609, 611, 618, 620, 634,
but no statistical evidence that the presence of persistent or recurrent medullary thy-
roid carcinoma was dependent on the specific genetic alterations [50].
If we consider hereditary breast cancer development, current data coming from
basic research confirm that the genetic predisposition is 5-10% [48]. Women with
BRCA1 or BRCA2 mutation have a cumulative risk of invasive cancer ranging from
55 to 85% and of invasive epithelial ovarian cancer ranging from 15 to 65%. The
risk of developing breast cancer increases near the age of 25 years. The identifica-
tion of breast cancer susceptibility genes BRCA1 or BRCA2 was performed in 1994
and 1995 respectively according to the evidence of premature truncation of the
fBRCA1 or BRCA2 protein. Modern prophylactic surgery for women at high risk o
breast cancer, according to the molecular tests, include total bilateral mastectomy
d(TBM) without axillary lymph node dissection, skin-sparing total mastectomy, an
tsubcutaneous nipple-sparing mastectomy, reconstruction with artif icial breas
dimplants or tissue reconstruction options using transverse rectus abdominis flap an
the latissimus dorsi flap. A final procedure being discussed is areolar-sparing mas-
ftectomy [48, 51]. The efficacy of prophylactic TBM in reducing the incidence o
breast cancer at three years of follow-up has been demonstrated [52]. Prophylactic
TBM reduced the risk of breast cancer by 95% in women who also had a risk-reduc-
ing salpingo-oophorectomy and by 90% in women that had intact ovaries [48].
dKurian et al. recently demonstrated that prophylactic TBM at the age of 25 instea
of 40 offers minimal incremental benefit (1% to 2%). Prophylactic surgery is a
dhighly personal decision and the protective effects of surgery must be weighe
according to possible complications and psychological problems.
fAdvances in molecular diagnostic techniques have changed the landscape o
Lynch syndrome, the hereditary syndrome that predisposes to colorectal cancer. The
common mutations concern the mismatch repair (MMR) genes, in particular MLH1,
MSH2, MSH6 and PMS2. The benefits of prophylactic hysterectomy and bilateral
salpingo-oophorectomy in preventing gynecologic cancers in women with Lynch
syndrome after the age of 35 have been demonstrated [53]. Colorectal cancer occurs
in 78% to 80% of MMR mutation-positive patients at a mean age of 46 years.
Endometrial cancer occurs in 43%, gastric cancer in 19%, urinary tract cancer in
18% and ovarian cancer in 9% of Lynch syndrome affected individuals [51].
Molecular analysis indicates that each mutated MMR gene has a distinguishable
cancer risk profile with different clinical management. Female MSH6 mutation car-
riers have a lower colorectal cancer risk and higher risk for developing endometrial
carcinoma reported to be around 71%. For these patients biennial colonscopic sur-
rveillance at an age of 30 years has been advocated and prophylactic surgery fo
gynecologic hereditary cancer may be considered from an age of 45 years or once
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childbearing has been completed [54]. Inherited colorectal cancer comprises famil-
ial adenomatous polyposis (FAP) caused by mutations in the tumor suppressor ade-
dnomatous polyposis coli (APC) gene. Three surgical options are currently propose
for FAP patients: total proctolectomy with permanent ileostomy, total colectomy
with ileorectal anastomosis, and proctolectomy with ileal pouch anal anastomosis.
The risk of incomplete excision due to uncontrolled rectal polyposis may be estimat-
ed by the specific location that causes APC mutation [51]. Mutations located at
codons 1250 and 1464 had a 6.2-fold increased risk of rectal cancer compared with
those with mutation before codon 1250 or after codon 1464. The choice of the opti-
mal surgical treatment depends on several factors. Its interventional timing is still
discussed and no general consensus has been expressed. Differences in phenotype
expression of cancer mandate different surgical approaches in FAP or Lynch syn-
drome, including the type and timing of colorectal surgery. Although the importance
of genotype-phenotype relations, the considerations in choosing surgical therapies
have to underline primarily the clinical outcome and associated quality of life [51].
Prospective trials to determine the efficacy of surveillance and surgical therapies in
FAP or Lynch syndrome families are needed.
fPatients with evidence of E-cadherin (CDH1) germline mutation in the setting o
a family history of hereditary diffuse gastric cancer (HDGC) must be considered as
candidates for prophylactic total gastrectomy (PTG) [55]. In a retrospective study,
Hebbard et al. demonstrated that patients who underwent PTG had a truncating muta-
tion of the CDH1 gene with mutation 2398delC of exon 15 and 1189A>T in exon 9
of CDH1. Interestingly, preoperative mucosal biopsies revealed the disease only in
9% of cases while evaluation of surgical specimens showed evidence of carcinoma
micro-foci in 96% of cases [56]. If the CDH1 test is positive, PTG should be consid-
ered. However, the published data supporting this evidence are still limited.
Findings in molecular research have provided new impetus for the use of stem
cells in the treatment of gastrointestinal and liver diseases. Interestingly, adminis-
tration of autologous CD133+ bone marrow stem cell to the liver significantly
increases hepatic regeneration [57]. Portal vein embolization may be easily associ-
ated with CD 133+ bone marrow stem cell administration to augment hepatic regen-
eration in cases of large hepatic malignancies. Patients who received bone marrow
stem cell portal application and portal vein embolization had mean daily hepatic
growth rates 2.5 fold higher compared with subjects that received portal vein
embolization alone [57]. The intravenous administration of stem cells induces pro-
liferation of hepatocytes in time for safe oncologic surgical resection. The implica-
tion of rapid liver growth suggests the possibility of enrolling patients with an insuf-
ficient remnant liver volume to curative surgical resection after the selective exclu-
rsion of the tumor mass for example by using portal vein embolization procedures o
other interventional strategies and to reduce the time to surgery by an average of 18
days [58]. Preliminary data coming from molecular biology are encouraging but
liver regeneration is a complex process and much additional work is needed to
define factors required in liver cellular differentiation as well the safety, efficacy
and tolerability of stem cells.
n ancreatic ductal adenocarcinoma PDAC  molecular anal sis has shown thatI p ( ) y
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around 10% of pancreatic cancer is hereditary in origin. Some studies have evaluat-
ed matrix metalloproteinase-7 (MMP-7) as a biomarker, measuring its level in plas-
ma and pancreatic juice, with the observation that combined MMP-7 and CA19-9
rassessment gave a positive predictive value of 100% [59]. Combination molecula
analysis able to detect DNA abnormalities characteristic of PDAC (K-ras, p d16 an
p53) in pancreatic juice increase the discrimination between patients with malignant
rand benign disease [60]. Prophylactic pancreatectomy based on today’s molecula
knowledge is not indicated and the screening and surveillance of high risk members
of FPC using ultrasound and endoscopic retrograde cholangiopancreatography is
currently an effective method. Patients who have evidence of PanIN III lesions (car-
cinoma in situ) might be indicated the option of pancreatectomy. There is an urgent
need to discover biomarkers and to improve early diagnosis in high-risk PDAC
patients.
Tissue engineering is the new frontier of plastic reconstructive surgery [61].
Recently attention has been focused on adipose-derived stem cells (ASCs) [62].
Breast augmentation is one of the most frequently performed cosmetic surgeries.
Nowadays most surgeons use artif icial implants or augmentation with lipoinjection,
with various complications such as capsular contracture or postoperative atrophy. To
overcome these problems a novel strategy known as cell-assisted lipotransfer (CAL)
which uses autologous ASCs and lipoinjection techniques, was developed. Recent
results demonstrated that breast circumference increased by 4 to 8 cm at 6 months
fin the observed cases [63]. Compared with breast augmentation using implants o
the same size, augmentation with CAL showed a lower height but a more natural
dcontour of the breast. Further improvements in stem cell biotechnologies may lea
these experimental procedures as future gold standard treatments in plastic recon-
structive surgery.
Molecular biology is modifying surgical approaches and the interventional tim-
ing, but further improvements in translational research have to be reached to define
individualized treatment especially in sporadic malignancies.
3.4
Cellular Biology: A Way of Predicting Cancerogenic Progression, Prognosis and
Response to Adjuvant Treatment
M. Balzi, P. Faraoni, A. Taddei
fIn adults, the epithelia are steady state systems with a continuous production o
cells that substitute the differentiated cells when they become senescent and die.
Proliferation is a strictly controlled process and in the course of the cell cycle, seri-
ous DNA alterations are recognized and driven to apoptosis at different checkpoints.
This mechanism preserves the integrity of the cell population.
Many physical, chemical and biological environmental factors induce cell alter-
ations that can modify the percentage of proliferating cells. Proliferating cells are
very sensitive to DNA damage because during DNA synthesis the molecule is no
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longer wrapped around histones and it is exposed to injury with a greater frequen-
cy than differentiated cells.
In the 1990s the hypothesis mitogenesis stimulates mutagenesis was formulated
and this led to verifying whether different agents able to influence proliferation are
involved in the steps of carcinogenesis.
Our research group has been studying human gastric epithelium in patients with
increased risk of gastric cancer. We analyzed two models: (1) subjects affected with
functional dyspepsia tested for the presence/absence of Helicobacter pylori (Hp);
h(2) partial gastrectomized patients with different surgical reconstruction. In bot
groups proliferative activity was determined on multiple biopsies collected from
different sites of the stomach.
fBiopsies were placed immediately on a rigid support to maintain orientation o
the foveolae and incubated in a culture medium containing 3H-thymidine. After one
hour the samples were washed several times in cold saline, f ixed in Carnoy’s solu-
tion and embedded in polystyrene. Sections 3 μm thick were cut oriented according
to the longitudinal axis of the pits and were submitted to autoradiography. The cells
constituting the epithelial row were counted from the neck to the mucosal surface.
rMoreover, both the number and the position of labeled cells were determined fo
each left side of the well aligned pits. Mean value of the total cell number, labeling
index, mitotic index and the localization of labeled cells were calculated in normal-
ized pits obtained after counting 50 foveolae of each patient. In Hp negative subjects
fthe results were different in the corpus respect to the antrum, where the number o
epithelial cells was more than double. The percentage of labeled cells in the pits was
higher in the central part and lower in the upper part near the gastric lumen. Hp pos-
itive subjects showed a statistically significant increase in the total cell number both
in the antrum and in the corpus and a significant increase of thymidine labeling
index (TLI) only in the corpus when compared to Hp negative patients. The distri-
bution of labeled cells along the pits in the antral mucosa appeared slightly differ-
ent in the Hp positive and Hp negative subjects; more specifically, Hp positive
patients showed an upward shift of the maximal frequency of labeled cells in the pits
twhen compared with Hp negative subjects. A shift of the proliferative compartmen
towards the luminal surface was observed in Hp positive patients when severe gas-
tritis was present. These results show that the Hp infection is associated with mod-
ifications of the proliferative compartment of the gastric mucosa and this is espe-
fcially evident in patients with gastritis. The increase and shift towards the surface o
proliferating cells expose cycling cells to mutagenic and carcinogenic molecules
present in the gastric lumen. The action of these factors and the chronic inflamma-
tory condition could explain the increased risk of cancer in patients affected with
Hp infection [64].
The second model to explain the increase of carcinogenesis in the stomach is
trepresented by subjects submitted to partial gastrectomy for benign ulcer disease a
least 12 years earlier. In three homogeneous groups of patients, with Billroth II
(BII), Billroth I (BI) or total biliary diversion reconstruction (TBD), the relation-
ships between bile acid reflux, gastric histology and cell proliferation were studied.
The concentration of bile acids in the stomach remnant was higher in BII patients
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than in BI and bile reflux was absent or very low after TBD. Experimental studies
have previously demonstrated that bile acids are able to stimulate cell proliferation
in the ileal and colonic mucosa and for this reason they are thought to play a role in
the initiation and promotion steps of intestinal carcinogenesis. For each patient mul-
tiple biopsies were collected in three different areas of the gastric stump: immedi-
ately perianastomotic, 2 cm from the anastomosis and at the level of the proximal
body. As described above, TLI and the distribution of labeled cells were determined
for each biopsy. Moreover, the concentration of bile acids in the gastric aspirates
was assayed. The highest degree of foveolar hyperplasia was observed in perianas-
tomotic mucosa of BII patients with a progressive decrease with increasing distance
from the anastomosis. Hyperplastic changes were less evident in BI and virtually
absent in TBD patients. Total pit cell number and TLI were significantly higher in
perianastomotic biopsies of BII subjects. These results showed that patients with the
highest concentration of bile salts in the stomach had a more severe degree of fove-
olar hyperplasia and the highest values of proliferation parameters, whereas the low-
est levels of all the parameters were found in TBD patients. An evident shift towards
the luminal surface of the proliferative compartment was observed in BII perianas-
dtomotic biopsies in which a significant increase of labeled cell frequency was foun
along the whole length of the pit and particularly in its upper half. These findings
rdemonstrate a close relationship between postgastrectomy bile reflux, foveola
hyperplasia and cell kinetic parameters. Histologic and cell kinetic findings are
probably the expression of gastric adaptation to chronic bile reflux exposure. The
type and entity of cell kinetic modifications and its relationships to foveolar hyper-
plasia and bile salt reflux may be an important biological tool in postgastrectomy
follow up in order to identify high risk patients. Moreover, they could help to clar-
ify the pattern of gastric carcinogenesis [65].
Our other study which we started a few years ago aims to assess the possible
prognostic role of some biological/molecular markers in patients with colorectal
cancer. The cases were recruited on the basis of strictly controlled criteria (only pri-
mary carcinomas, no systemic or local treatment before surgery and no distant
metastases at surgery).
Fragments of tumors and normal mucosa were used for the evaluation of the
dimmunohistochemical expression of proteins influencing apoptosis, such as p53 an
Bcl-2, adhesion molecules like β-catenin and Ki-67 antigen as proliferation index.
Moreover, for each case the flow cytometry DNA content was assayed and ploidy
and cell cycle distribution of the neoplastic cells were determined. Some prelimi-
nary study conclusions concerning the biological characteristics of 400 colorectal
adenocarcinomas can preview the proportion of non diploid tumors is 60% and the
frequency of non diploid tumors is higher in the distal colon and lower in the prox-
imal colon. There is a progressive increase of S-phase fraction (SPF) levels compar-
ing diploid and the different classes of non diploid tumors. P53-positive cases are
82.5% and Bcl-2 positive tumors are 49.6%. The expression of the antiapoptotic
protein is more frequent p( <0.05) in stage I than in stage II and stage III tumors. As
regards β-catenin immunoreactions, the three cell compartments where the protein
can be found were separately evaluated: location in the membrane was registered in
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89.7% of the cases, in the cytosol in 80.6% and the nucleus in 54.0% of carcinomas.
One interesting finding is the co-expression of β-catenin in the nucleus and in the
cytoplasm and the corresponding lack of expression at the membrane level. The
presence of the protein in the nucleus of neoplastic cells is more prevalent in the dis-
tal colon when compared with the proximal colon.
The aims of the study are to verify the prognostic independent predictive value
of biological markers and to explore the possibility of a biologic staging system
which could be complementary to conventional staging so as to better define the
rseverity of the disease. These studies seem to be at a more advanced stage for othe
cancers [66, 67].
At present we have assayed the ability to predict prognosis for single biological
parameters in univariate analysis dividing the cases on the basis of TNM stage. In
particular, the group of patients with stage II carcinoma was chosen and the overall
survival (OS) probability was analyzed for the different expression of biological
rmarkers. As an example, the pattern of OS in the groups with and without nuclea
β-catenin expression is given in Figure 3.1. Patients with nuclear β-catenin positive
tumors have lower levels of OS (73.2%) when compared with the group in which
nuclear β-catenin is not expressed (87.1%). This datum seems perfectly understand-
able if we consider that the translocation of β-catenin into the nucleus corresponds
to a change in its function, from adhesion molecule to transcriptional activator,
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Nanotechnology is an emerging science that studies how to control matter on an
atomic and molecular scale. Generally nanotechnology deals with structures of the
size of 100 nanometers or smaller in at least one dimension, and involves develop-
ing materials or devices within that size. Nanotechnology ranges from extensions
of conventional device physics to completely new approaches based upon molecu-
lar self-assembly, from developing new materials with dimensions on the nanoscale
to investigating whether we can directly control matter on the atomic scale.
Nanotechnology has the potential to create many new materials and devices
with a wide range of applications in fields such as in medicine, electronics and
energy production. However, nanotechnology raises many of the same issues as
with any introduction of new technology, including concerns about the toxicity and
the environmental impact of nanomaterials.
Nanofabrication is a set of techniques which allow the construction of objects,
devices and small materials with nanometer dimensions, where small means a bet-
ter outcome, more economic, faster operations and higher performances. In a
broader meaning, nanofabrication is one of the different disciplines of precision
engineering which takes advantage of such techniques for the realization of small
3D structures which can find applications in different sectors of the electronics
industry, and now in the biomedical f ield too. The classical technique used to pro-
duce geometrically patterned devices with nanometric dimensions is lithography
which is based on the transfer of a determined pattern copied onto solid materials.
F. Rosso ()
Department of Anesthesiology, Surgical and Emergency Sciences, Second University of Naples,
Naples, Italy
Over the years, lithography has developed into photolithography, X-ray lithography,
and ionic or electronic beam lithography [1].
Usually these expensive techniques are used for the fabrication of electronic
microcircuits or in semiconductor technology, although on rigid materials such as
metals, quartz and glass. Recently, alternative not-photolithographic techniques
have been developed, such as microcontact printing, replica molding etc., which are
called soft lithography [2]. The characteristic of soft lithography is to replicate,
rather than fabricate, the pattern. These methods are cheaper than the photolitho-
graphic techniques, the procedure is quite simple and it requires no special equip-
ment. The main advantage is the application of such fabrication techniques to dif-
ferent kinds of materials which may be less rigid, such as polymer materials [3].
fThe possibility of adapting nanofabrication techniques to different kinds o
materials, including the polymers which form the basis of many biomaterials, has
made them useful for the realization of nanostructured devices for the biomedical
field. This means the fabrication of medical devices which may show better biocom-
patibility, biointegration and functional properties [4]. Many tolerance problems
have to be faced when a prosthesis is implanted in any part of the body: these arise
from the interaction between the prosthesis surface and the physiological environ-
ment with which it comes into contact.
The realization of nanostructured surfaces means building intelligent complex
biomaterials able to guide, accelerate or condition determined biological processes.
It is well known that the surface control of cell behavior such as adhesion, prolifer-
dation, movement and differentiation plays an important role in tissue formation an
repair [4]. The migration ability (the cell’s ability to move) more than any other fac-
tor plays an important role in many biological processes such as tissue repair, arti-
ficial prosthesis epithelialization and vessel endothelialization. The control of cell
morphogenesis is a fundamental requirement for obtaining advanced tissue devices,
that is to say artif icial devices on which cells can spontaneously and precisely
forganize and mimic natural tissue morphology and functionality. The presence o
microdomains and nanodomains on a surface may allow the control and manipula-
tion of two external signals – the cell-substrate and the cell-cell interactions – to
produce a unit of highly oriented and differentiated cells able to organize them-
selves into a tissue.
The realization of devices having on their surface topographic and/or chemical
nanometric domains means being able to comprehend the interaction occurring
between the prosthesis surface and the first factors with which it comes into con-
tact, such as physiologic liquid proteins, blood cells and tissue cells.
The cell guide depends on the characteristics of the structured surfaces in terms
of dimensions of the domains with different topography and/or chemical composi-
tion. The domain dimensions can be as big as those of the biological entity with
which they interact. In fact, we have to be aware of the average dimensions of a cell,
which vary within a range of 10-20 micron, but the cell surface also has functional
domains which can be 50-100 nm [5].
Most studies aim at the realization of surfaces with only topographic domains
with different kinds of geometric configurations [6]. The presence of a stripy geom-
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etry, for example, stimulates the orientation of cells and alters their morphology,
sometimes into a very extended form; for this reason studying cell movement
appears to be the most promising approach. Some kinds of cells, such as fibroblasts
dand endothelial cells, tend to fall into line on the concave side of stripes hollowe
out on silicon surfaces [7]. In particular, it has been shown that the primary fibrob-
last orientation increases when in contact with stripes 10-30 nm in size [8]. It is not
yet clear whether this alignment in the grooves is due to a particular conformation
assumed by the cell when in contact with the groove or to other events, such as
medium accumulation in these particular geometries. The contact of macrophages
with a particular topography causes some change in the cytoskeleton in short times,
and stimulates cellular phagocytosis. All this suggests that cell behavior depends on
the cells investigated.
Structures with chemical stimulus can also be realized. For example, by alternat-
ing on the same surface adhesive nanometric domains for cells, such as those made
of proteins like fibronectin and vitronectin, with nonadhesive domains, such as
polymers like polyethylene glycol, cells can be forced to adhere, migrate and prolif-
erate only on the adhesive areas. Plasma enhanced chemical vapor deposition (PE-
CVD) and plasma treatments (surface modification for functional group grafting)
are used for this purpose [9]. Figure 4.1 shows an example of fibroblast adhesion on
polyethylene terephthalate (PET) substrates treated with the plasma-deposition
rocess to o ta n nanostructure  fluorocar on coat s. Rosso et a . [10] sp b i d b ing l howed
that both cell morphology and internal signal transduction pathways of the adhering
fibroblasts on rough surfaces were quite different compared to cells adhering on
smooth ones.

















Fig. 4.1 Interrelations between nanomedicine and nanobio-technology
Metals with nanostructured surfaces can be used in orthopedics and the dental
field. Mechanical and chemical characteristics make metals (Ti, etc.) f it to play a
supporting role, while the presence of nanostructures on the surface makes the pros-
thesis suitable for favoring the process of biointegration.
Other studies have been devoted to the preparation of organic/inorganic hybrid
materials, with particular chemical and morphological characteristics, aiming to
fcontrol or favor biomineralisation processes of hard tissues [11]. The realization o
organic/inorganic hybrid materials means developing new nanostructured materials
which can be used as hard tissue fillings or orthopedic and dental prosthesis coat-
ings.
The application of nanotechnology for treatment, diagnosis, monitoring, and con-
trol of biological systems is now often referred to as nanomedicine: the complex inter-
relations between nanomedicine and nanobiotechnology are shown in Figure 4.2.
fAmong many possible applications of nanotechnology in medicine, the use o
dvarious nanomaterials as pharmaceutical delivery systems for drugs, DNA, an
imaging agents has gained increasing attention. Many varieties of nanoparticles are
available [1], such as different polymeric and metal nanoparticles, liposomes, nio-
somes, solid lipid particles, micelles, quantum dots, dendrimers, microcapsules,
cells, cell ghosts, lipoproteins, and different nanoassemblies.
The paradigm of using nanoparticulate pharmaceutical carriers to enhance the in
vivo efficiency of many drugs, anti-cancer drugs first of all, has become well estab-
lished over the past decade, in both pharmaceutical research and the clinical setting.
Numerous nanoparticle-based drug delivery and drug targeting systems have
already been developed or are under development [12]. Their use aims to minimize
drug degradation and inactivation upon administration, prevent undesirable side
effects, and increase drug bioavailability and the fraction of drug delivered to the
at gica  area. In enera , p armaceut ca   carr ers, espec lly ose usep holo l g l h i l drug i ia th d
for parenteral administration, are expected to be biodegradable, easy and reasonably
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Fig. 4.2 Environmental scan-
ning electron microscopy
(ESEM) image of fibroblast
adhesion on fluorocarbon
nanostructured surface
cheap to prepare, to have a small particle size, to possess a high loading capacity, to
demonstrate prolonged circulation, and ideally to accumulate specifically or non
specifically in required sites in the body.
Some time ago, it was found that high-molecular-weight long-circulating macro-
molecules as well as various long-circulating nanoparticulate pharmaceutical carri-
ers are capable of spontaneous accumulations in various pathological sites, such as
solid tumors and infarcted areas, via the so-called enhanced permeability and reten-
tion (EPR) effect [13]. This effect is based on the fact that pathologic vasculature,
unlike vasculature of normal healthy tissues, is leaky – that is, penetrable for large
dmolecules and even for small particles – which allows for their extravasation an
accumulation in an interstitial tumor space. Such accumulation is additionally facil-
itated by the virtual lack in many tumors of a lymphatic system, responsible for the
drainage of macromolecules from normal tissues. It has been found that the effec-
tive pore size in the endothelial lining of the blood vessels in most peripheral human
rtumors ranges from 200 nm to 600 nm in diameter, and the EPR effect allows fo
passive targeting of tumors based on the cutoff size of the leaky vasculature.
The most extensively studied particulate drug carriers are liposomes, micelles,
and polymeric nanoparticles, which possess the most suitable characteristics for the
encapsulation of many drugs, genes, and diagnostic (imaging) agents. These drug
dcarriers as well as any other pharmaceutical nanocarriers can be surface modifie
by a variety of different moieties to impart them with certain properties and func-
tionalities. These functionalities are expected to provide nanocarriers with:
1. prolonged circulation in the blood and ability to accumulate in various patholog-
ic areas (e.g. solid tumors) via the EPR effect (protective polymeric coating with
polyethylene glycol [PEG] is frequently used for this purpose);
2. the ability to specifically recognize and bind target tissues or cells via the sur-
face-attached specific ligands such as folate and thiamine, peptides such as
RGD, and sequences identified by phage display, proteins such as transferrin,
lectins, antibodies and antibody fragments, polysaccharides such as galactose,
and aptamers;
r3. the ability to respond to local stimuli characteristic of the pathologic site by, fo
example, releasing an entrapped drug or specifically acting on cellular mem-
branes under the abnormal pH or temperature in disease sites (this property
could be provided by surface-attached pH-sensitive or temperature-sensitive
components);
4. the ability to penetrate inside cells bypassing lysosomal degradation for efficient
targeting of intracellular drug targets (for this purpose, the surface of nanocar-
riers is additionally modified by cell-penetrating peptides).
fThese are just the most evident examples. Figure 4.3 shows fibroblast uptake o
hyaluronic acid nanoparticle loaded with fluorescent rhodamine. Some other specif-
ic properties can also be listed, such as an attachment of diagnostic moieties. Even
the use of individual functionalities is already associated with highly positive clini-
dcal outcome; the success of Doxil, doxorubicin in a long-circulating PEG-coate
liposome, is a good example [14].
Patient research has shown the impressive effects of doxorubicin in PEG lipo-
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somes against metastatic breast carcinoma, unresectable hepatocellular carcinoma,
cutaneous T-cell lymphoma, sarcoma, squamous cell cancer of the head and neck,
and ovarian cancer [15].
4.2 
Biosensors
Biosensors are versatile analytical tools used in many fields such as clinical diag-
nostics, detection of industrial pollution, control of fermentation and also in the
field of security and safety for the monitoring of both chemical and biological haz-
ardous agents.
fThe main requirements for a biosensor approach to be valuable in terms o
research and commercial applications are the identification of a target molecule,
availability of a suitable biological recognition element, and the potential for dis-
osa e porta e etect on s stem  to e pre erre  to sens  orator asep bl bl d i y s b f d itive lab y-b d
techniques in some situations. Some examples are given below:
- glucose monitoring in diabetes patients;
- other medical health related targets;
- environmental applications e.g. the detection of pesticides and river water con-
taminants;
- remote sensing of airborne bacteria e.g. in counter-bioterrorist activities;
- detection of pathogens [16];
- determining levels of toxic substances before and after bioremediation;
- detection and determining of organophosphate;
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Fig. 4.3 Fibroblast uptake of
hyaluronic acid nanoparti-
cle loaded with fluorescent
rhodamine. Image from
laser confocal microscopy
- routine analytical measurement of folic acid, biotin, vitamin b12 and pantothenic
acid as an alternative to microbiological assay;
- determination of drug residues in food, such as antibiotics and growth promot-
ers;
- drug discovery and evaluation of biological activity of new compounds;
- detection of toxic metabolites such as mycotoxins [17].
dA biosensor is a device for the detection of an analyte (a chemical compoun
that you want detect) that combines a biological component with a physicochemical
detector component. It consists of three parts:
- the sensitive biological element; a biological material (e.g. tissue, microorgan-
isms, organelles, cell receptors, enzymes, antibodies, nucleic acids, etc), a bio-
logically derived material or biomimetic, or sensitive elements created by bio-
logical engineering;
- the transducer or the detector element (works in a physicochemical way; optical,
piezoelectric, electrochemical, etc.) that transforms the signal resulting from the
interaction of the analyte with the biological element into another signal (i.e.
transducers) that can be more easily measured and quantified;
- associated electronics or signal processors that are primarily responsible for the
display of the results in a user-friendly way [18].
Hence, a biosensor uses biologically active molecules called probe (enzymes,
receptors, proteins, nucleic acids) or molecules that can recognize with high speci-
ficity an analyte present in a complex matrix. The biological response that comes
from probe-analyte interaction (conformational changes of biomolecules) is con-
dverted into a quantifiable electrical, optical or chemical signal which is amplifie
and then converted by a microprocessor in concentration units. Furthermore, a
biosensor has another important component which is the microfluidic device, with
micro-pump for the transport of the solution that will be analyzed. Moreover, the
fuse of enzymes and proteins as biosensors is largely supported by the progress o
genetic engineering that allows not only the production of large amounts of protein
but also the modification of its properties.
An important part in a biosensor is the attachment of the probes (small mole-
cules/protein/cells) to the surface of the sensor (be it metal, polymer or glass). The
simplest way is to chemically functionalize the surface in order to coat it with the
iolo ical elements. This can be done b  pol sine, aminosilane, epox silane ob g y yly y r
nitrocellulose in the case of silicon chips/silica glass. Subsequently the bound bio-
logical agent may be for example fixed by layer-by-layer deposition of alternatively
charged polymer coatings [19].
Alternatively, the probe can be immobilized on materials such as graphite, gold,
silicon crystal f ixed to the glass, or polymer-porous silicon (PSi), which is the most
innovative and most widely used for its high biocompatibility. The porous silicon
due to its characteristic sponge-like morphology is a nearly ideal material to use as
a transducer optical biosensors. Its inner surface in fact, has a specific area that is
of the order of 200-500 m2/cm3 so that the interaction with the adsorbed substances,
liquid or gas is very effective.
The porous silicon is produced by electrochemical attack of a silicon crystal
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wafer. When the reaction is complete, the entire surface of porous silicon appears
covered with Si-H bonds, which are thermodynamically unstable. These are then
replaced with Si-C bonds, which are very stable and resistant to chemical attack.
This makes it possible to functionalize the porous silicon with enzymes, antibodies,
proteins or DNA sequences: for example, the silicon group will react with a car-
boxylic acid amide group of a lysine, thus obtaining a protein covalently linked to
the surface of the biosensor. To test the protein bond on the silicon wafer, polypep-
tides are labeled with a fluorophore (e.g. rhodamine) and if after a series of exten-
sive washes the fluorescence persists, the reaction has been successful.
Physical probe trapping is achieved using three dimensional lattices (hydrogel).
The most commonly used hydrogel is a glassy silica generated by the polymeriza-
tion of silicate monomers in the presence of the biological elements (along with
fother stabilizing polymers, such as polyethylene glycol) [18]. Another group o
hydrogels, which set under conditions suitable for cells or protein, are acrylate
hydrogel, which polymerizes upon radical initiation [20].
Regardless of the probe immobilization method on silicon wafers, the partial
replacement of the air inside the pores with the biomolecule and/or the biomolecule-
fligand complex corresponds to a gradual increase in the average refractive index o
porous silicon. This increase results in a shift toward longer wavelengths (red-shift)
of the reflection spectrum, which is obtained by hitting the porous silicon with a
beam of collimated light.
Several methods have been used for the realization of stable and specific biosen-
sors. Fluorescence spectroscopy, due to high sensitivity, low cost and ease of use, is
the gold standard in biotechnology.
fThe stability properties of these biosensors are primarily derived from the use o
hthermostable proteins and enzymes isolated from extremophile organisms, whic
constitute a rich source of molecules with unique specificity and stability even
funder extreme conditions of temperature, pH and salinity or in the presence o
adetergents and organic solvents. The enzymes isolated from extremophiles show 
dhigher stability than their mesophilic counterparts, even in conditions considere
optimal for mesophilic organisms.
Protein biosensors have been developed in the biomedical f ield for the quantita-
tive determination of glucose using the glucose binding protein (GBP) as a probe.
At present the use of enzymes (e.g. alcohol dehydrogenase) as a biosensor has
the disadvantage of consuming the substrate, this represents a real problem in the
design of implantable biosensors, that besides being precise and minimally invasive
instruments allow a continuous monitoring (night and day) of analytes such as
ethanol in the blood.
Recently, it was demonstrated that apo-enzymes (enzymes without coenzyme)
can be used as probes for the development of fluorescent biosensors. Apo-enzymes,
antibodies and proteins belonging to the family of receptor-binding protein can then
bind the substrate without turning it into product. This biosensor is not only accu-
rate but also stable and reversible. The biomolecule-substrate interaction triggers




Recently, arrays of many different detector molecules have been applied in so-
called electronic nose devices, where the pattern of response from the detectors is
used to fingerprint a substance. Current commercial electronic noses, however, do
not use biological elements.
4.3
Nanodiagnostics
G. Marino, F. Papale
Nanodiagnostics can be defined as the use of nanotechnology for clinical diagnos-
tic purposes. The increased demand for sensitivity requires that a diagnostically sig-
nificant interaction occurs between analyte molecules and signal-generating parti-
cles, thus enabling detection of a single analyte molecule. Nanotechnology has
enabled one-to-one interaction between analytes and signal-generating particles
dsuch as quantum dots (QDs; 2-8 nm) in the size range of proteins (1-20 nm) an
other important biomolecules [1].
Nanotechnology implemented within current diagnostic equipment has the
potential of analyzing entire genomes in minutes instead of hours. Based on which
DNA sequences are deviated from the normal, we will be able to determine an indi-
vidual’s predisposition to either cancer or a specific disease. 
A recent development is the nanochip, which employs the power of an electron-
ic current that separates DNA probes to specific sites on the array based on charge
and size on specific sites of the nanochip. The test sample (blood) can then be ana-
lyzed for target DNA sequences by hybridization with these probes. The DNA mol-
decules that hybridize with target DNA sequences fluoresce, which is detected an
relayed back to an onboard system through platinum wiring that is present within
the chip. The secret behind this nanochip is that each test site can be controlled elec-
tronically from the system’s onboard computer. In other words, the chip can place
different probes in different sites according to what DNA sequence is of interest.
Therefore, if a mutation in the DNA sequence of a gene that causes a disease is
known, we will be able to know whether or not a person is predisposed to that par-
ticular disease if hybridization with that probe occurs.
The newest technologies within nanodiagnostics involve microfluidic or lab-on-
a-chip fsystems. The idea behind this kind of chip is simple: the combination o
numerous processes of DNA analysis are combined on a single chip composed of a
dsingle glass and silicon substrate. The device itself is composed of microfabricate
fluidic channels, heaters, temperature sensors, electrophoretic chambers, and fluo-
rescence detectors to analyze nanoliter-size DNA samples.
Related to microfluidic systems are microelectromechanical systems or MEMS. The
difference between MEMS and microfluidic systems are that MEMS do not require
dreagents or a fluidity based substrate to react upon. Although MEMS are primarily use
in drug-delivery systems, one primary application of MEMS in diagnostics are the swal-
lowed capsule technology pills that allow doctors to visualize internal bleedings.
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rPractically, the patient swallows a capsule containing a light emitting diode fo
illumination, a CMOS (complementary metal-oxide semiconductor) video camera
and optics for taking images, a battery, and a transmitter [21]. The images are then
transmitted to a receiver worn on the patient’s belt and the doctor is then able to
diagnose the cause of the ailment.
In recent years, studies on nanoparticles have given a considerable impetus to
nanodiagnostics. Nanoparticles possess certain size-dependent properties, particu-
larly with respect to optical and magnetic parameters, which can be manipulated to
achieve a detectable signal. The primary event in most nanoparticle-based assays is
the binding of a nanoparticle label or probe to the target biomolecule that will pro-
fduce a measurable signal characteristic of the target biomolecules. A variety o
ro es  een use  or this purpose, nc di  QDs, cantilevers, nanos lls, anp b have b d f i lu ng he d
metal nanoparticles [22].
QDs are the most used and promising nanostructures for diagnostic applications.
QDs are semiconductor nanocrystals, with a diameter of 2-8 nm, characterized by
strong light absorbance, that can be used as fluorescent labels for biomolecules.
QDs can be conjugated to antibodies, an oligonucleotide or aptamer, or coated with
streptavidin. This helps direct the QD toward the target analyte. In addition, QDs
can be used as nonspecific fluorescent labels.
When a QD absorbs a photon with energy higher than the band-gap energy of the
composing semiconductor, an exciton, or electron-hole pair, is created. As a result,
fa broadband absorption spectrum occurs because of the increased probability o
absorption at shorter wavelengths. The return of the exciton, characterized by a long
lifetime >10 ns, to a lower energy state leads to emission of a photon with a narrow
symmetric energy band [23]. QDs are reported to emit with lifetimes of 5-40 ns,
awhereas conventional organic dyes emit in the 0.5-2 ns range. This produces 
strong, stable fluorescence signal.
Methods for tracking and detecting QDs are numerous and include fluorometry
and several types of microscopy, such as fluorescence, confocal, total internal
reflection, wide-field epifluorescence, atomic force, and multiphoton microscopy
[22]. The choice of monitoring or detection technique depends on the type of appli-
cation, such as in vitro diagnostics or imaging, for which QDs are used.
The advantages of QD over conventional organic dyes and fluorophores is their
optical tunability, resistance to photobleaching, excitation of various QDs by a sin-
gle wavelength of light (for multiplexing), narrow emission band, and exceptional
stability of optical properties after conjugation to a biomolecule. Currently, up to
40,000 assays can be run simultaneously with the current capabilities of the QD
technology [1].
The use of QD labels for DNA detection would help overcome two of the most
important problems encountered when using organic dyes for DNA labeling; cleav-
fage of DNA molecules as a result of photobleaching and subsequent formation o
free radicals, and disturbing DNA–protein interactions.
rQDs are at the core of a fluoroimmunoassay introduced by Härmä et al. [24] fo
dthe detection of prostate-specific antigen (PSA). QDs have also recently been use
to optically detect acetylcholine [25]. Peptides have also been conjugated to QDs, as
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dexemplified by the work of Akerman et al. [26]. These investigators conjugate
three different peptides to QDs to target lung endothelial cells, brain endothelial
cells, and breast carcinoma cells, both in vitro and in vivo. Microinjection of QDs
conjugated to suitable peptides can also target cellular organelles such as the nucle-
us or mitochondria.
Another promising area for application of QDs is the detection of cancer. An
assay has been developed for detection of the receptor Her2 (hairy-related 2) on
SKBR-3 breast cancer cells [27].
QDs have applications in cellular imaging. Antibody-coupled QDs injected into
the tail veins of mice were successful in detecting prostate cancer xenografts. The
spectral image of the mice clearly showed the location of the target-bound QDs
[23]. A more generalized imaging application was described by Larson et al. [28],
who injected water-soluble QDs into mice to image skin and adipose tissues.
Despite the fact that both of these tissues have high light-scattering properties, the
vasculatures containing QDs at about 1 μmol/L were clearly visible by multipho-
ton microscopy.
The most eminent problem regarding QDs is toxicity. The fact that QDs have
basic components that are highly toxic to humans, e.g. cadmium, raises serious safe-
ty issues. Many of the studies mentioned previously used QDs with concentrations
just high enough to achieve optimal labeling, and the duration of use ranged from
several hours to several days. The authors of these studies found no adverse effects
on cellular functioning or development during the study. However, at higher QD
concentrations (>5 x109 QDs/cell), Xenopus embryo development was affected [23].
For in vivo studies, the question that remains is whether the surface coating, assum-
ing one is used, of the QD will be sufficiently robust to guard against leakage of the
core metals and semiconductors into the biological system being studied.
rThe same factors that lead to questions concerning the safety of QDs and othe
nanostructures for use in humans lead to questions of environmental safety.
Specifically, can QDs be stored and disposed of without leakage of the toxic metals
used?
Gold nanoparticles and gold nanoshells provide great sensitivity for the detec-
tion of DNA and proteins. They can be used to label DNA or protein molecules
(including antibodies), which can then bind to their respective targets [1].
The optical technique called surface plasmon resonance measures the optical
change produced from the interaction of locally adjacent gold nanoparticle (bound-
ed to a specific target) and then uses this optical change for target detection [29].
The bio-barcode assay (BCA) has been used for the detection of proteins such as
PSA, which is an important marker for prostate and breast cancers [30]. BCA has
also been used to successfully detect a biomarker for Alzheimer disease. In a study
y Georganopoulou et al. [31], the BCA was used to determine the concentration ob f
the biomarker, amyloid beta-derived diffusible ligands (ADDLs), in cerebrospinal
fluid.
The assay, which is one million-fold more sensitive than the current ELISA tech-
nique, could be developed for the measurement of ADDLs in blood, thus providing
an early diagnostic tool for Alzheimer disease.
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rThe promise of increased sensitivity and speed and reduced cost and labo
makes nanodiagnostics an appealing alternative to current diagnostic techniques.
The potential diagnostic uses of QDs are numerous, with the most promising appli-
cations being in the areas of tumor detection, tissue imaging, intracellular imaging,
immunohistochemistry, infectious agent detection, multiplexed diagnostics, and flu-
oroimmunoassays.
QDs also have considerable potential for in vivo imaging, but there are concerns
over their toxicity, both to patients and the environment. The technologies are
numerous and the applications are constantly increasing, with QDs, gold nanoparti-
dcles, and BCAs in the lead. The numerous types of nanoparticles differ in shape an
properties, which could be used for specific diagnostic applications.
PCR could soon lose its lead position as the gold standard for DNA detection to
BCA, which offers increased sensitivity and safety. In time, nanodiagnostics may
become very cost-effective, as is currently the case with some magnetic nanoparti-
cles. This should allow better clinical diagnostic services, particularly in economi-
cally deprived regions. These technologies can also be applied to point-of-care test-
ing and lab-on-a-chip technologies. Whether nanodiagnostics will replace current
diagnostic methods remains to be seen. Many aspects of these nanodiagnostic tech-
niques need to be evaluated further, especially the safety issues.
References
1. Jain KK (2003) Nanodiagnostics: application of nanotechnology in molecular diagnostics. Ex-
pert Rev Mol Diagn 3:153-161
2. Whitesides GM, Xia Y (1998) Short review of soft lithography. Ann Rev Mater Sci 28:153-
184
3. Qin D, Xia Y, Whitesides GM (2010) Soft lithography for micro- and nanoscale patterning.
Nat Protoc 5:491-502
4. Park H, Cannizzaro C, Vunjak-Novakovic G et al (2007) Nanofabrication and microfabrica-
tion of functional materials for tissue engineering. Tissue Eng 13:1867-1877
r5. Curtis AS, Wilkinson CD (1998) Reactions of cells to topography. J Biomater Sci Polyme
Edn 9:313-329
6. Kataoka K, Suzuki Y, Kitada M (2001) Alginate, a bioresorbable material derived from brown
rseaweed, enhances elongation of amputated axons of spinal cord in infant rats. J Biomed Mate
Res 54:373-384
d7. Wallman L, Zhang Y, Laurell T, Danielsen N (2001) The geometric design of micromachine
silicon sieve electrodes influences functional nerve regeneration. Biomaterials 22:1187-1193
8. Dalby MJ, Riehle MO, Sutherland DS et al (2004) Fibroblast response to a controlled nanoen-
vironment produced by colloidal lithography. J Biomed Mater Res A 69:314-322
9. Favia P, Pinto Mota R, Vulpio M et al (2000) Plasma deposition of Ag-containing, polyethile-
neoxide-like coatings. Plasmas and Polymers 5:1-14
10. Rosso F, Marino G, Muscariello L et al (2006) Adhesion and proliferation of fibroblasts on
plasma-deposited nanostructured fluorocarbon coatings: evidence of FAK activation. J Cell
Phys 207:636-643
11. Bigi A, Boanini E, Panzavolta S, Roveri N (2000) Biomimetic growth of hydroxyapatite on
gelatin films doped with sodium polyacrylate. Biomacromolecules 1:752-756
Biotechnology in Surgery72
4
12. Campbell N (2002) DNA technology and genomics. In: Wilbur B (ed) Biology: sixth edition.
Pearson Education Inc, San Francisco, pp. 391-392
r13. van Vlerken LE, Vyas TK, Amiji MM (2007) Poly(ethylene glycol)-modified nanocarriers fo
tumor-targeted and intracellular delivery. Pharmaceut Res 24:1405-1414
14. O’Shaughnessy JA (2003) Pegylated liposomal doxorubicin in the treatment of breast cancer.
Clin Breast Cancer 4:318-328
15. Torchilin VP (2007) Targeted pharmaceutical nanocarriers for cancer therapy and imaging.
The AAPS J 9:128-147
f16. Pohanka M, Skladal P, Kroca M (2007) Biosensors for biological warfare agent detection. De
Sci J 57:185-193
17. Pohanka M, Jun D, Kuca K (2007) Mycotoxin assay using biosensor technology: a review.
Drug Chem Toxicol 30:253-261
18. Cavalcanti A, Shirinzadeh B, Zhang M, Kretly LC (2008) Nanorobot hardware architecture
for medical defense. Sensors 8: 2932-2958
19. Gupta R, Chaudhury NK (2007) Entrapment of biomolecules in sol-gel matrix for applica-
tions in biosensors: problems and future prospects. Biosens Bioelectron 22:2387-2399
20. Liao KC, Hogen-Esch T, Richmond FJ et al (2008) Percutaneous fiber-optic sensor for chron-
ic glucose monitoring in vivo. Biosens Bioelectron 23:1458-1465
21. Walt DR (2005) Miniature analytical methods for medical diagnostics. Science 308:217-219
22. Rosi NL, Mirkin CA (2005) Nanostructures in biodiagnostics. Chem Rev 105:1547-1562
23. Michalet X, Pinaud FF, Bentolila LA et al (2005) Quantum dots for live cells, in vivo imag-
ing, and diagnostics. Science 307:538-544
24. Härmä H, Soukka T, Lovgren T (2001) Europium nanoparticles and time-resolved fluores-
cence for ultrasensitive detection of prostate-specific antigen. Clin Chem 47:561-568
25. Jin T, Fujii F, Sakata H et al (2005) Amphiphilic p-sulfonatocalix[4]arene-coated CdSe/ZnS
quantum dots for the optical detection of the neurotransmitter acetylcholine. Chem Commun
(Camb) 4300-4302
26. Akerman ME, Chan WC, Laakkonen P et al (2002) Nanocrystal targeting in vivo. Proc Natl
Acad Sci U S A 99:12617-12621
27. Wu X, Liu H, Liu J et al (2003) Immunofluorescent labeling of cancer marker Her2 and oth-
er cellular targets with semiconductor quantum dots. Nat Biotechnol 21:41-46
28. Larson DR, Zipfel WR, Williams RM et al (2003) Water-soluble quantum dots for multipho-
ton fluorescence imaging in vivo. Science 300:1434-1436
29. Green RJ, Frazier RA, Shakesheff KM et al (2000) Surface plasmon resonance analysis of dy-
namic biological interactions with biomaterials. Biomaterials 21:1823-1835
30. Nam JM, Thaxton CS, Mirkin CA (2003) Nanoparticle-based bio-bar codes for the ultrasen-
sitive detection of proteins. Science 301:1884-1886
31. Georganopoulou DG, Chang L, Nam JM et al (2005) Nanoparticle-based detection in cere-
dbral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Aca
Sci U S A 102:2273-2276
4 Technology for Biotechnology 73
Biotechnology in Surgery. Alfonso Barbarisi (Ed.)
© Springer-Verlag Italia 2011
75
Regenerative Medicine: Current 
and Potential Applications
A. Barbarisi, F. Rosso
5
5.1
Scaffold and Molecular Signals for Tissue Engineering
There is a substantial unmet demand for tissues to repair injured, degenerated or
congenitally defected tissues. The field of tissue engineering has emerged to fill the
void where neither native physiology nor purely artif icial implantable materials can
sufficiently replace or repair these damaged tissues. While tissues such as bone or
skin can effectively repair a small injury given sufficient time, many tissues such
as myocardium and cartilage do not regenerate properly without intervention.
To achieve this, it is necessary to combine the use of cells together with natural
or synthetic scaffolds in or onto which cells can develop, organize and behave as if
they are in their native tissue. Therefore, cells must receive signals from the envi-
ronment to carry out in an orderly way proliferation and differentiation programs
aimed at tissue/organ formation [1].
With regard to these biological process cells need a continuous flow of signals
from the surrounding extracellular environment that allow for specif ic genetic pro-
gram fulf illment. It is tempting to generalize that in all tissues cells live in contact
with matrices or scaffolds. From the early developmental phases onwards, embry-
onic cells produce their own extracellular scaffolds by secreting many types of
molecules in the surrounding space, according to a well defined program of differ-
entiation [2]. The different spatial organization of these secreted molecules gives
rise to a great variety of natural scaffolds in which cells continue to proliferate and
to organize themselves to build tissues and to accomplish all their natural func-
tions. The understanding of cell differentiation and functions means the under-
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standing of cell–cell and cell–extracellular matrix (ECM) communication mecha-
nisms. In this respect, if one looks considering the complexity of tissue ECM com-
ponents, it is not surprising to f ind the same great variety and complexity of exist-
ing interactions between cells and ECM. Bearing these basic considerations in
mind, our efforts in trying in vitro tissue reconstruction must be driven toward the
exact knowledge of cell function on the one hand, and on the other toward the
knowledge of interactions and signals that cells must receive from the environment
to behave as in natural tissues [1].
Tissue-engineering approaches typically employ exogenous three-dimensional
ECMs to engineer new natural tissues from natural cells. The exogenous ECMs are
designed to bring the desired cell types into contact in an appropriate three dimen-
dsional environment, and also to provide mechanical support until the newly forme
tissues are structurally stabilized and specific signals occur to guide the gene
expression of cells forming the tissue [3].
All synthetic ECMs used to engineer tissues have three primary roles. First, the
synthetic ECMs facilitate the localization and delivery of cells to specific sites in
the body. Second, they define and maintain a three dimensional space for the forma-
tion of new tissues with the appropriate structure. Third, they guide the development
of new tissues with their appropriate functions.
The synthetic ECM should provide temporary mechanical support sufficient to
withstand in vivo forces and maintain a potential space for tissue development. This
dmechanical support by the synthetic ECM should be maintained until the engineere
tissue has sufficient mechanical integrity to support itself, as in the case of the Kim
and Mooney [4] studies that showed the ability of synthetic ECMs based on non-
woven mesh of polyglycolic acid bonded at their f iber cross points with poly-L-lac-
tic acid to resist cellular contractile forces and maintain their predefined structure
during the process of smooth muscle tissue development in vitro.
The cells composing the engineered tissue must express the appropriate genes to
dmaintain the tissue specific function of the engineered tissue. The function of seede
dcells is strongly dependent on the specific cell surface receptor (e.g. integrins) use
by the cell to interact with the material, on interactions with surrounding cells, and on
the presence of soluble growth factors. These factors can be controlled by incorporat-
ing or integrating a variety of signals, such as cell-adhesion peptides and growth fac-
tors [5] into the synthetic ECM or by subjecting it to mechanical stimuli [6].
The exogenous ECMs for tissue engineering can be fabricated from two classes
of biomaterials: naturally derived materials and synthetic materials. Naturally
occurring materials are composed of polypeptides, polysaccharides, nucleic acids,
hydroxyapatites, or their composites. Biological materials have some remarkable
advantages over synthetics, that is, their excellent physiological activities such as
selective cell adhesion (e.g. collagen and fibrin), mechanical properties similar to
natural tissues (e.g. animal heart valves and blood vessels), and biodegradability
(e.g. gelatine and chitin). However, as with synthetics, biological materials have
several deficiencies including risk of viral infection, antigenicity, unstable material
supply and the deterioration which accompanies long-term implantation. In addi-
tion, naturally derived materials offer limited versatility in designing an exogenous
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ECM with specific properties (e.g. porosity, mechanical strength). Synthetic mate-
rials, by contrast, can be manufactured reproducibly on a large scale, and can also
be processed into an exogenous ECM in which the macrostructure, mechanical
properties, and degradation time can be readily controlled and manipulated.
Exogenous ECMs fabricated by biodegradable polymers will eventually erode in the
body, avoiding a chronic foreign-body response.
The greatest disadvantage of synthetic materials, however, is the lack of cell-
recognition signals. Toward this end, efforts are being made to incorporate cell
adhesion peptides into biomaterials, which normally exhibit few cellular interac-
tions. Mechanical signals conveyed to cells via their adhesion to the matrix also
clearly regulate the development of various tissues and the gene expression of many
cell types in culture. The concept of combining synthetic materials with cell-recog-
nition sites of naturally derived biomaterials is very attractive. These hybrid materi-
als could possess the favorable properties of synthetic materials, including widely
varying mechanical and degradative properties, reproducible large-scale production,
and good processability, as well as the specific biological activity of naturally
derived materials. This latter property may be needed to engineer complex tissue
with multiple cell types organized in specific patterns. Several cell-adhesion ligands
with highly specific recognition could potentially be displayed spatially in a desir-
able pattern to induce specific cell-organization schemes [7].
Many researchers have been focusing on the development of semi-synthetic
materials that are targeted to assist tissue regeneration [8, 9]. Placed at the site of a
defect, such materials should actively and temporarily participate in the regenera-
tion process by providing a platform on which cell-triggered remodeling could
occur.
rIn particular, the ability to supply molecular signals able to guide the cellula
response on these new semi-synthetic biomaterials represent a tremendous innova-
tion in the area of tissue engineering.
5.2
Cell Source for Tissue Engineering
The choice of cells for creation of body structures is a major challenge in tissue
engineering. The main goal in this regard – the large-scale fabrication of structures
– may be to create large cell banks composed of universal cells that would be
immunologically transparent to an individual. These universal cells could be differ-
entiated cell types that could be accepted by an individual or could be stem cells,
which could respond to signals to differentiate into differing lineages for specific
structural applications. Our knowledge about the biology of stem cells and their
existence in various mesenchymal tissues (muscle, bone, and cartilage), endoder-
mally derived tissues (intestine and liver), or ectodermally derived tissues (nerves,
pancreas, and skin) expands on a daily basis. A new area of stem cell biology involv-
 em on c stem cells lds prom se or t ssue engineer . T e opment oing bry i ho i f i ing h devel f
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immunologically inert universal cells may come from advances in genetic manipu-
lation as well as stem cell biology. As intermediate steps, tissue can be harvested as
allograft, autograft, or xenograft. The tissues can then be dissociated and placed into
cell culture, where proliferation of cells can be initiated. After expansion to the
appropriate cell number, the cells can then be transferred to templates, where fur-
ther remodeling can occur. Which of these strategies are practical and possibly
applicable in humans remains to be explored. Large masses of cells for tissue engi-
neering need to be kept alive, not only in vitro but also in vivo. Moreover, not only
fwill one need to have a sufficient supply and one that can be ensured to be free o
pathogens and contamination, but one will need to decide whether the source to be
femployed is to be autologous, allogeneic, or xenogeneic. With regard to the use o
autologous cells, there are a number of potential sources. These include both differ-
entiated cells and adult stem/progenitor cells. For some tissue-engineering applica-
tions currently under development the ability to obtain a tissue biopsy and expand a
sufficient number of autologous cells is well established. In other circumstances it
dis not clear how a patient’s own cells could be harvested and/or expanded to yiel
enough material for production of the needed neo-tissue or organ. Cardiomyocytes,
neurons of the central nervous system, hepatocytes and other liver cells, kidney
cells, osteoblasts, and insulin producing pancreatic beta-cells are examples of dif-
ferentiated cell types for which new sources could enable novel therapies to address
significant unmet medical needs.
Immature precursor cells present within tissue samples are essential for the
expansion of cells from biopsies of skin, bladder, or cartilage that enables the engi-
neering of the corresponding neo-tissues. The ability to extend tissue engineering to
other tissue and organ systems will depend greatly on finding sources of appropri-
ate stem and progenitor cells. Three major sources currently are under intensive
minvestigation: (1) embryonic stem (ES) and embryonic germ (EG) cells derived fro
discarded human embryos and germ line stem cells, respectively; (2) ES cells creat-
ed by somatic cell nuclear transfer (therapeutic cloning); and (3) adult stem cells
from fetal, neonatal, or adult tissue, either autologous or allogeneic.
Hence, there is a variety of different stem cells. It is the adult stem cells and pro-
genitor cells that are being and will be used first clinically; however, in the long
term there is considerable interest in embryonic stem cells. These cells are pluripo-
tent, i.e. capable of differentiating into many cell types, even totipotent, i.e. capable
of developing into all cell types. Although we are quite a long way from being able
to use embryonic stem cells, a number of companies are working with stem cells in
the context of tissue engineering and regenerative medicine. It needs to be recog-
fnized, however, that immunogenicity issues may be associated with the use o
embryonic stem cells. Furthermore, different embryonic stem cell lines, even when
din a totally undifferentiated state, can be significantly different. This is illustrate
by the results of Rao et al. [10] in a comparison of the transcriptional profile of two
different embryonic stem cell lines. This difference should not be considered sur-
prising, since the lines were derived from different embryos and undoubtedly cul-
tured under different conditions. To take full advantage of stem cell technology,
however, it will be necessary to understand more fully how a stem cell differentiates
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rinto a tissue-specific cell. This requires knowledge not just about the molecula
at ways o  different at on, ut, even more mpo tant  o t t e identificat on op h f i i b i r ly, ab u h i f
the combination of signals leading to a stem cell’s becoming a specific type of dif-
ferentiated tissue cell. In addition, however, we will need to develop the technolo-
gies necessary to expand a cell population to the number necessary for clinical
application, be able to do this in a controlled, reproducible manner, and deliver cells
at the right place and at the right time.
The ES cells have a great degree of plasticity, which is the most attractive fea-
ture of the use of these cells for regenerative medicine. A major remaining chal-
dlenge is to direct the eff icient production of pure populations of specif ic desire
dcell types from human ES cells. In fact, undifferentiated ES cells of murine an
human origin form teratomas in vivo containing an array of cell types, including
representatives of all three embryonic germ layers [11, 12]. Therefore, it will be
important to document rigorously the exclusion of undifferentiated stem cells from
any tissue-engineered products derived from ES cells [13]. Strategies have been
envisaged to increase safety by introducing into ES cells a suicide gene, which
would render any escaping tumor cells sensitive to the drug ganciclovir [14].
However, the genetic manipulation is itself not without risk, and the need to vali-
date the engineered cell system would likely extend and complicate regulatory
review of therapeutic products.
dA central issue that must be addressed for tissue engineered products derive
from ES cells, and also from any nonautologous adult stem cells, is immune rejec-
tion based on mismatches at genetic histocompatibility loci [15]. It generally has
been assumed that, because human ES cells and their differentiated derivatives can
be induced to express high levels of MHC Class I antigens (e.g. HLA-A and HLA-
B), any ES cell-based product will be subject to graft rejection [16].
Therapeutic cloning offers a potential means to generate cells with the exact
genetic constitution of each individual patient so that immune rejection of grafts
based on mismatched histocompatibility antigens should not occur.
The approach entails transferring the nucleus of a somatic cell into an enucleat-
ed oocyte (SCNT), generating a blastocyst, and then culturing the inner cell mass to
obtain an ES cell line [17].
If required, genetic manipulation of the cells may be carried out to correct an
inherited defect prior to production of the therapeutic graft. Adult bovine fibroblasts
dwere used as nuclear donors and bioengineered tissues were generated from clone
cardiac, skeletal muscle, and kidney cells [18]. The grafts, including functioning
renal units capable of urine production, were successfully transplanted into the cor-
responding donor animals long term, with no evidence of rejection. Although SCNT
technology is the subject of study by both private and public research, it is still the
focus of political, ethical, and scientific debate.
The clinical application of ES cells for tissue engineering will depend on the
development of robust methods to isolate and grow them under conditions consis-
tent with good manufacturing practice and regulatory review for safety. In particu-
lar, it is important to eliminate the requirement for murine feeder cells by using
human feeders or, better, feeder free conditions. In addition, development of culture
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conditions without the requirement for nonhuman serum would be advantageous.
Progress has been made in the derivation and expansion of human ES cells with
human feeder cells [19, 20] or entirely without feeders [21, 22].
Perhaps the greatest challenge remains in directing the differentiation of human
ES cells to a given desired lineage with high efficiency. To induce differentiation in
vitro, ES cells are allowed to attach to plastic in monolayer culture or, more fre-
quently, to form aggregates called embryoid bodies [23]. Over time within these
faggregates cell types of many lineages are generated, including representatives o
dthe three germ layers. The production of embryoid bodies can be enhanced an
made more consistent by incubation in bioreactors [24]. Further selection of specif-
ic lineages generally requires sequential exposure to a series of inducing conditions
based on known signaling pathways. As summarized in recent reviews, the cell lin-
feages that have been generated in vitro include, among others, several classes o
neurons, astrocytes, oligodendrocytes, multipotent mesenchymal precursor cells,
osteoblasts, cardiomyocytes, keratinocytes, pneumocytes, hematopoietic cells,
hepatocytes, and pancreatic beta-cells [25-27]. In general, it appears easier to obtain
adult cells derived from ectoderm, including neurons, and mesoderm, including car-
diomyocytes, than cells derived from endoderm. This may help determine the earli-
est areas in which ES-derived cells enter clinical translation, once the barriers just
ddiscussed are surmounted. Dopaminergic neurons generated from primate an
human ES cells already have been tested in animal models of Parkinson’s disease,
with encouraging results [28]. Cardiomyocytes derived from human ES cells, simi-
larly, are candidates for future clinical use, although the functional criteria that must
e met to ensure p gica  competence will e str ent ecause o  e r  b hysiolo l b ing b f th isk of
inducing arrhythmias [29, 30].
In many cases adult stem cells may provide a more direct route to clinical trans-
lation. Lineage-restricted stem cells have been isolated from both fetal and postna-
tal tissues based on selective outgrowth in culture and/or immunoselection for sur-
face markers.
Their ability to expand may be less than that for ES cells, as they are multipo-
tent not pluripotent. Neural stem cells can yield neurons, astrocytes, and oligoden-
drocytes. Cardiac stem cells are reported to yield cardiomyocytes, smooth muscle,
and endothelial cells. Muscle-derived stem cells yield skeletal muscle and can be
induced to produce chondrocytes. Hepatic stem cells yield hepatocytes and bile duct
epithelial cells. The lineage restricted adult stem cells all appear non tumorigenic.
dThus, unlike ES cells, it is likely that they could be used safely for bioengineere
products with or without prior differentiation.
rIt is possible that some lineage-specific adult stem cells are capable of greate
plasticity than might be supposed based solely on their tissue of origin. For exam-
ple, there is evidence that mesenchymal stem cells (MSC), initially described in
bone marrow, are able to give rise to differentiated cells of connective tissues,
including bone, cartilage, muscle, tendon, and fat. The MSC have therefore gener-
ated considerable interest for musculoskeletal and vascular tissue engineering [31,
32]. Cells with similar differentiation potential and marker profiles have been iso-
lated from a number of tissues in addition to the bone marrow. A notable source is
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fadipose tissue, in which the cells are abundant and easily obtained by processing o
suction-assisted lipectomy (liposuction) specimens [33, 34].
In general it seems better to view MSC as mixed populations of progenitor cells
with varying degrees of replicative potential, rather than homogeneous stem cells.
Cells originating in a developing fetus and isolated from amniotic fluid or chorion-
ic villi are a new source of stem cells of great potential interest for regenerative
nmedicine [35]. Fetal-derived cells with apparently similar properties also have bee
ddescribed in the amnion of term placenta [36]. Amniotic fluid stem (AFS) cells an
amniotic epithelial cells can give rise to differentiated cell types representing the
three embryonic germ layers [35]. Formal proof that single AFS cells can yield this
full range of progeny cells was obtained using clones marked by retroviral insertion.
fThe cells can be expanded for well over 200 population doublings, with no sign o
telomere shortening or replicative senescence, and retain a normal diploid kary-
otype. They are readily cultured without need for feeder cells. A broadly multipo-
tent cell population obtained from umbilical cord blood may have certain key prop-
erties in common with AFS cells, and it was termed unrestricted somatic stem cells
(USSCs) [37].
Similar approaches to those being taken with ES cells, such as genetic modifi-
ncation with expression vectors for lineage specific transcription factors, may help i
athe generation of differentiated cell types for which it proves difficult to develop 
straightforward induction protocol using external signals.
Keeping in mind that the only cell based therapies guaranteed to be histocom-
atible would conta n auto ogous cells, w en we use ot er cell sources, t e questp i l h h h ion
of immune compatibility comes up.
There are many experimental data showing the immune privilege of stem cells.
In fact, human ES cells express low levels of class I major histocompatibility com-
plex (MHC) antigens (HLA-A, HLA-B) and are negative for MHC class II [16].
Differentiated derivatives of the ES cells remain negative for MHC II but show
some increase in MHC class I that is up-regulated by exposure to interferon. These
observations gave rise to the natural assumption that ES cells and their differentiat-
ed progeny would be subject to rejection based on MHC mismatches and led to a
search for strategies to induce immunological tolerance in recipients of transplant-
ed cells derived from ES lines.
However, it was observed that ES cells in the mouse could be transplanted suc-
cessfully in immunocompetent animals despite mismatches at the major histocom-
atibili  oc  [38, 39]. Even more remar , uman ES cells an  different atep ty l i kably h d i d
derivatives were not rejected by immune-competent mice in vivo, nor did they
stimulate an immune response in vitro by human T lymphocytes specif ic for mis-
matched MHC.
An independent study using mice with a humanized dimmune system confirme
a very low T-cell response to human ES cells and differentiated derivatives [40].
The successful therapeutic use of allogeneic MSC has been confirmed in animal
models [41]. Beyond the use of MSC as regenerative cells, it is possible that they
could be employed to induce immune tolerance to grafts of other cell types. The
mechanisms underlying the immunomodulatory properties of MSC are under active
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investigation, and understanding them may have a profound impact on regenerative
medicine [42, 43]. Taken together these data support the idea that allogeneic bio-
engineered products may not require intensive immunosuppressive treatment.
Finally, for all tissue engineered products, a critical issue will be how they are
delivered and made available to the clinician. In other words there is a need to
develop an appropriate product quantity and a cost-effective manufacturing
process. A lot of the research on manufacturing technology has focused on biore-
actor technology. A bioreactor is simply a controlled environment in which a tis-
rsue-like construct can be grown [44]. The design of a bioreactor involves a numbe
of critical issues such as the configuration of the bioreactor, its mass transport
characteristics, and its scalability. Hence an important issue in developing a tissue
engineered product is how much of the maturation of a substitute is done in vitro
in a bioreactor as compared to what is done in vivo through the remodeling that
takes place within the body itself.
5.3 
Skin
A tissue engineered product replacing skin should principally contain these factors:
- the extracellular matrix;
- dermal fibroblasts;
- the epidermis;
- a semipermeable membrane (between dermis and epidermis).
These components may act synergistically as part of a fully integrated tissue to
protect the underlying tissues of a wound bed and to direct healing of the wound.
Dermis containing fibroblasts may be necessary for the maintenance of the epider-
mal cell population. Actually, tissue-engineered skin products on the market would
be distinct in cellular-based and acellular products.
The immediate wound coverage is one of the needs of wound management.
Engineered epidermal constructs with qualities similar to those of autologous skin
have been used to facilitate repair of split-thickness wounds.
Autologous cultured keratinocyte grafts have been used in humans since the
1980s. As a result there has been extensive experience with cultured epidermal
grafts for the treatment of burns as well as other acute and chronic wounds [45].
Although they act as permanent wound coverage, since the host does not reject
them, disadvantages include the two to three-week time interval required before suf-
ficient quantities of keratinocytes are available.
Cultured keratinocyte allografts were developed to overcome the need for biop-
sy and cultivation to produce autologous grafts and the long lag period between epi-
dermal harvest and graft production. Cultured epidermal cells from both cadavers
and adult donors have been used for the treatment of burns [46]. Although a previ-
ous study showed that allografts made from neonatal foreskin keratinocytes were
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more metabolically active than those from cadaver, a recent study has shown that
dsuch allografts are immunogenic [47]. As an alternative, a chemically modifie
hyaluronan membrane acting as keratinocyte delivery systems was developed. In
this graft cells were delivered to the injury site via a biodegradable scaffold.
Keeping in mind that good skin regeneration requires an appropriate dermal
layer, allografts (containing dermis) from other sources have been used for many
years, although they provide only temporary coverage due to their tendency to
induce acute inflammation. However, this skin can be chemically treated to remove
the antigenic epidermal cellular elements and has been used alone or in combination
dwith cultured autologous keratinocytes for closure of various chronic wounds an
burns. In spite of these modifications, allogeneic grafts, when compared with autol-
ogous grafts, have been shown to promote lower percentages of re-epithelialization
and excessive wound contraction [48].
An acellular composite skin graft containing bovine collagen and chondroitin-6-
sulfate with an outer silicone covering was developed in the 1980s. After placement
on the wound, the acellular dermal component recruits the host dermal fibroblasts
while undergoing simultaneous degradation. About two to three weeks later, the sil-
icone sheet is removed and covered with an autograft. This composite graft has been
used successfully to treat burns [49]. However, these constructs cannot be used in
patients who are allergic to bovine products.
Another type of dermal substitute consists of an inner nylon mesh in which
human fibroblasts are embedded, together with an outer silicone layer. After an
rappropriate time, fibroblasts are lysed in the final product by freeze-thawing. Prio
dto that time, f ibroblasts  produce autologous collagen, matrix proteins, an
cytokines, all of which promote wound healing by the host.
rThis product has been used successfully as a temporary wound coverage afte
excision of burn wounds, until the appearance of the modified product on the mar-
ket. The new graft contains a biodegradable polyglactin mesh, in which fibroblasts
dretain viability, instead of the nylon mesh. The use of this dermal substitute has ha
limited success in the treatment of diabetic foot ulcers, owing largely to its inabili-
ty to form stable adhesions with the final epidermal graft [50].
Full-thickness wounds involve the loss of both the epidermal and dermal layers
of the skin. To treat such extensive wounds, a bilayered skin composite was devel-
oped consisting of a collagen sponge containing dermal fibroblasts covered with
depidermal cells. A subsequent amendment containing type I bovine collagen an
live allogeneic human skin fibroblasts and keratinocytes has been developed. It has
een use  success lly n surgica  woun s an  ve ous u cers [51]. In a mu centeb d fu i l d d n l lti r
trial, this product produced accelerated healing of chronic nonhealing venous stasis
ulcers when compared to standard compressive therapy [52].
Several other composite skin substitutes combining dermal and epidermal ele-
ments have been developed. Composite cultured skin composed of an overlay of strat-
ified neonatal keratinocytes on fibroblasts embedded in distinct layers of bovine type
I collagen is currently being evaluated in clinical trials for the treatment of burns.
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5.4 
Lung Epithelium
P. Spitalieri, M.C. Quitadamo, F.C. Sangiuolo
The adult lung is lined with numerous distinct types of epithelial cells in various
anatomical regions, progressing proximally in the order trachea  bronchi  bron-
chioles  ralveoli. The conducting airways can be further divided into two majo
rcompartments, the tracheo-bronchial and bronchiolar airways, while the alveola
regions of the lung make up the gas exchanging airspaces. Each of these regions
consists of distinct epithelial cell types with unique cellular physiologies and stem
cell compartments. In a normal steady state airway, epithelial cell proliferation in
the adult lung is much lower compared with highly proliferative compartments in
the skin, gut, and hematopoietic system. As in other adult tissues and organs, stem
cells in the adult lung are a subset of undifferentiated cells with the capacity to
maintain multipotency in the context of the physiologic domain in which they
reside. Experimental studies [53] in animals have shown the presence of different
types of stem cells along the airways, but regardless of the dominant cell type,
endogenous repair is not sufficient for the prevention of respiratory diseases and is
thus a major cause of human mortality and morbidity worldwide. Current treatments
offer no prospect of cure or disease reversal, and lung transplantation is an accept-
able means of treating several end-stage lung disease, even though donor shortage
is a major problem. Over the past few years, the number of lung transplantations
performed annually has reached a plateau as the donor pool is approaching its lim-
its and cannot be expanded further. Therefore other sources of a replacement gas-
exchange units are being sought. Xenotransplantation [54] and bioartif icial devices
[55] are possible candidates. Another possibility would be to engineer a gas-
exchange unit with some viable components in vitro. Alveoli are the basic function-
al units of lungs, and gas exchange occurs across their membranes. Therefore, the
ffirst step in tissue engineering of a lung lobe needs to be aimed at the generation o
alveolar tissue. The epithelium of an alveolus is an endoderm-derived tissue com-
posed of two main cell types: type I (ATICs) and type II (ATIICs) pneumocytes. The
dATICs are large yet highly flattened cells with multiple apical surfaces that exten
into adjacent alveoli. These cells, together with the endothelium of the surrounding
capillaries, form the very thin blood–air interface that is essential for O2/CO2
exchange. In contrast, ATIICs are small cuboidal cells that secrete surfactant, which
reduces surface tension, preventing collapse of the alveolus. It is known that the
lung is constantly exposed to environmental toxins and pathogens that can destroy
alveolar epithelial cells, in particular the thin injury-prone ATICs. If ATI cells are
lost after a peripheral lung injury, ATII cells undergo proliferation and differentia-
tion to the type I phenotype. Thus, ATII cells are crucial to the natural regenerative
process of the alveoli. In fact, ATII cells are considered as putative alveolar stem
cells [56]. Therefore, generation of ATII pneumocytes would be a good basis for tis-
sue engineering of the alveolar functional unit [57].
Inadequate, delayed, or impaired re-epithelialization of the injured alveolus is
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regarded as a key factor in the pathogenesis of several life-threatening pulmonary
diseases, including acute lung injury, acute respiratory distress syndrome, and
chronic obstructive pulmonary disease. Severe pulmonary diseases can be caused by
deficiencies or genetic mutations in proteins synthesized by ATII cells that are
important in maintaining normal lung homeostasis. For example, complete deficien-
cy of surfactant protein B (SPB) is caused by genetic mutations in the SPB gene.
This deficiency results in impaired pulmonary surfactant composition and function
and is a major cause of fatal neonatal respiratory disease. Cystic fibrosis is thought
to be primarily a disease of the upper airway and submucosal epithelia and is caused
by mutations in the cystic fibrosis transmembrane conductance receptor (CFTR)
[58]. CFTR is an important regulator of Cl- and liquid transport in the lung and is
functionally expressed by human ATII cells, strongly suggesting a critical role for
CFTR in regulating ion and fluid transport in the lung alveolus in addition to the
upper airway. Current treatments for lung alveolar epithelial injury at best provide
rsymptomatic relief but offer no prospect for repair of the damaged epithelium o
reventin  lun  fibrosis. Consequentl , there is a pressin  need for the developmenp g g y g t
yof novel therapies that facilitate the regeneration of alveolar epithelium destroyed b
acute and chronic lung diseases.
Embryonic stem cells (ESCs) are self-renewing pluripotent cells, which can be
dinduced to differentiate into a wide range of different cell types. Recently publishe
data has demonstrated that ESCs cells can be differentiated into ATII cells via embry-
onic body (EB) formation [57] or coculture of EBs with pulmonary mesenchyme [59].
ATIICs derived from ESCs may be promising as a transplantable source of cells that
rcould be used therapeutically to treat distal lung injury [60]. In fact lung progenito
fATIICs derived from human ESCs can be transplanted into a mice model o
eomyc n- uce  acute y amage  li an  at t ese ES-ATIICs arreste  bl i ind d l d d alveo d th h h d or
reversed BLM-induced pathological changes of acute lung injury, including fibrosis.
Moreover, the therapeutic benefits provided by the transplantation of hES-ATIICs
were long- term and without the development of teratomas [61].
Recently, a new source of human stem cells was isolated from amniotic fluid
(hAFSC) [62] and umbilical cord blood (uMSCs) [63]. These are multipotent, show-
ding the ability to be integrated into developing as well as injured lung tissues an
differentiate therein into lung epithelial lineages. Other authors have shown the in
vitro ability of the fetal human umbilical cord collected from pre-term newborns
(HUCPC) to migrate towards an alveolar type II cell line damaged with bleomycin,
dan anticancer agent with known pulmonary toxicity. The secretory profile exhibite
by fetal HUCPC in the migration assay suggested a paracrine effect that could be
exploited in various clinical conditions including lung disorders [64]. These sources
of stem cells could overcome all of the ethical issues concerning use of embryonic
stem cells. The possibility of deriving specific lung lineages from stem cells in vitro
has already been shown, as well as evidence that allogeneic and xenogeneic trans-
plantation of lung epithelium cells can reduce bleomycin-induced lung fibrosis in
mice after intratracheal and/or intraperitoneal injection [65]. Additional experi-
ments and different approaches are needed to optimize hES-ATIICs integration, sur-
vival and recovery of damage in mouse-model in vivo to then move on to clinical
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trials on humans for cell-based therapy, and further studies toward the use of these
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The bioartif icial liver (BAL) is an extracorporeal circulation therapeutic system
consisting of two components, an artif icial one (bioreactor) and a biological one
(hepatocytes). This system was created for the temporary treatment of patients with
acute liver failure during the wait for spontaneous recovery or an organ transplant.
Despite the increased production of the number of BAL and their current experi-
mentation, few models have been used for clinical applications.
5.5.1
Introduction
Acute liver failure (ALF) is a clinical heterogeneous entity in terms of etiology,
pathophysiology, severity and prognosis. ALF can be divided into fulminant hepat-
ic failure (FHF), which represents the most severe form; acute liver failure occur-
ring in chronic hepatitis (acute on chronic liver failure, AoCLF) and liver failure
after liver transplantation (Primary non function, PNF). Despite considerable
progress in understanding the pathophysiologic mechanisms leading hepatic failure,
the birth of special liver intensive care units and the implementation of various ther-
apies, the mortality rate for FHF today still varies from 50% to 80% cause depend-
ing. In Italy it is estimated that there are about 300-350 FHF cases each year, while
rthe figure in the United States is about 2000-3000 cases each year. Although live
transplantation has radically revolutionized the therapy of this disease, unfortunate-
ly this method is limited by the number of donated organs. For this reason there is
a need to experiment alternative approaches for liver support, which can assist the
patient with ALF until the spontaneous recovery of function or the retrieval of an
organ for transplantation. Traditional medical and pharmacologic support were
therefore flanked by artif icial biological and bioartif icial liver support techniques.
The artif icial support techniques consist of cell-free systems that exploit detoxify-
ing principles of adsorption and filtration to remove circulating toxic substances.
One interesting application is MARS, which exploits the ability of albumin to bind
the toxic substances present in the plasma of a patient with severe renal failure.
Although this method has shown an increase in patients survival with AoCLF, it has
not demonstrated improved survival in patients with fulminant hepatitis. According
to many authors, the main limits of artif icial systems are due to their inability to
substitute the metabolic and synthetic liver component.
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Recently the most studied technique of biological support has been the trans-
plantation of hepatocytes. Though promising, this method is still preclinical, since




BAL is composed of a biological component and an artif icial one. These two com-
ponents together exploit the detoxifying skills of the artif icial systems and the syn-
dthetic-metabolic ability of the liver cell. The biological component may be derive
from an isolation cell enzyme or cell lines. The cells are then incubated on three-
dimensional supports inside bioreactors of different models, but all these bioreac-
tors have as a general principle the creation of two separate compartments: the cel-
rlular compartment for hepatocytes and the circulation compartment for plasma o
human blood. The two compartments are separated by physical means which act as
semipermeable barriers, which allow the passage of toxic substances and chemical
components derived from cellular metabolism.
5.5.3
BAL Structure
The various bioreactors used differ in terms of cell types, circuitry and materials used.
dOur group has developed its experience using the Performer O. Liver BAL, produce
fin Italy in cooperation with the firm Rand Srl of Medolla (MO). The artificial part o
the O. Liver BAL consists of a plasmapheresis machine (Performer BAL), an extra-
corporeal circuit for the perfusion of hepatocytes, a bioreactor inside of which the
cells are contained, a plasma oxygenator for the perfusion of the hepatocytes and a
resin cartridge which selectively adsorbs bilirubin and bile acids (Fig. 5.1).
The extracorporeal circuit is connected to the patient through a double lumen
catheter inserted into the superficial femoral vein. The Performer BAL is a complex
device consisting of pumps for extracorporeal circulation, connected to filters in
hollow fibers of polypropylene (0.2 m2 of total strained surface) for the plasma sep-
aration with a cut-off of 0.4 mm. Using a plasma reservoir with a capacity of 2 L
and an additional peristaltic pump, a second circuit allows the plasma circulation
through the oxygenator, the bioreactor and the cartridge of synthetic resin, with a
speed of 200-250 mL/min. Oxygenation of the hepatocytes is maintained through an
oxygenator integrated in the circuit which under conditions of clinical use supplies
a mixture composed by O2 (95%) and CO2 (5%). The flow of blood is usually main-
tained at 80±20 mL/min, while the flow of plasma is 22±8 mL/min. In the liver sup-
ort s stem in question, we used an adsorbent cartrid e containin  a copol mep y g g y r
k(artif icial resin) with porosity of 300-1000 μm, with the aim of replacing the lac
r of an excretory bile tract in BAL. For our model of BAL a bioreactor (O. Live
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dcart-A, RanD S.r.l., Cavezzo, MO, Italy) has been developed specifically designe
for use with liver cells. The principle on which it has been designed is to allow
direct contact between the patient’s plasma and liver cells. For this reason the geom-
etry of radial flow was adopted, according to which the plasma diffuses from inside
to outside the bioreactor, after passing through the compartment occupied by the
cells. The porosity of the polyester membrane (1 micron) allows a broad exchange
of solutes and molecules but not the escape into the circulation of liver cells con-
tained in the bioreactor, neither during the filling phase of the bioreactor with hepa-
tocytes, nor during subsequent clinical use.
5.5.4
Clinical-Laboratory Parameters Assessed
The evaluation of patients with fulminate hepatitis and treated with BAL provides
an analysis of clinical parameters (such as neurologic function) and blood chemistry
Biotechnology in Surgery88
5
Fig. 5.1 Performer BAL and extracorporeal circuit. (Courtesy of RanD S.r.l.)
parameters (blood count, liver and kidney profile, blood clotting and blood ammo-
nium). At the same time we carry out an investigation on the functionality of the
bioreactor, espec lly w  t e execut on o  se uent  oo  as ana s on p asmia ith h i f q ial bl d g lysi l a
entering and leaving the bioreactor.
5.5.5
Clinical Trials
Many clinical applications have been conducted to date, some with excellent results
[66-68]. At the Institute Anphioxus Cell Technologies of Houston 11 patients were
treated using hepatocyte cell lines (C3A). In these 11 patients there was an average
improvement of bio-humoral parameters and in 10 of them an improvement of neu-
rological presentation. In Pittsburgh 4 patients with fulminant hepatitis were treat-
ed, using porcine hepatocytes, with a decrease in ammoniemia during treatment
being reported, but no improvement from a neurological point of view. Even in
China, at the Chinese PLA General Hospital of Beijing clinical applications have
been conducted of BAL loaded with porcine hepatocytes in 3 patients with fulmi-
nant hepatitis, with a decrease n ammoniemia and an improvement of neurological
presentation during treatment being reported. In Germany, at the Charité, Humboldt
University of Berlin 7 patients with fulminant hepatitis were treated using a BAL
loaded with porcine hepatocytes. All the patients received a transplant operation,
while not showing a sharp decrease in ammoniemia during treatment. At the same
dcenter, 4 patients with fulminant hepatitis were recently treated using BAL loade
nwith human hepatocytes from organs rejected by transplant. All patients showed a
improvement of neurological conditions, but a worsening of coagulation during
treatment. In Rome and Naples BAL loaded with porcine hepatocytes assembled at
the Academic Medical Center University of Amsterdam was used to treat 12 patients
with FHF. Improvements in neurological conditions during treatment were also
described in this case. Demetriou et al. in Los Angeles conducted the largest
prospective, randomized, controlled, multicenter trial in patients with severe hepat-
ic failure treated with the BAL loaded with porcine hepatocytes (Hepatassist
System) [69]. The study was conducted on 171 patients of whom 85 treated with
BAL and 86 patients as a control. This trial showed the safety and effectiveness in
terms of survival of BAL treatment. At our Institute of Ferrara 9 patients with ful-
minant hepatitis were treated using a BAL (O. Liver) loaded with fresh porcine
hepatocytes in 7 patients [70] or human hepatocytes from organs deemed unsuitable
for transplant in 2 patients. Of these, 7 patients received transplant after treatment
with only one death. One died while waiting for a transplant and another showed a
spontaneous recovery of liver functions. In our case we also evaluated improvement
of the neurological situation as well as the bio-humoral parameters.
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5.5.6
Conclusions
Although BAL has been shown to have a therapeutic effect, the case reports pub-
lished up to now are not enough to say with certainty that this method may produce
ra significant increase in survival in patients with severe liver failure waiting fo
transplant. In addition, various bioartif icial livers adopted to date by different
researchers differ in terms of the extracorporeal systems used and the cell source. It
is logical to think that the fresh cells, derived from healthy and young organs would
be the ideal source for this type of clinical application. It is possible to obtain the
above using porcine cells isolated and used fresh, as we did in the first 7 clinical
cases described. In many European countries, however, like in Italy, the use of ani-
mal cells is banned for health safety reasons. Therefore alternative sources need to
be used, such as human cells derived from organs deemed unsuitable for transplan-
tation. However, the inability to match the emergency clinic with the presence of an
immediately available organ prompts the need to establish a bank capable of cryop-
reserving these cells. On the other hand, although human cryopreserved cells have
shown in vitro a specific detoxifying activity and different biosynthetic activities,
when used within the bioreactor they have demonstrated limits in the biosynthesis
and duration of functional hepatocyte activity. The causes of this limitation obvious-
ly includes the cell microenvironment, consisting of the toxic patient’s plasma,
which does not facilitate the functional recovery of hepatocytes already stressed by
the processes of isolation, cryopreservation, thawing and loading in the BAL. A sig-
nificant evolution could be represented by the joint and integrated use of artif icial
and bioartif icial systems, with the first component having the role of selective
detoxif ication and the second component the role of synthesis-metabolism.
Moreover, if we continue to use human cells, it is essential to increase knowledge
dabout the cryopreservation phenomenon, to have available a cell pool as vital an
functional as possible and ensure the best performances when used within the BAL.
Many research groups are increasingly tending towards more complex bioengineer-
ing, with a reduction in the artif icial component in favor of the biological one. This
rwill develop real liver organelles, the function of which is still disputed. Even at ou
center we have performed studies on organelles consisting of porcine hepatocytes
encapsulated in a matrix of calcium alginate (Fig. 5.2). Such studies now have a role
of preclinical testing in vitro, although with encouraging preliminary results.
In conclusion, it should be borne in mind that ALF currently causes more than
30,000 deaths in Europe each year, ranking it the eighth cause of death. So there is
a constant need to work harder to develop valid liver support systems as an alterna-
tive to or interim procedure in the wait for liver transplantation. A more wide con-
sensus will be necessary in future clinical trials on BAL, particularly in the choice
of objectives, controls and indications to treatment. It is therefore desirable to
implement controlled trials in phase II and III to arrive later to clinical application
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In Vivo Imaging of Regenerated Tissue:
State of Art and Future Perspectives




Mesenchymal stem cells (MSCs) are multipotent cells which can give rise to mes-
enchymal and nonmesenchymal tissues in vitro and in vivo [1]. The distribution of
resident MSCs throughout the post-natal organism is mainly related to their exist-
ence in perivascular niches [2]. They can differentiate into osteogenic, adipogenic,
chondrogenic, myocardial, or neural lineages when exposed to specific stimuli,
making them attractive for tissue regeneration [3, 4]. Emerging evidence has shown
that MSC transplantation offers a means to stimulate tissue repair either by direct
(exogenous) or indirect (endogenous) cell replacement or angiogenesis [5, 6]. In
fact, exogenous MSCs have shown the ability to support a paracrine activation of
endogenous stem cells for tissue repair by secreting chemokines, as stromal derived
factor-1 alpha (SDF-1α), and/or growth factors, as vascular endothelial growth fac-
tor. Despite the rapid research advancement, possible tissue repair by adult stem
cell therapy is currently hampered in vivo by poor cell viability and delivery effi-
ciency, uncertain differentiating fate, and therefore the use of this approach has
raised a number of bioethical questions [7]. Hence, the strong need for more effec-
tive therapeutic approaches emphasizing the physiological plasticity of postnatal
organs following an injury [8, 9], and more accurate imaging methods to allow a
long-term in vivo monitoring of tissue regeneration [10]. Indeed, one of the most
important accomplishments of modern physiology is the development of imaging
techniques able to explore biochemical/molecular processes in the intact organism,
i.e. in the absence of confounding effects inevitably caused by invasive procedures
or ex vivo experimental preparations. Modern imaging technologies allow for
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visualization of multidimensional and multiparameter data. Imaging is increasingly
dused to measure physical parameters, such as concentration, tissue properties, an
surface area, and to glean temporal insight on biological functions. With the advent
of molecular probes, imaging can be conducted not only to visualize gross anatom-
ical structures, but also to visualize substructures of cells and monitor molecule
ddynamics. Thus, different modalities can be used for non-invasive conventional an
molecular imaging of regenerated tissues in vivo, such as positron emission tomog-
raphy (PET), single photon emission computed tomography (SPECT) and magnetic
resonance imaging (MRI). Moreover, targeted and conventional ultrasound modali-
ty is even starting to play a role in regenerative medicine due to resolution, low-cost
dand availability compared to SPECT, PET, MRI, computed tomography (CT) an
optical imaging [11]. The translation of new integrated imaging approaches into
effective noninvasive follow-up of tissue repair is emerging as an outstanding area
dof progress for regenerative medicine over the next decades and has already foun
broad application in cardiac cell therapy (Fig. 6.1). 
6.2 
Conventional Imaging of Regenerated Tissue
The regenerative process involves the replacement of dysfunctional and/or fibrotic
atissue with differentiated and organ-specific new cells, well organized both from 
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Fig. 6.1 Conventional noninvasive imaging techniques in cardiac regeneration
structural that functional aspect, also in response to extracellular matrix (ECM)
kdegradation products [12]. The regenerated tissue needs to be perfused by a networ
of well differentiated neovessels branching within the ECM and functionally adapt-
red to the resident vascular architecture [13]. PET modality is the gold standard fo
noninvasive assessment of tissue viability and allows an accurate detection of vas-
cular network by measurement of tissue blood flow, respectively through the
intravascular injection of 18F-fluorodeoxyglucose (18F-FDG) or C-11-acetate [14]
and 13N-labeled ammonia (13NH3 r) [15]. Other PET radiotracers are currently unde
investigation to visualize cell proliferation within viable tissue, such as 3’-deoxy-
3’-[18F]-fluorothymidine [16] which could be very useful in the potential monitor-
ing of the activated resident stem cells during regeneration. Recent studies demon-
strated the utility of PET in visualizing the tissue before and after a regenerative
therapy in different types of tissue, such as the heart [17] and the nervous system
[18]. Although radiotracers visualize certain normal anatomical structures, the spa-
tial resolution is generally inadequate for accurate anatomic localization of the
treated region. Conversely, MRI provides high resolution anatomical images that
fallow accurate regional evaluation of tissue structure and function, detection o
interstitial f ibrosis following cell therapy in the heart [19], cartilage [20] and nerv-
ous tissue [21]. MRI is a highly versatile imaging technique that enables different
applications to be performed depending on the type of study. Functional MRI
(fMRI), a specialized MRI application, is able to measure the hemodynamic
response (changes in blood flow) related to neural activity in the brain or spinal
cord. It might provide new insights into the role of adaptive changes in limiting the
clinical consequences of irreversible structural damage. In fact, when nerve cells are
active they increase their consumption of oxygen, switching to more rapid anaero-
bic glycolysis, and thus the regional blood flow increases [22]. Furthermore, MRI
could also be a sensitive and efficient tool to study tissue metabolism in vivo using
hyperpolarized 13-C pyruvate, a well known substrate of oxidative metabolism [23].
As a well established index of cell viability in vivo, pyruvate metabolism might
dtherefore particularly benefit from noninvasive regional imaging of regenerated an
injured tissue. Combining PET with a high-resolution anatomic imaging modality,
such as CT or MRI, can resolve the localization issue as long as the images from the
two modalities are accurately coregistered [24]. Compared to two stand-alone
machines, the combination of a PET and CT/MRI scanner into a single gantry also
rovides greater conven ence, fl ibility, an  spee  o  mu mo lity mag ng op i ex d d f r lti da i i f
tregenerated tissue, which would seem like normal tissue. In this regard, a recen
study by Lionetti et al. [8] showed that the regenerated myocardium in a rodent
model of myocardial infarction is characterized by normalization of 18F-FDG
myocardial uptake, assessed by mini-PET, reduction of fibrosis, detected by
gadolinium delayed-enhancement MRI, and improvement of left ventricular remod-
eling and contractile function.
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6.3 
Molecular Imaging of Regenerated Tissue
Molecular imaging describes a heterogeneous family of noninvasive imaging tech-
niques that have been developed for use in both basic and clinical settings. This
modality encompasses the myriad of different optical techniques that have been
developed to profile cell properties, such as protein expression, cellular and molec-
ular traff icking, gene expression, enzyme activity, and pH. The techniques
employed for these diverse applications differ in terms of the capabilities of the
detectors (spatial resolution and sensitivity); properties of the imaging probes (tox-
icity, bio-distribution and specificity for target); and practical issues such as image
dacquisition time and costs [25]. Ultimately, the use of a molecularly targete
nanoplatform affords many advantages over established approaches. First, more
imaging labels or a combination of labels for different imaging modalities can be
attached to a single nanoparticle, which can lead to merge different signals from the
same target tissue in vivo. Second, multiple, potentially different, targeting ligands
on the nanoparticle can provide enhanced binding affinity and specificity. Third, the
ability to integrate a means to bypass biological barriers can enable enhanced tar-
geting efficacy [26].
The visualization of biological processes in living systems, such as regeneration
and repair of injured tissue, has the main expectation in localization and quantifica-
tion of molecular changes associated with a disease at an early stage rather than
later when morphological changes have occurred [27]. For this purpose, the appli-
dcation of nanotechnology to imaging allows transplanted stem cells to be tracke
and guided, as well as understanding the roles of paracrine signals following the
secretion of soluble factors, the cell-cell interactions or the action of physical
forces. An innovative approach to harnessing the respective strengths of various
dimaging platforms is the creation and use of specific contrast agents [26] an
reporter genes [28]. Fusion reporter constructs, such as red fluorescent protein
(RFP) [29], f irefly luciferase (fluc) [28], herpes simplex virus thymidine kinase
(HSV-tk) [30] and heavy chain of ferritin (FTH) [31], have been identified as poten-
tial tools in molecular imaging of regenerated tissue (Fig. 6.2). Non-invasive molec-
dular imaging of dynamic processes, such as tissue regeneration, has benefite
tremendously from the use of reporter genes encoding for proteins that emit light,
bind radiolabeled probes, or modulate MRI contrast. Indeed, the above constructs
mainly make available the use of the following imaging modalities: optical fluores-
dcence, bioluminescence, PET and MRI. In addition, contrast-enhanced ultrasoun
(CEU) techniques using site-specific microbubbles have been developed for the
molecular imaging of the vascular phenotype, which characterizes neoangiogenesis,





MRI Molecular Imaging: Contrast Agents and Reporter Genes
In providing information regarding the transplanted stem cells, MRI offers several
advantages, such as high resolution, speed, easy accessibility and 3D capabilities. A
significant advantage of MRI is that it provides information regarding the surround-
ing tissues (e.g. edema, lesion or inflammation), which may have an effect on the
fate of grafted stem cells or may hinder the recovery of damaged tissues. Due to its
biocompatibility and strong effects on T2(*) relaxation, iron oxide nanoparticles
(SPIONs) appear to be the contrast agent of choice, and several methods now exist
to shuttle sufficient amounts of these compounds into stem cells. Dextran and other
polymer-coated SPIONs are currently used in a number of biomedical applications
[33]. Stem/progenitor cells can be acutely labeled with dextran-coated SPIONs by
modifying their surfaces with internalizing ligands, such as the HIV-Tat peptide,
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Fig.6 2 Reporter genes in vivo.
a PET image of stem cells la-
beled with herpes simplex
virus thymidine kinase (HSV-
tk) injected in skeletal muscle
(green circle) compared to
untreated leg (orange circle);
b MRI T2* image of stem
cells labeled with human





dendrimers and polycationic transfection agents [34]. In particular, dendrimer com-
posites of iron oxide nanoparticles, also known as magnetodendrimers, represent a
versatile new class of contrast agent for MRI. They were developed by Bulte et al.
and label living cells efficiently, including stem/progenitor cells without affecting
their phenotype and growth rate [35]. In a recent study, Wang et al. labeled neural
stem cells with gold-coated monocrystalline SPIONs [36]. The MRI signals persist-
ed 1 month postsurgery and the gold surface protected the nanoparticles from being
digested by the macrophages. It was concluded that gold-coated SPIONs may repre-
sent a class of superior MRI labels for long-term in vivo tracking of stem cells.
Despite these promising results, the contrast agents listed above do not allow a sta-
ble visualization of stem cell-derived cells or dividing cells in vivo. For this pur-
pose, it is conceivable to label stem cells with reporter genes [37].
Several strategies exist to modulate MRI contrast by expression of reporter gene
finto transplanted stem cells: using enzyme-catalyzed chemical modification o
metal-based contrast agents or (phosphorus) metabolites, such as creatine kinase, an
enzyme that catalyzes ATP conversion to ADP producing phosphocreatine (PCr),
detected by 31P magnetic resonance spectroscopy [38]; iron-binding and iron-stor-
age proteins to accumulate iron as a contrast agent, such as transferrin receptor [39]
and heavy chain of ferritin [40]; artif icial proteins for imaging based on chemical
exchange saturation transfer (CEST), such as a lysine rich protein (LRP), contain-
ing a high density of amide protons [37]. Ultimately, CEST contrast agents have two
major advantages. First, they are switchable, i.e. the contrast is detectable only when
a saturation pulse is applied at the specific frequency characteristic of an agent’s
dexchangeable protons. Otherwise, the contrast agent is MRI-invisible. The secon
advantage is that different contrast agents with different excitation frequencies can
be used for imaging simultaneously more than one target. This property might be
exploited for imaging multiple cells (e.g. for studying neuronal circuits) or the
expression of multiple genes (such as in genetic circuits). Despite the technological
rdevelopment, MRI reporter genes need further improvement to facilitate their wide
use to track stem cells and follow their specific differentiation during regeneration
of injured tissue in vivo. In addition, the acquisition of more specific reporter-
dinduced MRI contrast may be achieved using optimized pulse sequences an
improved ways of image processing. Reporter genes might be improved through
directed evolution in a fashion similar to that accomplished for the fluorescent
reporter genes. A key challenge would be to resolve multiple targets while perform-
ing simultaneous imaging. This could include different reporters driven by different
inducible promoters or developing sophisticated data processing algorithms to dis-
tinguish gene expression temporally as well as spatially. However, from the clinical
point of view there are still a few significant hurdles before reporter genes can be





With the rapid increase of reported cases of stem cells being used to treat tissue
injury, it has become apparent that an urgent need exists to track stem cells in vivo
during clinical trials. The problem of imaging small numbers of cells in the living
subject is not limited to stem-cell-based treatments in cardiology, but has broad
applicability in oncology, surgery, and transplantation. Successful in vivo imaging
requires that a contrast agent or reporter genes associated with a stem cell exert an
effect size sufficient for detection by imaging hardware. In addition, the exogenous
contrast agent and reporter genes must be biocompatible, safe, and nontoxic.
Imaging technology has also a significant clinical relevance, but no currently avail-
able imaging technology is ideal. MRI provides excellent 3-dimensional anatomy
but some contrast techniques have low sensitivity. However, multimodality contrast
agents might improve the prospects for stem cell tracking both in vivo and ex vivo
in regenerative medicine. First and foremost, impending clinical trials utilizing stem
cells must carefully define the limits of the imaging technology chosen.
References
1. Bernardo ME, Locatelli F, Fibbe WE (2009) Mesenchymal stromal cells. Ann N Y Acad Sci
1176:101-117
2. da Silva Meirelles L, Caplan AI, Nardi NB (2008) In search of the in vivo identity of mes-
enchymal stem cells. Stem Cells 26:2287-2299
3. Benayahu D, Shefer G, Shur I (2009) Insights into chromatin remodelers in mesenchymal stem
cells and differentiation. Front Biosci 14:398-409
r4. Ventura C, Cavallini C, Bianchi F et al (2008) Stem cells and cardiovascular repair: a role fo
natural and synthetic molecules harboring differentiating and paracrine logics. Cardiovasc
Hematol Agents Med Chem 6:60-68
5. Anversa P, Leri A, Rota M et al (2007) Concise review: stem cells, myocardial regeneration,
and methodological artifacts. Stem Cells 25:589-601
d6. Gnecchi M, Zhang Z, Ni A et al (2008) Paracrine mechanisms in adult stem cell signaling an
therapy. Circ Res 103:1204-1219
7. Hyun I (2010) The bioethics of stem cell research and therapy. J Clin Invest 120:71-75
8. Lionetti V, Cantoni S, Cavallini C et al (2010) Hyaluronan mixed esters of butyric and retinoic
acid affording myocardial survival and repair without stem cell transplantation. J Biol Chem
285:9949-9961
9. Forini F, Lionetti V, Ardehali H et al (2010) Early long-term L-T3 replacement rescues mito-
chondria and prevents ischemic cardiac remodeling in rats. J Cell Mol Med doi: 10.1111/j.1582-
4934.2010.01014
10. Lee Z, Dennis JE, Gerson SL (2008) Imaging stem cell implant for cellular-based therapies.
Exp Biol Med (Maywood) 233:930-940
11. Leong-Poi H (2009) Molecular imaging using contrast-enhanced ultrasound: evaluation of an-
giogenesis and cell therapy. Cardiovasc Res 84:190-200
6 In Vivo Imaging of Regenerated Tissue: State of Art and Future Perspectives 101
12. Agrawal V, Johnson SA, Reing J et al (2010) Epimorphic regeneration approach to tissue re-
placement in adult mammals. Proc Natl Acad Sci U S A 107:3351-3355
13. Kilarski WW, Samolov B, Petersson L et al (2009) Biomechanical regulation of blood vessel
growth during tissue vascularization. Nat Med 15:657-664
14. Schröter G, Schneider-Eicke J, Schwaiger M (1994) Assessment of tissue viability with flu-
orine-18-fluoro-2-deoxyglucose (FDG) and carbon-11-acetate PET imaging. Herz 19:42-50
15. Endo M, Yoshida K, IinumaTA et al (1987) Noninvasive quantification of regional myocar-
dial blood flow and ammonia extraction fraction using nitrogen-13 ammonia and positron emis-
sion tomography. Ann Nucl Med 1:1-6
r16. Grierson JR, Shields AF (2000) Radiosynthesis of 3’-deoxy-3’-fluoro-thymidine: 18F-FLT fo
imaging cellular proliferation in vivo. Nucl Med Biol 27:143-156
17. Kendziorra K, Barthel H, Erbs S et al (2008) Effect of progenitor cells on myocardial perfu-
sion and metabolism in patients after recanalization of a chronically occluded coronary ar-
tery. J Nucl Med 49:557-563
18. Jackson J, Chapon C, Jones W et al (2009) In vivo multimodal imaging of stem cell trans-
plantation in a rodent model of Parkinson’s disease. J Neurosci Methods 183:141-148
19. Fuster V, Sanz J, Viles-Gonzalez JF et al (2006) The utility of magnetic resonance imaging in
cardiac tissue regeneration trials. Nat Clin Pract Cardiovasc Med 1:S2-S7
20. Watrin-Pinzano A, Ruaud JP, Cheli Y et al (2004) T2 mapping: an efficient MR quantitative
technique to evaluate spontaneous cartilage repair in rat patella. Osteoarthritis Cartilage
12:191-200
21. Filippi M, Agosta F (2009) Magnetic resonance techniques to quantify tissue damage, tissue
repair, and functional cortical reorganization in multiple sclerosis. Prog Brain Res 175:465-
482
22. Raichle ME, Mintun MA (2006) Brain work and brain imaging. Annu Rev Neurosci 29:449-
476
23. Yen YF, Kohler SJ, Chen AP et al (2009) Imaging considerations for in vivo 13C metabolic
mapping using hyperpolarized 13C-pyruvate. Magn Reson Med 62:1-10
24. Pichler BJ, Wehrl HF, Kolb A et al (2009) Positron emission tomography/ magnetic resonance
imaging: the next generation of multimodality imaging? Semin Nucl Med 38:199-208
25. Hoffman JM, Gambhir SS (2007) Molecular imaging: the vision and opportunity for radiol-
ogy in the future. Radiology 244:39-47
26. Cormode DP, Skajaa T, Fayad ZA et al (2009) Nanotechnology in medical imaging: probe de-
sign and applications. Arterioscler Thromb Vasc Biol 29:992-1000
27. Schroeder T (2008) Imaging stem-cell-driven regeneration in mammals. Nature 453:345-351
28. Serganova I, Mayer-Kukuck P, Huang R et al (2008) Molecular imaging: reporter gene imag-
ing. Handb Exp Pharmacol (185 Pt 2):167-223
29. Lee SW, Padmanabhan P, Ray P et al (2009) Stem cell-mediated accelerated bone healing ob-
served with in vivo molecular and small animal imaging technologies in a model of skeletal
injury. J Orthop Res 27:295-302
30. Wang X, Mao X, Xie L et al (2009) Involvement of Notch1 signaling in neurogenesis in the
subventricular zone of normal and ischemic rat brain in vivo. J Cereb Blood Flow Metab
29:1644-1654
31. Liu J, Cheng EC, Long RC et al (2009) Noninvasive monitoring of embryonic stem cells in
vivo with MRI transgene reporter. Tissue Eng Part C Methods 15:739-747
32. Lionetti V, Paddeu S (2010) Towards ultrasound molecular imaging. In: Paradossi G, Pelle-
rgretti P, Trucco A (Eds.): Ultrasound contrast agents: targeting and processing methods fo
theranostics. Springer-Verlag Italia, Milan, pp 1-11
33. Corot C, Robert P, Idée JM et al (2006) Recent advances in iron oxide nanocrystal technolo-
gy for medical imaging. Adv Drug Deliv Rev 58:1471-1504
34. Lewin M, Carlesso N, Tung CH (2000) Tat peptide-derivatized magnetic nanoparticles allow
Biotechnology in Surgery102
6
in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18:410-414
35. Bulte JW, Douglas T, Witwer B (2001) Magnetodendrimers allow endosomal magnetic label-
ing and in vivo tracking of stem cells. Nat Biotechnol 19:1141-1147
36. Wang FH, Lee IH, Holmström N et al (2006) Magnetic resonance tracking of nanoparticle
labelled neural stem cells in a rat’s spinal cord. Nanotechnology 17:191
37. Gilad AA, Ziv K, McMahon MT et al (2008) MRI reporter genes. J Nucl Med 49:1905-1908
38. Ki S, Sugihara F, Kasahara K et al (2006) A novel magnetic resonance-based method to meas-
ure gene expression in living cells. Nucleic Acids Res 34:e51
39. Pawelczyk E, Frank JA (2008) Transferrin receptor expression in iron oxide-labeled mesenchy-
mal stem cells. Radiology 247:913
40. Campan M, Lionetti V, Aquaro GD et al (2009) Stem cells transduction with ferritin as a re-
porter gene to track their fate by 1.5 Tesla MRI, in the beating heart. Circ Res 105:e62
6 In Vivo Imaging of Regenerated Tissue: State of Art and Future Perspectives 103
Biotechnology in Surgery. Alfonso Barbarisi (Ed.)
© Springer-Verlag Italia 2011
105
Biotechnological Approaches 
to Hemostasis and Molecular 
Mechanisms of Wound Healing
A. Grimaldi, F. Rosso, A. Barbarisi
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7.1
Biotechnology for Hemostasis Control
Wounds today remain a difficult clinical problem due to early or late complications
that are a frequent cause of mortality. To try to resolve this problem, many studies
have focused on understanding physiologic healing and wound care, with particular
emphasis on new therapeutic approaches and the continued development of
biotechnology for the management of acute and long term injuries. Normal wound
healing is a dynamic and complex process involving a series of coordinated events,
including bleeding, coagulation, initiation of an acute inflammatory response to the
initial injury, regeneration, migration and proliferation of connective tissue and
parenchyma cells, as well as synthesis of extracellular matrix proteins, remodeling
of new parenchyma and connective tissue and collagen deposition. Lastly, increas-
ing wound strength takes place in an ordered manner and culminates in the repair
of severed tissues [1].
Hemostasis is the first event involved in wound healing; it is an ensemble of
biotechnology processes which act to prevent or stop both arterial and venous
bleeding, with subsequent lesion repair in blood vessels and restoration of the func-
tionality of damaged tissue. Hemostasis occurs spontaneously through the coagula-
tion processes, or can be mechanically induced in surgery, which is the crucial part
of surgery.
The process of coagulation and subsequent tissue repair can be broken down
into four basic steps:
- when vascular trauma occurs, there is a reflex constriction to restrict blood
flow;
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- subsequently the platelets are activated by thrombin. They aggregate at the site
of the lesion and form a temporary plug. The protein fibrinogen is primarily
responsible for platelet aggregation. When platelets are activated, several impor-
tant factors in the coagulation cascade are released, such as the nucleotide ADP,
the eicosanoid TXA2, serotonin, phospholipids and lipoproteins. Moreover,
platelets also change their shape to accommodate plug formation;
- at this point a fibrin network is formed, known as a clot, which traps the plug to
ensure stability;
- lastly the clot must be dissolved to allow normal blood flow once tissue repair
has occurred. This is done by plasmin [2].
There are two pathways for fibrin clot formation: the intrinsic and extrinsic
pathway. The intrinsic pathway is mainly activated by exposed collagen, following
vessel rupture. It binds to factor XII and the coagulation cascade starts. The extrin-
sic pathway instead is activated by tissue factor, which is released after tissue
injury; it forms an activated complex with factor VII to initiate coagulation process-
es. Both pathways converge in a common pathway, where thrombin converts f ibrino-
gen into fibrin monomers, which cross-link with the help of factor XIII and calci-
um to form a fibrin polymer and then the clot [2].
7.2 
Hemostatic Agents and their Mechanism of Action
Adequate hemostasis is a prerequisite for the success of any surgical procedure [2].
Hemorrhages and bleeding that occur during surgery are usually due to ineffective
local hemostasis, although hemostatic defects arising from the patient can occur.
Currently, the procedures used in surgery for hemostatic control can be chemical,
dmechanical and thermal. However, these systems may not be sufficient for goo
hemostasis, so much so that the search for biomaterials that can repair damaged tis-
dsues and simultaneously stop the bleeding is intense. Of course, these agents shoul
not be considered substitutes for meticulous surgical practices.
Biomaterials may have a biological nature such as blood products, a natural
source such as collagen, or they may be of synthetic origin such as polymers of var-
ious substances, chemical composition and physical appearance. They must have
basic characteristics to be useful in surgery, such as bio-reabsorption, biodegrada-
tion, biofunctionality, sterility and lack of immunogenic reaction from foreign bod-
ies [3].
Biomaterials that support surgery in hemostasis resolution can be divided into
topical hemostats, sealants, and adhesives. Hemostats are capable of clotting blood;
sealants can provide a sealing barrier in the presence or absence of blood; and adhe-
sives bond tissues together [4]. Hemostatic agents include collagen, gelatin and cel-
lulose, while an example of a sealant is f ibrin glue. Sealants or adhesive can also be




Collagen and Gelatin Sponges
dCollagen is derived from bovine collagen and can be produced in fibrillar an
microfibrillar forms. These agents act as a matrix for clot formation and strength-
nening and also reinforce platelet aggregation, degranulation, release of coagulatio
rfactors, which combined with the plasma factors produce a fibrin clot. The majo
concerns with bovine collagen, in term of safety, are swelling with tissue compres-
sion, a potential nidus of infection, or adhesion formation. For these reasons, sur-
geons tend to make limited use of it and remove any excess material. As all bovine
collagen products contain small amounts of bovine serum proteins, which may
increase immunologic titers, these bovine collagen products should not be used in
patients who are allergic to the material. In fact all of these agents can cause foreign
body reactions. Their absorption occurs in about 8 to 10 weeks and they should not
be used for skin closure as this may prevent healing in the presence of methyl
methacrylate glues as they reduce glue adherence, nor should they be used with
lood salvage systems because their strands can be smaller than the 40-mm filteb r
rsize available in such systems. Lastly, these products have a potential for alveola
osteitis in dental extractions and in otolaryngologic surgery. With respect to effica-
cy, when conventional techniques are ineffective these products may provide hemo-
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Fig. 7.1 Hemostatic agent: site of action in coagulation cascade
stasis within 1 to 5 minutes. They are supplied in a variety of sponge sizes and some
of the flours are provided in syringes and laparoscopic applicators to enhance the
applicability of the product. These products are not to be re-sterilized. They are
inactivated by autoclaving and their combination with ethylene oxide produces eth-
ylene chlorohydrin. Both in vitro and in vivo studies suggest that bovine collagen
products may be the most efficacious of the mechanical hemostats [5].
The most commonly used hemostatic collagens include Floseal®, Tissufleece®
and Gentafleece®. Tissufleece® is a collagen sponge with hemostatic effect but
without adhesive properties; with the addition of gentamicin it becomes
Gentafleece® [3], a flap of native collagen of equine origin that promotes adhesion
and aggregation of platelets; it can be stored at room temperature and can also be
used in combination with the application of fibrin glue.
fFloseal® consists of thrombin and a gelatin matrix produced by the extraction o
collagen from bovine corneal tissue. Both components act synergistically to allow
clot formation at the bleeding site. Floseal® matrix, in the form of a high viscosity
gel, conforms to any type of injury. It can act on all types of bleeding: capillary,
venous and arterial. It works in minutes and its absorption typically occurs 6-8
dweeks after application. Floseal® also allows the excess product to be removed, an
in this way its effectiveness can be verified to ensure a lower risk of foreign body
reaction and always ensure the clean field at the site of bleeding. The effectiveness
of Floseal® has been demonstrated in studies of general, vascular and cardiotho-
racic surgery [2].
Gelatin sponges are a protein mixture obtained from collagen and materials rich
in collagen. They have the ability to dissolve in hot water to form colloidal solutions
that, if sufficiently concentrated, cold coagulate into a colloidal solid mass (hydro-
gel). In the strictly medical f ield they are used for their hemostatic properties in
internal bleeding, by parenteral administration or more often for local application.
dThanks to their composition they have the advantage of being completely absorbe
by the tissues and can therefore be left in situ during surgery. Typically, the gelatin
sponge is used to stop bleeding in the cavity communicating with the outside,
because once soaked in blood, despite the addition of antibiotics or antiseptics, it
becomes the site of microbial growth.
Spongostan®/Surgifoam® is a gelatine based absorbable hemostat. It absorbs
d45-50 times its own weight in blood and within 4-6 weeks it is completely absorbe
by the human body. The gelatine sponge is available in different sizes to address
specific surgical needs and it can be cut into the desired size or shape without frag-
mentation. The sponge can be applied dry or moistened with sterile saline or throm-
bin. Spongostan®/Surgifoam® has an impressive safety record. It has been used in
over 100 million surgical procedures throughout the world. The easy preparation,
the versatility and the unique safety profile makes Spongostan®/Surgifoam® an
excellent choice when a professional and reliable hemostatic product is needed.
Spongostan®/Surgifoam® is also available as powder. The powder is mixed with
saline or thrombin and after mixing it becomes a pliable mass that can be applied on
rough and uneven cut surfaces, it covers them completely and induces hemostasis
rapidly. Spongostan® Powder/Surgifoam® Powder is supplied in a ready to use ster-
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ile mixing container that makes mixing easier, ensures mix consistency and prevents
the powder from dispersing.
7.2.2
Oxidized Cellulose
rThese products are derived from cotton cellulose and can be provided in single o
multiple sheets. There are three formulations provided for oxidized regenerated cel-
dlulose, and they come in a variety of sheet sizes. The standard form is a perforate
single sheet, the fibrillar form is of a more cotton sponge-like consistency, and the
more tightly knitted form comes as a thicker almost fabric-like material.
Oxidized cellulose sheets are able to create an acidic environment and are bac-
tericidal. When conventional methods are impractical or ineffective, oxidized regen-
erated cellulose is indicated for control of capillary, venous, and small arterial
bleeding. Beyond the mechanical effect, the cellulosic acid within the product facil-
itates hemostasis by denaturing blood proteins. This agent is absorbed in about 14
hdays. They are best used dry and can be best removed by gentle irrigation wit
saline. The acidic pH inactivates thrombin so the effectiveness of oxidized regener-
ated cellulose may not be enhanced with thrombin. Oxidized regenerated cellulose
dis not compatible with autoclaving or gas sterilization, thus it cannot be re-sterilize
[5]. The most commonly commercial agent used in this group is Surgicel®
(Ethicon), which has high tensile strength and can give excellent coverage in the
presence of heavy bleeding. Two forms are available, a tightly woven knitted patch
and a fibrillar form that can be used in thin layers, as tufts, or in a roll or pad. Once
hemostasis has been obtained, the product should be removed, although it can be
absorbed by the body [6].
7.2.3
Fibrin Glue
Fibrin glue has been considered by many surgeons as the product that comes clos-
est to the ideal topical glue [7, 8]. Fibrin glue is composed of a fibrinogen concen-
trate (concentrate which also contains other factors active in hemostatic processes
such as factor XIII, f ibronectin and aprotinin) and thrombin solutions. Upon use the
two components are mixed in the presence of calcium ions, thus reproducing the
final stages of the coagulation process: thrombin induces detachment of fibrinopep-
tides A and B from the respective fibrinogen chains A-alpha and B-beta and forma-
tion of fibrin monomers which polymerize immediately by weak hydrogen bonds to
form a first gelatinous and unstable clot. Factor XIII, following thrombin activation
and in the presence of calcium ions, catalyzes the conversion of the weak hydrogen
bonds between fibrin monomers in strong covalent bonds and consequently induces
the formation of a stable, insoluble and non-friable clot. Factor XIII also induces the
plasmin inhibitor (a2 plasmin inhibitor) to bind to the clot and protect it from pre-
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mature degradation by the plasmin in plasma. Factor XIII, lastly, interacts with
ffibronectin and other plasmatic glycoproteins to contribute to increased adhesion o
the clot at the site of the lesion [8, 9]. The fibrin glue is nontoxic to the tissue on
which it is applied; it promotes the formation of a clot with good adherence to the
tissues in seconds; it is completely reabsorbed in a few days and it is able to stimu-
late the processes of tissue repair and growth of the injured tissue on which it is
applied [7]. Currently different types of fibrin glue are used; they are normally
divided into two categories, commercial products and those made in the laboratory
(or home-made), which differ in the methodological preparation of fibrinogen con-
fcentrate. Fibrinogen in commercial products is extracted from a large number o
plasma units, while in the home-made fibrin glue fibrinogen is obtained from indi-
vidual units of allogeneic or autologous plasma mainly through a process of cryo-
recipitation. Both fibrin lue preparations trade and home-made  are widel  usep g ( ) y d
in various fields of surgery with the following objectives: facilitate tissue adhesion,
assist surgical sutures and facilitate hemostasis [7, 9-11]. The most common clini-
cal applications of fibrin glue are in cardiovascular surgery, thoracic surgery, and in
rneurosurgery. Important results have also been obtained in abdominal surgery, live
and maxillofacial surgery. The wider experience of fibrin glue is probably in the
cardiovascular area where these products have been used as hemostatic agents to
rreduce slow and diffuse bleeding which occurs over large areas of cut surfaces o
along lines of anastomosis vascular suture or needlestick sites. Several studies pub-
lished in this area seem to show the effectiveness of fibrin glue in reducing bleed-
ing in coronary bypass and congenital heart disease surgery [12]. Important results
have been obtained in thoracic surgery, particularly for the treatment of bronchial
injuries or fistulas leaking gas, and in resection or pulmonary decortication. In the
field of neurosurgery fibrin glue has been used successfully in the treatment of dura
breaches with liquor loss and as a sealant in vascular intracranial anastomosis or in
dura suture after craniotomy. Fibrin glue has also been successfully used to control
bleeding after dental extractions or during minor surgical procedures in patients at
high bleeding risk due to congenital clotting defects or anticoagulant therapy [8,
10]. Lastly, f ibrin glue has been widely used with excellent results in plastic surgery
(especially to facilitate the engraftment of skin grafts in burns patients) and in max-
illofacial surgery. In Europe several commercially available products are currently
ridentified as fibrin glue, among which the most commonly used are known unde
their trade name: Tissucol® / Tissel®, Beriplast®, Tachosil® and Quixil®.
Tissucol®/Tissel® is a two-component fibrin glue consisting of human fibrino-
gen and human thrombin. Mixing the two components reproduces the latter stages
of the natural coagulation cascade. It also contains fibronectin, factor XIII, plas-
minogen, aprotinin, grown factors (EGF, bFGF, TGFβ1, VEGF) and calcium chlo-
ride. The fibrin clot formed by tissucol has a similar structure to that of a physio-
logical clot. It has a preparation time of ten minutes, forming a strong bond that
interacts with the molecular structure of damaged tissue and renders the open tissue
channels impermeable. The product provides significant adhesive force and joins
elevated flaps to underlying tissues, promotes hemostasis and renders capillaries
impermeable. Tissucol® is efficacious in active or capillary bleeding, in association
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with topical hemostatic collagen. It also is independent of coagulation system of the
patient and contains a safe inhibitor of fibrinolysis that allows the product to remain
intact for 7-10 days.
fAlso Beriplast® is a two component plasma-derived fibrin glue composed o
human fibrinogen and human thrombin. It also contains fibronectin, factor XIII,
plasminogen, aprotinin, and calcium chloride. It activates fibrinogen by thrombin
and is used simultaneously with specific devices. The product is adapted to promote
fhemostasis and sealing in all f ields of surgery. Unlike Tissucol, the inconsistency o
the clot formed by Beriplast, the transparency of the clot itself (which renders it
fmore difficult to identify at the site of application and to remove it in the event o
excess) and above all its dubious biocompatibility may reduce or even eliminate its
regenerative power at the tissue level.
Tachosil® is a solid state fibrin glue on a support of equine collagen, with
human fibrinogen and human thrombin; it also contains riboflavin, human albumin,
rsodium chloride, sodium citrate and L-arginine-hydrochloride. No aprotinin, facto
XIII or f ibronectin are present. It is indicated as a treatment support for improving
hemostasis in surgery where standard techniques are insufficient. Efficacy has only
been demonstrated in liver surgery.
Quixil® consists of a concentrate of human clottable proteins, tranexamic acid,
human thrombin and CaCl2 f; no aprotinin is present. It activates clottable proteins o
thrombin and forms an instant f ibrin clot. The product is transparent in appearance,
non physiological and non elastic. It is an antifibrinolytic and is very safe thanks to
the presence of high concentrations of tranexamic acid and double viral inactivation.
The application site should be dry; the product is indicated to facilitate hemostasis
in all surgical branches (except neurosurgery) although its effectiveness has only
been demonstrated in liver surgery and orthopedics.
7.2.4
Synthetic Sealants and Adhesives
The cyanoacrylates are a group of fast-acting adhesives currently approved for top-
ical use and not internally. Glubran® is a synthetic surgical glue based cyanoacry-
late with marked hemostatic and adhesive properties which, once solidified, builds
an effective antiseptic barrier against the most common infective or pathogenic
agents in surgery. Glubran® is a transparent, light yellow liquid ready for use. It
polymerizes rapidly upon contact with live tissue and wet environment, creating a
thin elastic film with high tensile strength that ensures strong adhesion of tissues.
This film conforms naturally to the tissues on which it is applied, is impermeable
and is not affected by blood and organic fluids. The film, once solid, can be easily
crossed by a suture needle. Polymerization time varies depending on the type of tis-
sue with which the glue comes into contact, the nature of liquid present and the
amount of product applied. Under conditions of correct application, the glue begins
rto solidify after about 1-2 seconds, completing its solidification reaction afte
around 60-90 seconds. After this reaction, the glue reaches its maximum mechani-
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cal strength. Once solidified the glue has no adhesive power. Under normal surgical
roce ures t e adhes  m s remove   ro c ra at on; t e urat on op d h ive fil i d by hyd lyti deg d i h d i f
this process varies by tissue type and the amount of glue applied. Glubran® is used
in traditional surgery and laparoscopy and in digestive tract endoscopy, interven-
tional radiology and vascular neuroradiology. It can be applied alone or in combina-
tion with sutures even in patients undergoing treatment with heparin.
Coseal® is a synthetic hydrogel composed of two ethylene glycol solutions which
polymerize with a HCl buffer solution to form covalent bonds with tissues and synthet-
ic surfaces. It seals mechanically and needs a dry surface. Coseal® is biocompatible,
transparent and thus allowing the result of hemostasis to be verified, it can be sutured,
it does not affect the surgery technique, it is elastic and removable, so does not dam-
age tissues and lastly it acts as a safety barrier in the postoperative period.
7.2.5
The Future: Innovative Biotechnology for Hemostasis Control
Control of hemostasis during surgery is a problem which still has not been fully
rresolved. In that regard biotechnology research could suggest new methods fo
ensuring better hemostatic control.
dOne of the main lines of research in pharmaceutical biotechnology has focuse
on the development of formulations that can release drugs into the body at con-
trolled quantities and rates. There are already many pharmaceutical forms by which
the release may be delayed, or by which the speed and duration of the release of the
active ingredient can be programmed. These formulations are therefore defined con-
dtrolled-release system and they allow for the blood level of the drug to be adjuste
in order to avoid an under- or overdose and minimize unwanted side effects. The
fresult of research conducted in this area is also represented by the innovative use o
special polymers as a means of releasing and managing biologically active mole-
cules. Such polymers are capable of allowing an increase in residence time of a drug
in the bloodstream or in the application, reduced antigenicity, increased stability
against enzymes, and therefore greater bioavailability. These biotechnological inno-
vations, identified as drug delivery systems, are not only used for systemic admin-
istration, but also for topical applications of the treatment of wounds, or the dress-
ing of the epidermis and mucous membranes. In this case, drug delivery at the site
of interest can be tracked using micro- or nanoparticles of polymeric nature as a
reservoir of the drug [13]. This approach could be used for hemostasis control, as
many studies on this are already present in literature [14-16].
fBy way of example a group of researchers at the Massachusetts Institute o
Technology and the University of Hong Kong is working to develop new synthetic
hemostatic agents based on self-assembling proteins. In a series of experiments on
animal models, Ellis-Behnke et al. [17] have verified that these proteins, located on
the wound site, organize into nanowires that form a barrier able to stop bleeding in
less than 15 seconds. There are also other advantages: the protein solution used is
completely nontoxic and non-allergenic and little by little is degraded, releasing
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amino acids used by cells in tissue repair. Results were excellent in rats and ham-
sters, and similar f indings are expected in humans.
As described in Sections 7.2.1-7.2.3 many commercially available products have
been based on the extracellular matrix. These formulations are basically founded on
tissue engineering approaches. These products have shown good clinical perform-
ance, but some improvements are still being made. The regenerated tissues resem-
ble scar tissue and in plastic surgery this effect is better avoided. The ideal treatment
would be to preserve the epidermis and promote normal collagen and elastin forma-
tion in the dermis. Regenerative medicine is a new therapeutic approach finalized at
regenerating biological tissue rather than its replacement. The term autologous
bioregeneration refers to a cell concentration from whole blood or bone marrow of
the patient, obtained by physical means, which is used in situ to stimulate cell pro-
liferation and consequent tissue regeneration. For this purpose various strategies can
be used such as platelet gel or cell concentrates. Platelet gel is obtained by mixing
two components: platelet concentrate to release growth factors and autologous
thrombin as activator (thrombin is rich in growth factors that accelerate tissue
regeneration with osteoinduction and mild hemostasis). The rationale for use is
based on the fact that activated platelets release growth factors (PDGF) or express
membrane molecules that favor the repair processes. Cell concentrates, however,
contain several important growth factors able to stimulate various cellular mecha-
nisms for tissue growth including: angiogenesis, macrophage chemotaxis, f ibroblast
proliferation and migration and collagen synthesis. Where there is significant loss
of tissue, totipotent stem cell concentrates able to differentiate directly in situ can
be applied. Hence, many studies are underway to ensure that wound healing occurs
without the formation of scar tissue [18-20].
rHemostatic agents in previously treated fibrin glues seem to show particula
potential as vehicles for drug release [21]. Several features make fibrin glues suit-
able for this role, such as biodegradability, due to the natural mechanism of action,
the application site and biocompatibility. Some features that make the glue potential
dcarriers of drugs, such as flexibility, high binding affinity to biological surfaces an
controllable biodegradation, makes them applicable to tissue engineering, as
described in the literature [22].
Given the current state of the art as presented in this chapter, the challenge lies
open to provide greater support to surgical practice in an attempt to resolve the issue
of hemostatic control. This challenge is being taken up by integrating our increas-
ing knowledge of the hidden mechanisms of the coagulation cascade with knowl-
edge of the molecular mechanisms that regulate wound repair and new develop-
ments in biotechnology.
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Gene Therapy 




Technological developments in gene isolation and DNA sequencing have been
important factors contributing to the knowledge of the genes associated with
numerous diseases. This information has been critical for enhancing our under-
standing of the genetic basis of disease and the role that specific genes play in
human physiology.
Knowledge of data on DNA sequences has allowed the development of innova-
tive gene therapy protocols, designed to replace or correct defective genes or insert
copies of a functionally normal gene into the genome.
The goals of gene therapy are as different as:
- the correction of pathological phenotypes resulting from genetic mutations, the
replacement and/or correction of a missing or defective gene;
- the expression of protein proper and permanent correction;
- the fast and efficient transfer of a drug while respecting the environment and
cellular gene;
- the introduction into the cell of genes designed to eliminate cancer cells;
- the viral or bacterial gene transfer for the purpose of vaccination;
- the transfer of genes that stimulate growth or regeneration of damaged tissues.
The theoretical advantage of gene therapy is that of a radical and permanent
correction of defects and the possibility of acting on the molecular mechanisms for
which it is extremely difficult to develop specific drugs.
The candidate-disease (or target-disease) for gene therapy are Mendelian dis-
eases in which the conditions or disorders arise from mutations in a single gene.
F.C. Sangiuolo ()
Department of Biopathology, Tor Vergata University of Rome, Rome, Italy
Multigene or multifactorial disorders could be treat effectively using gene therapy,
but unfortunately some of the most commonly occurring disorders, such as heart
ddisease, high blood pressure, Alzheimer’s disease, arthritis, and diabetes, are cause
by the combined effects of variations in many genes, so these would be especially
difficult to treat.
Other diseases might be tumors, such as leukemia or solid tumors and infectious
diseases, such as AIDS.
Researchers may use one of several approaches for correcting faulty genes:
- a normal gene may be inserted into a nonspecific location within the genome to
replace a nonfunctional gene. This is the most common approach;
- an abnormal gene may be swapped for a normal gene through homologous
recombination;
- the abnormal gene may be repaired through selective reverse mutation, which
returns the gene to its normal function;
- the regulation (the degree to which a gene is turned on or of ) of a particularf
gene may be altered.
Gene sequences must be delivered to the cell using a carrier, or a vector. A num-
ber of gene-transfer vehicles have been developed that can broadly be divided into
two categories – non-viral and viral vectors. Non-viral vectors include naked DNA
and DNA encapsulated with cationic lipids, known as liposomes. These vectors
offer the advantages of relative ease of production and reduced toxicity. They are,
however, not very effective at delivering therapeutic genes in vivo, and gene expres-
sion mediated by non-viral vectors is often transient.
The viral vectors most commonly used in gene therapy are viruses that have
been genetically altered to carry normal human DNA. Viruses have a unique ability
to recognize certain cells and insert genetic material into them. Given the need, in
many diseases, for sustained and often high-level expression of the transgene, atten-
tion has turned to viral vectors. Viruses have the ability to gain access to specific
cells and exploit the host’s cellular machinery to facilitate their replication.
Recombinant viral vectors are designed to harness the viral infection pathway.
However, they lack the ability to replicate in the host cell, as the coding sequences
for viral replication are replaced with the gene of interest, such as β r-globin o
human factor IX for thalassemia of hemophilia B, respectively. The number of dif-
ferent viruses that are under development as gene-therapy vectors is steadily
increasing, but they can be divided into two general categories – integrating and
non-integrating. At present, retroviral vectors based on onco-retro or lentivirus are
the only gene-transfer systems that can mediate efficient integration of the trans-
gene into recipient cells. The latter are particularly advantageous in that they can
infect both dividing and quiescent cells and confer stable transgene expression for a
long time. Despite their advantages, safety concerns have been an obstacle to the
application of lentiviral vectors in human trials. In contrast, the genome of vectors
based on herpes, adeno-associated or adenovirus vectors is mainly maintained as
episomes. They do not usually integrate into the host genome and are consequently
lost over time. Therefore, expression from non-integrating vectors is often transient,
es eciall  in tissues/or ans with a hi h cellular turnover. This ma  be ideal for p y g g y a
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number of cardiovascular and malignant disorders where only transient expression
is required, but may necessitate repeated vector administration if used for the treat-
ment of chronic disorders [1].
Non-viral vectors include microinjection and/or electroporation, for inserting
DNA directly into the nucleus. 
The technology of gene targeting through the process of homologous recombi-
nation is an approach focused on modifying a specif ic sequence target of the cel-
lular genome. Gene targeting induces a site-specif ic chromosomal modification
that leads to long-term and genetically inheritable expression of the correct gene,
regardless of its size. Moreover, direct conversion of genomic sequences preserves
the integrity of the gene in such a way that the coding sequences and regulatory
elements remain intact. The availability of better delivery methods has made non-
viral transfer an increasingly safer and more viable method for gene therapy [2].
Among these, human artif icial chromosomes (HACs) are highly promising vectors
recently optimised in gene therapy applications [3]. They are able to maintain
expression of genomic-sized exogenous transgenes within target cells, without
dintegrating into the host genome. Although these vectors have huge potential an
benefits when compared with normal expression constructs, they are highly com-
plex, technically challenging to construct and diff icult to deliver to target cells.
HACs contain the capacity for large gene inserts, carrying genomic loci also with
regulatory elements, thus allowing for the expression of transgenes in a genetic
environment similar to the chromosome.
Another important key to the success of gene therapy is the target cell.
dEmbryonic or fetal stem cells are, for example, significantly more versatile an
plastic than their adult counterparts.
Stem cells are defined as cells that have the ability to renew themselves contin-
uously and possess a pluripotent ability to differentiate into many cell types.
Different types of mammalian pluripotent stem cells, embryonic stem (ES) cells
derived from the inner cell mass of blastocysts and embryonic germ (EG) cells
obtained from post-implantation embryos, have been characterized. Also tissue spe-
cific stem cells could be isolated from various tissues of more advanced develop-
mental stages such as bone marrow mesenchymal stem cells, hematopoietic stem
cells and neural stem cells, and also extra-embryonic foetal tissue like chorionic vil-
lus and amniotic fluid [4, 5]. However, the clinical applications of human embryon-
ic stem cells are limited by ethical concerns, as well as the potential for teratoma
formation. As a consequence, alternative forms of stem cell therapies, such as
induced pluripotent stem cells (iPS) and bone marrow-derived mesenchymal stem
cells, have become an area of intense study [6, 7]. To date, iPS cells resemble
pluripotent stem cells in all characteristics tested. These cells are similar to ES cells
in morphology, proliferation, telomerase activity, gene expression, epigenetic status
dand at the same time are able to differentiate into the three germ layer lineages an
to give rise to adult chimeras. The power of induced pluripotent stem (iPS) cells is
that they do not require the destruction of embryos and they may one day be pro-
duced from the patient’s own adult cells, allowing the generation of perfectly
matched tissues for transplantation therapies. Obtaining patient-specific pluripotent
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stem cells from adult differentiated somatic cells is a new exciting strategy that has
gained great impetus recently. When there is a genetic disease, iPS cells have the
same deficit and so gene therapy protocols have to be developed to correct them
before re-implanting back into the patient. Given the immense regenerative poten-
tial of these pluripotent stem cells, it will be imperative to understand each mile-
stone in the differentiation process for a particular organ or tissue type in order to
use them in stem cell therapy. 
However, the translation of human pluripotent stem cells into cell/gene therapies
will require the development of standardized tests for product consistency, repro-
ducible differentiation, stability, tumorigenicity, toxicity and immunogenicity.
After transplantation in combined cell/gene therapy approach, stem cells can
provoke the multiplication and function of the host stem cells, prevent further loss
and damage of host tissues, or stimulate the production of new blood vessels that
can help to restore host tissues. The transplanted cells presumably produce these
effects by producing growth factors and other products that are locally active.
Transplanted stem cells can also fuse with host cells, and this can help repair dam-
age even if the transplanted cells are not completely transformed into the target tis-
sue type.
dThe pluripotency of the cells allows generation of a wide array of differentiate
cell products, but it also entails the possibility of teratoma formation and the pres-
ence of unwanted cell types. The tumorigenic potential of hESC-derived products
may vary dramatically depending on cellular composition and host environment.
fIf feasible, implantation of the cell products should be performed in the context o
fthe appropriate disease and immunosuppressive therapy [8]. The determination o
fthe safety of any pluripotent stem cell product is inseparable from an assessment o
the risk/benefit ratio in each clinical indication. As with any other therapy, it is wise
to acknowledge that it is generally not possible to eliminate all risk.
Stem cells have considerable utility as targets for gene therapy because they can
self renew, thus precluding the need for repeated administration of the gene vector.
While this approach has already been validated in post-natal clinical trials with
HSCs [9-11], the occurrence of leukemia in three of 11 children treated in the
French trial and in one of ten children from the London trial [12] due to the inser-
tion of the transgene near a proto-oncogene has raised serious concerns about the
risk of insertional oncogenesis. Several lines of investigation are currently being
pursued to reduce this risk, such as the use of insertional site screening prior to re-
infusion, the use of safer and/or site specific vectors and the use of adjustable vec-
tors, which could be switched off, if an adverse event arises [13].
fDespite an abundance of promising studies in animal models, the translation o
preclinical experiments into clinical trials has been minimal. The success of gene
ftherapies has been limited because of persistent challenges relating to the choice o
gene transfer vehicle, efficiency of gene transfer, level of therapeutic gene expres-
sion and potential for unwanted immunological responses against the vector or the
transferred gene. Nonetheless, promising clinical trials using gene therapy have
been completed, and many more trials are underway. Recent examples of clinical
uccess in this area include the lon -term en raftment of retrovirall  transduces g g y d
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hematopoietic stem cells into patients with SCID [14], and the application of gene
therapy to patients with Leber’s congenital amaurosis (an inherited eye condition)
[15]. The development of novel gene therapy vectors with reduced immunogenicity
or toxicity will also be important to move forward the application of this research to
potential clinical applications for non-life-threatening diseases. 
Currently, cell therapy protocols are regulated under the US Food and Drug
Administration’s (FDA’s) Good Tissue Practices Final Rule. Although there are no
approved stem cell products, several are in late-stage clinical trials. Updated and thor-
rough information on gene therapy trials, showing the number of approved, ongoing o
complete clinical trials worldwide, is available on the web at http://www.wiley.co.uk/
genetherapy/clinical/.
Lastly, combined cell/gene therapy has the potential to move toward multiple
clinical applications within the next few years, and, in addition, is likely to be
increasingly valuable as a tool for investigating the mechanisms of acute and chron-
ic allograft loss in more detail.
8.2
Gene Therapy for Neurodegenerative Diseases
There are two broad categories of gene therapy: (1) ex vivo transplantation/implan-
tation of cells genetically modified in the laboratory; and (2) in vivo direct insertion
rof a gene into the patient’s own cells. Several in vivo approaches to gene therapy fo
dneurodegenerative diseases are currently being pursued both in animal models an
in early human clinical trials.
In this section different and novel approaches of both in vitro and in vivo gene
dtherapy for acute and chronic neurodegenerative disorders affecting neurons an
glial cells in the brain and spinal cord will be reviewed.
Specifically we will focus our attention on neuromuscular disorders (NMDs),
dsuch as Duchenne Muscular Dystrophy (DMD), myotonic dystrophy (MD) an
spinal muscular atrophy (SMA), characterized by loss of ambulation, chronic dis-
ability, and early death worldwide. Motor neuron diseases (MND) show a progres-
sive degeneration of upper and lower motor neurons. The most common forms
dinclude amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA) an
spinal bulbar muscular atrophy (SBMA). These disorders have genetic causes
because of mutations in different genes that lead to a variety of phenotypes that dif-
dfer in severity and/or target organ. Current therapies are largely palliative an
ddelayed and are unable to prevent the progressive loss of muscle and/or function an
increasing disability.
Research into therapeutic approaches for both recessive and dominant neuro-
muscular disorders has made great progress over the past few years. Replacing the
defective gene is unlikely to be therapeutic at all. It is therefore not surprising that
for dominant neuromuscular disorders, attention has focused on ways to restore
gene expression at (pre-) mRNA level. This can be achieved through antisense
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oligonucleotides (AONs), small synthetic RNAs, DNAs or analogs, which hybridize
specifically on their target sequence [16].
Myotonic dystrophy (MD) is an autosomal dominant disorder in which an inter-
fering gene product (DMPK mutant) is responsible for the disease [17]. The mutant
DMPK gene produces an mRNA that contains an expanded (CUG)n repeat in the 3’-
untranslated region. The expanded repeat (N>37) causes a disruption in global pre-
mRNA splicing resulting in expression of neonatal, rather than adult isoforms from
a variety of genes.
DMD is an X-linked recessive disorder that affects 1/3500 males caused by the
loss of dystrophin, a protein essential for maintenance of muscle fiber integrity.
AONs can be used to reframe dystrophin transcript, by hiding an exon from the
splicing machinery and causing the exon skipping [16]. This will allow the genera-
tion of a partly functional dystrophin protein causing Becker muscolar dystrophy
(BMD), thus converting a severe phenotype into a milder one.
Some of the most promising experimental therapies currently under investiga-
tion for the treatment of DMD focus on the restoration of dystrophin expression in
myofibers. Numerous strategies have emphasized either the introduction of a func-
tional, recombinant version of the dystrophin gene or modification of dystrophin
pre-mRNA splicing. Modification of dystrophin splicing via AOs was initially
demonstrated in a cell-free system [18] and soon progressed to evaluation in human
myoblasts. Through extensive analysis of AO targets, it has become apparent that the
skipping of each exon, or group of exons, will need to be evaluated on a case-by-
case basis. For example, skipping of exon 23 in the dystrophin-deficient mdx mouse
has been highly successful [19], demonstrating the restoration of dystrophin expres-
sion in the mdx mouse mediated by antisense oligonucleotides conjugated to an argi-
nine-rich cell-penetrating peptide. This is the first study to achieve successful car-
diac dystrophin expression following systemic injection of morpholino antisense
oligonucleotides. Questions remain about host immune system toleration of the
added peptide. Despite these challenges, research is rapidly progressing to evaluate
the feasibility of exon skipping in vivo.
Another attractive strategy for these disorders is a gene targeting approach by
which a mutated gene is converted to one with the normal (or desired) sequence
[20]. Small fragment homologous replacement (SFHR) is a site-specific gene mod-
ification approach that has the potential to maintain the genomic organization nec-
essary for expression. This method has been examined for mutations of the dys-
trophin [21] genes, and partial gene corrections were obtained. This study investi-
fgates the in vitro and in vivo application of a double-stranded method variant o
SFHR gene repair to the mdx mouse model of DMD. A 603-bp wild-type PCR prod-
uct was used to repair the exon 23 C-to-T mdx nonsense transition at dys locus in
cultured myoblasts and in tibialis anterior from male mdx mice. Conversion was
observed at both the DNA and RNA levels. The conversion of mdx to wild-type
sequence in vitro was about 15 % by PCR analysis, although there was no detection
of normal dystrophin protein. The correction efficiency in vivo was up to 0.1 % in
the tibialis anterior of male mdx mice, but again there was no evidence of gene
expression at either the transcript or protein level. Recently, the first development
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of a HAC vector containing the entire human dystrophin gene (DYS-HAC) has been
shown that is stably maintained in mice and in human immortalized mesenchymal
stem cells (hiMSCs) [22]. This kind of vector is very useful for transferring large
sequences together with their regulatory elements, such as dystrophin gene.
The SFHR approach was recently used for another genetic disease, spinal mus-
cular atrophy (SMA) [23], caused by SMN1 fgene loss in humans. The presence o
the SMN2 gene, the ortholog of SMN1 gene in humans, and the capacity that SMN2
has in rescuing embryonic lethality in SMN-deficient mice has illustrated the
importance of SMN protein for cell survival [24]. Thus, the replacement of SMN2
gene using a gene therapy approach to treat SMA patients appears to be an attrac-
tive therapeutic strategy. A gene targeting approach such as SFHR has been success-
fully used [23] in vitro in human chorionic villi (CVS) derived from SMA fetuses
allowing an increase of up to 53% in full-length SMN mRNA compared with
untransfected controls. Furthermore, genotype and phenotype of transfected cells
remained stable after several in vitro passages, demonstrating the stability of the
correction over time [23].
rAAV-mediated delivery of other therapeutic transgenes has also been explored fo
SMA and ALS. Thus far, no substantial therapeutic treatment exists for these disor-
ders, but hopes could come from progress in gene-based and cell-based therapies.
Azzouz et al. replaced the defective gene in a mouse model of SMA showing
beneficial effects following intramuscular injection of a lentiviral vector. However,
only a modest increase in life span was demonstrated (3 to 5 days) when SMA mice
were injected with lentiviral vectors expressing SMN gene [25]. This study shows
that this approach is attractive and a better therapeutic result might arise if the trans-
duction was more widespread (restore SMN expression in cell types other than only
motor neurons) and/or if the administration took place at an earlier stage (e.g. in
utero) in order to allow to the exogenous SMN protein, expressed by the vector, to
compensate the loss of the endogenous one.
More recently independent groups published two interesting paper [26, 27] in
which an altered virus (scAAV9-SMN) was used to deliver SMN1 into the facial
dveins of newborn SMA mice ranging in age from 1 to 10 days old. The SMN-lace
viral vector injected into the P1 mice reached almost half of their motor neurons,
resulting in improved muscle coordination, properly working electrical signals to
rthe muscles and longer survival than in untreated mice. This particular viral vecto
can cross the blood-brain barrier, a characteristic that is required to ensure that the
scAAV9-SMN vector can reach nerve cells in the spinal cord. Ten days after the
injection, about 42% of spinal motor neurons contained the fluorescent protein.
Similarly, SMA mice receiving the SMN viral vector at one day old showed a pro-
tein increase in the brain, spinal cord and muscles within 10 days, even though the
levels remained lower than the levels of SMN in normal mice. This study hopes to
progress to human clinical trials as soon as the requisite toxicology experiments are
in place and federal regulators will allow.
Utilizing the vectors described earlier, new therapies for neurodegenerative dis-
orders are being developed. As with standard medical therapies, there have been a
rnumber of approaches: neuroprotective/restorative therapies, aimed at slowing o
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reversing disease progression. Strategies utilizing genes coding for nerve growth
factors may be applied to all neurodegenerative disorders, but disease-specific
strategies are being developed as well. Several neurotrophic factors have shown
promise as therapeutic agents in animal models of neurodegenerative disorders.
Gene therapy with glial cell-line derived neurotrophic factor (GDNF) has shown to
be promising, for example in animal models of ALS. Regarding ALS disease an in
vivo strategy was reported by delivering GDNF, insulin-like growth factor-1 (IGF-
1) or vascular endothelial growth factor (VEGF). This treatment showed to be effec-
tive in preserving motor neurons in ALS mice and increasing their survival [28-31].
GDNF appears primarily to influence disease onset and not progression [29-31],
making it an unlikely candidate for gene therapy in ALS, while IGF-1 and VEGF
both demonstrated to be efficacious when delivered after clinical onset of the dis-
ease (50% motor neuron loss), making them effective in potential clinical trials [30,
31]. Although viral delivery of growth factor, appears to hold promise for future use
in patients with MND, careful considerations about delivery risk have to be evaluat-
ed. First of all, the virus could be transported to other regions of the central nerv-
ous system (CNS), potentially causing side effects [32]. Secondly, virus-integration
rin proximity to oncogenes could trigger malignant cell proliferation [33]. Howeve
the use of adeno-associated virus or lenti-viral vector is unlikely to cause toxicity
[34], because both vectors show capacity for retrograde transport from the muscle
to the spinal cord [30, 31, 35]. Undoubtedly the use of cellular transplants to deliv-
er growth factors could provide a safer method of delivery. For these purposes,
embryonic (ES) and neural stem cells (NSCs), and more recently induced pluripo-
tent stem (iPS) [36] are potential cellular sources which could be harnessed in the
ftreatment of numerous disorders. Several cell-based approaches for the therapy o
motor neuron disorders have been reported with the aim of creating trophic support
to preserve endogenous cells and for host cells replacement [37, 38]. The selective
degenerations of motor neurons in discrete regions of the brain and spinal cord,
characteristic of ALS, SMA and SBMA diseases, strongly encourage researchers to
experiment cell replacement strategies, by using stem-cell derived motor neurons
[39]. Towards this goal, mouse ES cell-derived motor neurons were recently used in
a rat model of virus-mediated acute motor neuron death [40]. More recently, murine
neural stem cells (NSCs) were also utilized for transplantation into presymptomatic
nmd mice [41] and SOD G93A rmice [42]. NSC populations were isolated from eithe
embryonic spinal cord and enriched by cell sorting (FACS) based on their high alde-
hyde dehydrogenase (ALDH) expression or from adult brain and purified based on
Lewis X and the chemokine receptor CXCR4-expression [42]. In both studies, the
fanimals showed a 3-week delay in onset, correlated with a partial preservation o
host spinal motor neuron, and also a 3-week increase in mean survival time. The
beneficial effects of grafted cells on host motor neuron survival and disease onset
appeared to be through trophic support, based on graft release of IGF-1 and VEGF.
In other study, Corti et al. isolated spinal cord NSCs from SMA mice express-
ing green fluorescent protein only in motor neurons and assessed their therapeutic
deffects on the phenotype of SMA mice [43]. Intratechally grafted NSCs migrate
nto t e parenc ma an  enerate  a small proport on o  motor neurons. Treatei h hy d g d i f d
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dSMA mice exhibited improved neuromuscular function, increased life span, an
improved motor unit pathology. NSC transplantation positively affected SMA phe-
notype, indicating that transplantation of NSCs may be a possible treatment.
However, most potential sources of cell therapeutics, such as fetal-derived primary
neurons, human ES cells, and endogenous neural stem cells, are associated with eth-
ical controversy or present technical limitations. The subsequent successful genera-
dtion of human iPS cells from skin fibroblasts opened the door for iPS cell base
therapies. To this end, Dimos et al. [44] obtained fibroblast lines from two elderly
rsiblings with early or late manifestations of ALS, and Ebert et al. took a simila
fapproach from SMA skin fibroblasts patients [45]. Therefore, the combination o
patient-specific iPS cells and HAC-containing defective genes represents a power-
ful tool for gene and cell therapies.
The generation of iPS cells from a patient’s own skin fibroblasts would potentially
allow auto-transplantation, with the elimination of immune rejection problems.
Despite several successful results, additional basic research is required to effec-
tively understand and control unknown mechanisms regulating the proliferation,
migration, differentiation, survival, and function of stem cells and stem cell-deriva-
tives to be used. In this way the clinical harnessing of stem cells to treat neurode-
generative diseases could be guaranteed.
8.3




dIn the past two decades, advances in cellular and molecular biology have expande
our understanding of tissue repair and regeneration [46]. Tissue repair encompasses
a complex process that requires the integration of cell rescue as well as extracellu-
lar matrix turnover, angiogenesis, and remodeling under genetic and epigenetic con-
trol [47]. Recent progress in basic [48] and clinical research [49] revived tissue
repair based on gene therapy as an attractive option for efficient and targeted treat-
ment of a wide range of inherited and acquired complex diseases, whose only ther-
apeutic option is the surgical approach or palliative long term drug treatment. It has
now been established that several crucial issues, such as gene delivery and molecu-
lar mechanisms of tissue repair, are still to be resolved prior to achieving clinical
success in regenerative medicine. The concept of gene-based tissue repair includes
the use of transgenes encoding several peptides that modulate the secretory and life-
saving capacity of resident cells. The targeted delivery of transgenes for local regen-
erative purposes, compared with pharmacological treatment, has shown several
advantages: (a) targeted expression of specific trophic factors in the native form
[50], (b) sustained and efficient modulation of intracellular target signaling activa-
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tion related to the trophic factor tissue availability [51], and (c) limitations of sys-
dtemic side effects. Therapeutic genes can be delivered in vivo as naked or package
into viral or non viral vectors. In vivo techniques are based upon the direct introduc-
tion of genes to the target tissue. The selection of an appropriate vector for the trans-
fer of genes is critical for overcoming the physiological barriers and is paramount
for success of gene-based tissue repair [52].
8.3.2
Barriers to the Delivery of Genes for Tissue Repair In Vivo
To mediate gene-based tissue repair, intact and active oligonucleotides have to be
introduced into the cytoplasm and efficiently integrated into the nuclear DNA of tar-
get cells. The cellular uptake is the main barrier for the delivery of nucleic acids,
which limits even the local transfer. In addition, many tissues in vivo may only be
reached through the systemic administration of genes via the blood stream. For this
purpose, to guarantee effective and non toxic systemic delivery, the genes have to
remain intact in the bloodstream, extravasate through the vessels, diffuse through
the extracellular matrix (ECM), pass the cellular membranes and be released into
the cytoplasm. Naked circulating nucleotides have a very short half-life, owing to
degradation by circulating nucleases, rapid renal excretion, aggregation with serum
proteins and phagocytosis by immunocompetent cells. Some of these issues, such as
plasmid degradation and inactivation, can be overcome by introducing chemical
modifications or assembling plasmid with proteins, lipids or polymers, which allow
resistance against nuclease degradation [53], or by packaging nucleotides in viral
vectors [54]. Even if they survive in the plasma, the next major barrier of gene
delivery is the tight vascular endothelial wall. Generally, molecules larger than 5 nm
in diameter do not readily cross the capillary endothelium [55]. Alternatively, vec-
tors could be locally injected in the damaged tissue by electroporation or gene gun,
or assembled into tissue engineering scaffolds and gradually released at the injury
site to overcome the endothelial barrier [56]. However, after the circulating gene
delivery complex passes through the vasculature, it must diffuse through the ECM,
rwhich is a dense network of polysaccharides and fibrous proteins that can hinde
nucleotides complex diffusion and limit efficiency of gene delivery in vivo. The
rintracellular barriers included cellular internalization, endosomal escape, vecto
dunpacking, and transport into the nucleus. The fundamentals underlying viral an
non-viral delivery system, and the more recent development of polymeric delivery
systems are described below.
8.3.3
Viral Vectors
Gene transfer using viral vectors relies on the efficient ability of viruses to carry
and express their genes into resident cells to enhance tissue repair [57]. Each viral
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dvector is developed by deleting the native viral genome and inserting the desire
dtherapeutic gene. Human adenoviruses (Adv) are double-stranded DNA viruses an
the most common vectors used in viral gene therapy allowing a stable and transient
gene expression in non dividing cells. Unfortunately, Adv are highly immunogenic,
probably due to the capsid proteins [58].
dHowever, adeno-associated viruses (AAV) are single-stranded, non-envelope
DNA viruses [54]. AAV transduce a variety of cells, including non dividing cells,
provide long-term gene expression, and are less immunogenic. New experimental
approaches with AAV indicate that different serotypes might influence the targeting
abilities and transduction rates of specific cells, such as endothelial cells, to pro-
mote gene expression and therapeutic angiogenesis [59].
Retroviruses (RV) are single-stranded RNA viruses that replicate through a DNA
intermediate and can be designed as highly tissue specific and safe vectors from
recombination after transfection [60]. They offer the potential for long-term gene
expression through integration into the host cell genome. However, RV are not able to
transduce non-dividing cells. Conversely, lentiviral vectors are able to make non-divid-
ing cells a target for long-term gene expression [61]. Unfortunately, the ability of viral
delivery to promote tissue repair is limited by the induced immune response, which
might be in part controlled by polymeric encapsulation of the viral vector. In fact, poly-
meric encapsulation shields the vector from neutralizing antibodies, reduces the quan-




Non-viral vectors are less toxic and immunogenic than viral vectors, yet the gene
delivery efficiency might be significantly lower. Several non-viral carriers devel-
oped to improve in vivo localized gene transfer, proved effective in enhancing tis-
sue repair. For this purpose, oligonucleotides might be linked to synthetic mole-
cules, such as cationic polymers (polyethyleneimine, chitosan) [63], peptides (HIV-
TAT) [64], liposomes (PEGylated lypsomes, stable nucleic acid-lipid particles) [65]
or aptamers (small synthetic highly structured nucleic acid molecules) [66]. These
fDNA-nanoparticles come through the cells by endocytosis, yet the low capacity o
intracellular esocytosis is considered the major limitation of their transfection effi-
ciency. Non-viral vectors/DNA repairing complex might be directly injected into the
damaged tissue, systemically injected under guidance of noninvasive imaging
(ultrasound, magnetic resonance imaging) or immobilized to biomaterial substrates
(coils, stents, membranes) by drying nonspecific adsorption or retained within
biodegradable scaffolds (hydrogels) to provide gradual release.
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8.3.5
Tissue Engineering Scaffolds
dViral or non-viral vector-loaded scaffolds can stimulate tissue formation and coul
be directly implanted into an injury site for delivery to cells within or near the scaf-
fold [67]. Scaffolds can distribute the gene material throughout the microenviron-
ment of damaged tissue, and have proven more effective than single injection. These
innovative biodegradable biomaterials are categorized according to the basic deliv-
ery mechanisms:
- polymeric release: sustained oligonucleotides delivery from polymer substrates
(collagen, collagen-gelatin, polylactic glycolic acid, polyethyleneimine) to
enhance efficiency of gene transfer by maintaining elevated, and not cytotoxic,
tissue levels of nucleotides and allowing repeated cellular uptake;
- substrate-mediated delivery: immobilization of gene complexes within biomate-
rials which serve as substrate for cell adhesion (i.e. biotin cationic polymers
binding neutravidin substrate, collagen membranes, hyaluronic acid-collagen
hydrogels). DNA is directly placed in the cell microenvironment to facilitate cell
internalization and allow spatially controlled gene delivery.
The mechanical properties of the scaffold and mechanical stimulation of the tis-




The relationship between gene delivery, transgene expression and tissue
repair/replacement remains a significant challenge in design and choosing innova-
tive tools for in vivo use of gene therapy in regenerative medicine. Although the
recent description of multiple targeted delivery systems heralds future therapeutic
applications, there are still a number of concerns and scope for improvement. The
potential risk of toxicities and lethal immune responses to the vehicle component as
well as to the targeting component needs more thorough evaluation. In this regard,
peptide-based systems, non toxic liposomes and less immunogenic viral vectors
might be clinically relevant in the future. The use of biodegradable scaffolds in gene
delivery can better modulate local transgene expression and guarantee a remarkable
increase of the duration of transgene expression than the duration of release within
the context of the signals present in the microenvironment. In conclusion, the excit-
ing technological advances in gene delivery here point to a bright future for gene-
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9.1
Philosophical and Lexical Issues
To fully understand the biological meaning of the term stem cell (SC) it is useful to
clarify the derivation of the root staminal, even though modern research published
in English-speaking journals never seem to use the term staminal. While there are
no doubts that the term SC originated in the context of two major embryological
questions, the continuity of the germ-plasm and the origin of the hematopoietic sys-
tem [1], it is not clear at all which is its etymological derivation. This is a relevant
point for the consequences and the impacts that SC biology has in society, particu-
larly on the beliefs of lay-people (i.e. decision makers) who so frequently impact on
research freedom. We would like to suggest that the term is in fact a neo-Latin word
(the adjective *staminalis, -e never existed in Latin!) that was coined in an English-
speaking scientific environment. In any case, the word originates from the Latin
stamen, -inis, a neutral noun that is formed by two distinct morphemes: the lexical
base (of Indo-European origin) *sta- to be firmly placed; to remain;  and the deriva-
tional morpheme (of Indo-European origin) *-men-, which is widely used to form
nouns that indicate firstly the production of the effect of an action, and hence, by
implication, the effect of the action itself. Some examples of the -men morpheme
in Latin include: ag-men army on the march; lu-men the glare of the light (vs. lux
absolute/real light); ful-men, the flash that precedes thunder; cri-men, fthe action o
separating/selecting and so figuratively, the object of selection; se-men, in the first
place, the action of sowing, and consequently that which is sown.
Stamen was, originally, a technical weaving term indicating the warp of the
cloth (literally that which is firmly fixed), onto which the weft is woven in order to
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form the final product. More generally, it indicates the thread and, metaphorically,
the fiber of life; destiny; fate; the thread of life. What is important to note in the
semantic value of the Latin word stamen, is the idea (abstract) of something that
remains firm, stable, which serves as a basic, founding  principle. Hence, basic,
founding stem cell. However, our original explanation of the term SC is not the only
one. Recently, Ramalho-Santos and Willenbring [1] suggested that: “One would be
tempted to assume that the term stem cell has some relation to the term meristem,
because meristems are the stem cell compartments of plants. The term meristem was
first used by the Swiss botanist Karl Nägeli in 1858 to refer to the areas of contin-
uing cell division in a plant (Nägeli, 1858). Nägeli derived the term meristem from
the Greek meristos (divided/divisible) and the suffix -em (as in phloem or xylem).
Hence, the terms stem cell and meristem, despite being similar and having overlap-
ping meanings, were developed independently and are etymologically unrelated.”
Regardless of the etymological derivation of the term, the SC is defined both as
a cell able to divide itself in such a way that it originates a daughter cell identical to
the mother cell (renewal capacity) and as a cell able to differentiate itself into a spe-
cific cell type of one of the many tissues that make up the animal body (differenti-
dating capacity). Therefore, it is a cell endowed with a double capability: renewal an
differentiation, two elements fundamental to the stable and steady physiological
maintenance of an organism. This extraordinary biological duality interests biolo-
gists who are trying to discover the molecular mechanisms at the basis of embryon-
dic development, cell differentiation and the genetic reprogramming of differentiate
fcells. Furthermore, it is of interest to the medical community in the conception o
technical applications for the development of cell replacement therapies in tissue
that has been damaged as a result of aging, trauma or of specific diseases.
dUntil the beginning of the 1950s the existence of SC was mostly conjecture an
based on the physiological concept of the dynamic state of body constituents. This
concept dates back to the 5th century BC; it was recorded by the philosopher-natu-
ralists long before Aristotle; in particular, Heraclitus (540-475 BC) records and uses
it frequently. The existence of cells reputed to renew tissue is intuitive (think about
skin and blood!); it follows, likewise intuitively, that these initially putative cells
would enable the complete renewal of the body and that, accordingly, they would be
involved in the longevity of an organism. All these intuitions return overwhelming-
ly as well established fact in our current knowledge of the role of SCs in the devel-
opment of many diseases (e.g. cancer) and more generally in the projected develop-
ment of cell-based therapies (regenerative medicine). In 2006, the European
dMolecular Biology Organization (EMBO) published a summary document title
rStem Cell Research - Status, Prospects, Prerequisites, which can be downloaded fo
free (http://www.embo.org/index.php), introducing the field of SC biology. The
freader is strongly advised to refer to this still valid document which outlines all o





Origin, Animal and Vegetal Models
SCs can be derived from various sources; from the early stages of embryonic devel-
opment, before implantation in the uterus (embryonic stem cells, ES), and from the
post-implantation and post-natal development stages (somatic or adult stem cells,
SSC). SCs are classified on the basis of their differentiation potential, a potential
that becomes increasingly limited as development progresses from the embryonic
and post-natal stages through to senescence. The totipotent SC is the single-cell
embryo, the zygote, which is formed by the union of the sperm and the egg cell.
tThrough embryonic and fetal development, the zygote forms a new organism that a
the adult stage (in humans) consists of about one million billion cells (1015). All
these cells originate from the zygote, and it is on account of this generative ability
that the zygote is called totipotent. The zygote and the embryo cells (blastomeres)
in the early stages of pre-implantation development (blastocysts) possess all the
information, at a nuclear and cytoplasmic level, needed to produce the different
types of cells that make up a new individual. Changes in the number and in the type
of genes that are expressed in every stage of development lead initially to the deter-
mination of the differentiation fate of the cells, and subsequently to their actual dif-
ferentiation into the different types of cells that are present in the adult organism.
The cells that make up the early stages of embryonic development (the blastocysts)
are called pluripotent because they are able to generate the cells that differentiate
themselves into the three embryonic layers, the endoderm, the mesoderm and the
ectoderm, which in turn will create all the cell types that make up the various tis-
sues and organs. Multipotent and unipotent stem cells are those that have a limited
differentiation ability and are found in the later stages of fetal development and in
the adult. These stem cells exclusively generate the cell type of the tissue in which
they are found: again, picture the self-renewal that characterizes blood and skin
stem cells.
The list of tissues and organs from which it is possible to obtain SCs is growing
by the day (recently SCs have been found in the pulp of deciduous baby teeth, as
well as in the nervous tissue of cadavers 18 hours after death). There are therefore
numerous sources for SCs, including of course the umbilical cord and material
derived from spontaneous and induced abortions. Additionally, cloning techniques
fhave very recently led to the development of methods that enable the derivation o
SCs from terminally differentiated cells (somatic cell nuclear transfer technique, the
use of cytoplasts, and retroviral transfection of SC genes) as will be shown later.
Regardless of its origin, a SC is defined by its intrinsic capacity for self-renew-
al. There are several hypotheses accounting for the SC self-renewal capacity, the
rmost favored being the asymmetric hypothesis which states that one of the daughte
cells keeps the peculiar stemness property of SCs while the other cells are commit-
ted to differentiation. Several molecular mechanisms have been put forward to
fexplain the stemness property based on the asymmetric mitotic division, but two o
them are much popular than others: the immortal strand hypothesis advanced by
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Cairns in 1975 [2-4] and the hub-niche hypothesis put proposed by Schofield in
1978 [5]. The first suggests that after DNA replication the segregation of the strands
follows a pattern by which the oldest template strands are continuously retained by
one of the new generated cells (that will become a SC) while the other new daugh-
dter cell will inherit all of the younger new template strands (and will be committe
to differentiate). This hypothesis is quite fascinating since it can account for the ori-
gin of cancer cells, namely for the origin of cancer stem cells (CSC), since the repli-
cation-induced mutations are all inherited by just one of the two new daughter cells,
the non-SC. As time passes, mutations accumulate in only one cell (in humans at an
faverage rate of one mutation per seven mitotic divisions, roughly a mutation rate o
something like 10-5 – 10-7 per gene per generation) thus easily reaching a critical
threshold which triggers an inflammatory (intermediate) state from which, as muta-
tions accumulate, the neoplastic (stemness) condition arises due to the deregulation
of the tumor suppressor genes activities [4, 6]. A clear datum supporting this view
comes from the demonstration by Reya and Clevers [7] that the Wnt signaling
deregulation phenomenon is the common and precocious event in malignant pro-
gression of colorectal, breast, skin and hematopoietic tumors. The Wnt deregulation
likely acts by activating the SC self-renewal within the SC’s niche. An inclusive
view of the CSC field is presented and continuously updated by Riccardo Fodde,
leader of the MCSCs European group (the “Migrating Cancer Stem Cells” consor-
tium: www.mcscs.eu).
The second hypothesis, known as the SC niche hypothesis, states that SC are
maintained in a very specialized anatomical compartment where both proximal (cell
surface molecules) and distal (secreted molecules) signals provide a definite
microenvironment (the niche) controlling cell proliferation and differentiation, thus
protecting the SC from exhaustion. This concept came out of seminal studies on the
hematopoietic system [5], the Caenorhabditis elegans germ cell development [8],
the Drosophila melanogaster ovary [9, 10] and some model plant systems like
Arabidopsis thaliana (see the 2007 review by Scheres on SC niches across king-
doms [11]). The SC niche is nowadays a paradigmatic concept in SC biology [12],
even when its role is critically considered [13].
9.3 
Somatic and Embryonic Stem Cells
A chronology of SC researches can facilitate comprehension, above all of the scien-
dtific problems, but also of the ethical and legal problems linked to the derivation an
use of such cells. They were first proven to exist by Canadian researchers at McGill
University (Montreal, Quebec, Canada) in the 1950s. This milestone was made pos-
sible thanks to the development of several histological techniques, which in turn
were linked to advances in the fields of nuclear physics and radioactive isotopes.
While cells and tissues were initially studied in terms of their 3-dimensional archi-
tectural relationships, the development in the 1930s and 1940s of autoradiography
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dtechniques added a fourth dimension: that of time. Accordingly, Charles Leblon
and his colleagues (H. Cheng, W. Chang, J. Marques Pereira, B. Messier, J. Nadler)
fdemonstrate the dynamic of synthesis, and the movement between different types o
cells, of substances (sugars, aminoacids) that had always occurred in cells but that
were now traced and stained with chemical elements capable of emitting electrons
(for example, radioactive isotopes of hydrogen, sulphur, and carbonium).
They were thus able to show that the cells at the base of intestinal villi are capa-
e o  di iding t emse ves asymmetr cally, as  ee  ypot es ze , an  so obl f v h l i had b n h h i d d f
renewing the epithelium that covers the villi: clearly, these cells were, and are, SCs.
Leblond proved the existence of SCs in the testicle by identifying a particular type
of cell, called Spermatogonium A, which, with the production of sperm, is capable
of ensuring the constant renewal of the seminiferous epithelium. The two
researchers who in the early 1960s established several tests which are still in use
dtoday to define the nature of the SC were also Canadian: Ernest A. McCulloch an
James E. Till launched the field of SC research with a study that was to become the
cornerstone of SC biology. This study regarded hematopoietic SCs, the tissue “study
model” that is able to provide many of the conceptual paradigms that we use today
for the molecular dissection of the stemness. Till and McCulloch developed tests to
measure the differentiation of SCs (in vitro) and their ability to repopulate a tissue
(in vivo). Of particular note are the clonogenicity test and the serial transplant test,
both still essential for SC researchers. The Canadians’ groundwork was followed by
a series of contributions from the scientific community at large which showed the
existence of SCs in all the different anatomical compartments. Thereafter, and as is
typical of scientific endeavor, there was a succession of many small advances in
dknowledge; though individually slow, collectively these advances rapidly enable
the use of SCs in numerous therapeutic applications. Some of these applications are
already well consolidated (bone marrow transplants, artif icial skin, cornea replace-
dment), while others are under trial (e.g. Parkinson’s Disease, heart infarction an
diabetes), and yet others are still at the experimental stage (spinal stroke,
Alzheimer’s disease, amyotrophic sclerosis). In the 1960s, at Glasgow University
(UK), R. Cole, R.G. Edwards and J. Paul (1964 and 1966) isolated the first colony
dof ES (immortal) from rabbit blastocysts, and R. L. Gardner (1968) demonstrate
the differentiation capacity of a single ES in the mouse. In the decade that followed,
M. J. Evans (1972) isolated and characterized mouse ES, while R. A. Fleischmann
and B. Mintz (1979) injected hematopoietic SCs into the placentas of immunosup-
pressed mice and thus cured a genetically determined anemia. In the 1980s, M. J.
Evans and M. H. Kaufman (1981) isolated and established the first mouse ES line,
and S. Fishel (1984) obtained the first human ES. The 1990s witnessed many
advances; of particular note, A. M. Wobus (1991 and 1995) obtained heart cells
from mouse ES, and E. Y. Snyder (1992) demonstrated that neural ES are trans-
planta e an  at t  e root n mouse cere llu . T e rst uman 3 ma e anbl d th hey tak i be m h fi h ( l d
2 female) and macaque monkey SC lines were prepared by J. A. Thompson (1998),
while M. J. Shamblott (1998) obtained the first lines of human germ cells.
The legislation that allows the cultivation of human ES from blastocysts on the
fourteenth day of development ordain the exclusive use of blastocysts that come
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from in-vitro fertilisation clinics and that are therefore excess embryos that have not
been transferred into the mother’s uterus, but that, with the parents’ consent, are
used for research. Some countries, including the United Kingdom and South Korea,
are debating whether to legalize the sale of oocytes by women who are willing to
receive injections of drugs (gonadotropins) that stimulate superovulation, and thus
enable oocytes to be collected for research purposes. Some bioethicists believe that
this practice is unacceptable, and assert that, if legalized, it must be treated like
organ donation and as such it must preclude any form of payment or future benefit
from the associated research results.
At the beginning of the current century (2000), S. H. Lee produced dopaminer-
gic neurons from mouse ES. In 2001, N. Lumelsky obtained insulin-secreting cells
from mouse ES, and various Scandinavian groups confirmed that the transplantation
fof neural SSCs, derived from aborted fetuses, are effective in the treatment o
Parkinson’s disease. In 2003, K. Hubner, H. Scholer and M. Boiani produced germ
cells (oocytes) from mouse ES. In Seoul, in 2004, W. S. Hwang received 242
oocytes from 16 donors and derived several human SC lines, but he altered the
results and reported false technique effectiveness percentages. The media response
was to present all of Hwang’s work as fraudulent, although this claim is groundless.
Still in 2004, T. Barbieri obtained millions of dopaminergic neurons from a single
human ES. From this year onwards the growth in SC research has enter a dfast an
furious crescendo that is quite difficult to account for. Thus, we will review papers
the references of which refer to the relevant details of SC biology. The most relevant
result of these last few years has no doubt been the achievement of Shinya
Yamanaka and his colleagues (see below) on the induction of pluripotency in fibrob-
lasts by the ectopic expression of four stemness genes [14], something similar to
what can be obtained by exposing somatic cell nuclei to the action of cytoplasts in
a test tube [15, 16] or to the oocytes environment by nuclear transfer [17, 18].
rYamanaka’s results are such a conceptual paradigmatic breakthrough that Professo
Sir Ian Wilmut [19] changed the name of the journal Cloning and stem cell into
Cellular Reprogramming. To explain the reasons behind this decision he wrote: “…
it is appropriate … rename the Journal with this very important, exciting, and rap-
idly expanding aspect of biology. … A completely new area of research was estab-
lished by Shinya Yamanaka and his colleagues when they demonstrated that, simply
by introducing four transcription factors, it is possible to reprogram skin cells from
mice so that they become equivalent to embryo stem cells.” There is a wide consen-
sus on the expectation that these milestone results greatly enhance Yamanaka’s
prospects in Stockholm for a Nobel prize.
In the last few years, methods for the derivation, isolation and culture of SCs, as
well as for the genetic reprogramming of terminally differentiated somatic cells
(reprogrammed to become embryonic or embryonic-like again), have improved. It is
this latter type of research that has produced the most important results, by demon-
strating that at least in some cases (cytoplasts and stem cell genes), embryonic-like
SCs can be obtained without having to confront the ethical problems that in some
ncountries arise from the legal protection assigned to the embryos. In fact, it has bee
ddemonstrated that terminally differentiated cells can be genetically reprogramme
Biotechnology in Surgery136
9
rto produce ES. Indeed, it is possible to restore to a somatic cell nucleus, taken fo
example from a biopsy, the totipotent characteristics it possessed in the zygote. This
dis possible in egg cells which have had their nuclei removed (i.e. enucleate
oocytes), thanks to a technique called somatic cell nuclear transfer. An extremely
important turning point in SC research was the cloning of Dolly dthe sheep an
Cumulina dthe mouse. I. Wilmut and K. Campbell’s experiments using sheep [17] an
subsequent experiments by R. Yanaghimachi on the mouse [18], have shown that
when the nucleus of terminally differentiated somatic cells is transferred into the
cytoplasm of an enucleated egg cell, it is able, despite its actual genetic program, to
acquire a new genetic program and to begin and end embryo development with the
birth of a new individual. The genetic program of a terminally differentiated cell
nucleus is therefore not irreversibly fixed but can be reversed, thanks to reprogram-
ming factors d, to that of an embryonic cell nucleus. These two studies stimulate
dresearch on the capacity for genetic reprogramming of non-human egg cells, an
culminated on 17 January 2008 in the decision by the British Human Fertilisation
and Embryology Authority (HFEA) to grant licenses to researchers who want to cre-
ate cytoplasmic hybrids between human cells and other animal cells. The HFEA thus
approved the creation of cytoplasmic hybrids with the use of animal eggs to incu-
bate somatic nuclei of human cells, the aim of which is to chemically reprogram the
human somatic nuclei to express the characteristics of ES cells: the derived blas-
tomeres must be broken up, and the SCs derived, within the first 14 days of cultiva-
tion. It should be pointed out that in the 18 years of its existence, the HFEA has
approved only three research requests that involved the creation of embryos and the
use of nuclear transfer for the derivation of ES. The completely arbitrary wording
in media coverage of this framework has led to great confusion about what experi-
ments are legal. Lay people tend to believe that in the United Kingdom it is possi-
e or researc ers to create uman chimera em o or uman c top asm c idbl f h h bry h y l i hybr
embryo types as and when they please, i.e. without going through the HFEA or any
other controlling bodies. Or, even worse, Mr. Average thinks that it is possible to
derive fantastical biological entities from the various lexical combinations of the
ftwo embryonic types: cybrid chimeras! Biomedical research has a long history o
fmixing together the genetic material of different animal species, including that o
man. Three different biological entities can be obtained by mixing the cells or cell
components of different species together: cybrids (cytoplasmic hybrids), stembrids
(stem cell hybrids) and chimera. These biological entities are completely different
from each another, as are the techniques used to obtain them. Cybrids and stembrids
are cytoplasmic hybrids produced by the respective insertion of the somatic cell
nuclei of a species into enucleated eggs of another species (cybrids) and into ES
cells (stembrids). Chimeras are produced by the co-mixture either of the embryonic
animal cells of different species, or of different strains of the same species, during
the pre-implantation stage of embryonic development. Nuclear transfer, a cell
microsurgery technique, is used to produce cybrids and stembrids. Chimeras are
produced by means of chemical substances and/or mechanical forces that disaggre-
gate the early embryonic stages (pre-implantation) of different species or strains;
rthe isolated embryonic cells (i.e. blastomeres) that are obtained are mixed togethe
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in varying percentages (but usually 50/50) and then re-aggregated into a chimera.
Cybrids and stembrids are produced in an attempt to derive ES cell lines; cybrids are
also used in the cloning of animals in attempts to preserve species at risk of extinc-
tion. Far from being new, the fusion of human and animal cells is standard practice
in biological research. Examples of its application in recent years include: human
genome sequencing in the late 1970s and 1980s; diagnosis of human sperm quality
on the basis of its use to fertilize hamster oocytes; the creation of transgenic ani-
mals, both for the production of molecules with pharmacological properties (e.g.
growth hormones) in the milk, serum or urine of various animals (mouse, pig,
sheep, goat, rabbit), and for the production of animal models for human diseases.
dThe creation of cybrid embryos between differing animal species has been practice
dfor more than a century: the creation of human-bovine cybrids that were develope
to the blastocyst stage, and the derivation, by a Chinese group, of human ES from a
human-rabbit cybrid, are well known undertakings. Research that uses nuclear trans-
fer between two different cells has a long history in biology. As far back as 1886,
August Rauber used small syringes to attempt interspecific nuclear transfers (frog-
turtle) in order to understand the role of the nucleus and the cytoplasm in heredity.
It was during this period that the great f igures of experimental embryology (Loeb,
Delage, Spemann) tried to clarify Weisman’s germ plasma theory. They tried, in
other words, to understand how cellular differentiation occurs during embryonic
development. More than 120 years of pertinent research have witnessed many
nuclear transfer experiments, both intraspecific and interspecific: the most famous
are the previously mentioned intraspecific experiments that culminated successful-
ly in the development, though in very low percentages, of the reconstituted embryo
and fetus that in turn led to the birth of Dolly the sheep and Cumulina the mouse.
dThe interspecific experiments, between species of the same genus, have been use
for the most part, and quite successfully, to save species at risk of extinction. The
significance of the fact that full-term pregnancies and live births are registered only
in species of the same genus, for example bovine, ovine, equine and feline intra-
rgenus species should be pointed out. Therefore, embryos produced between cow (o
pig) oocytes and Antarctic whale or rabbit nuclei do not reach the blastocyst stage.
What is more, interspecific nuclear transfers have already been used to obtain ES
cells. In 1999, Joseph Cibelli and collaborators (from Advanced Cell Technologies)
claim to have created a cybrid by introducing a human lymphocyte nucleus into a
bovine oocyte and to have derived a human ES line. This led to many other discov-
feries [20]: of note, in 2003, James Byrne and colleagues transferred the nuclei o
various types of human somatic cells into amphibian oocytes, thus definitively
demonstrating that the cytoplasm of Xenopus oocytes is able to genetically repro-
gram human somatic nuclei to express the OCT-4 gene, (a gene which indicates the
reacquisition of SC potential). Other groups too, from America, Korea and China,
have announced the production of human-bovine and human-rabbit cybrids.
Together these data highlight the fact that cybrids develop, in very low percentages,
dto blastocysts (in the copresence of human and bovine or rabbit mitochondria), an
that it is rare for these to reach implantation. Instead, they start to degenerate when
the enzymatic coupling mechanism of reactions governed by the mitochondrial
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rgenome has to synchronize itself with the reactions governed by the nuclea
genome. The HFEA’s stance denotes great responsibility, and guarantees that in the
assessment of researcher’s requests, the various ethical positions on human embryos
that circumscribe the research world are given serious consideration and attention.
In their decision of 17 January 2008, the HFEA acknowledged the fact that the
requests by English researchers for permission to introduce the nucleus of a skin
cell from patients with Alzheimer’s or Parkinson’s into bovine oocytes have great
scientific value. These researchers intend to disaggregate the cybrids after four days
of culture and to derive ES lines in order both to study their differentiation and to
test drugs still in the experimental stage. More generally, the idea is to construct cell
models of neurodegenerative diseases in such a way as to be able to isolate the dis-
eases in test tubes. Cybrids and stembrids are created in the hope of being able to
dissect the molecular composition of oocytes, those extraordinary, miniature, self-
dcontained molecular biology laboratories. Such dissection could help to understan
which factors activate the initial chemical reactions that reprogram somatic DNA
into embryonic DNA. It is important to note that quality control protocol requires
retrovirus monitoring for any SC line produced. Current evidence suggests, on the
one hand, that cross-species cybrids do not have the potential to develop into
embryos and fetuses that are endowed with organs and that are thus able to complete
the development process. By development process, we mean that which results in
the formation of a new individual with autonomous circulatory and nervous systems
(the occurrence of which constitute two of the gradualist criteria optionally used to
identify a new individual). On the other hand, research strongly suggests that it is
ossible to use uman cyb ids to pro uce ES cell lines w out t e ve ent op h r d ith h invol m f
human oocytes. This notion has prompted new research into identifying those fac-
tors in the egg cell cytoplasm that reprogram the nucleus of somatic cells to return
to their embryonic state.
9.4
Stemness Genes
fThis new type of research is pursuing two distinct strategies, which for the sake o
convenience are here respectively characterized as environmental/cytoplastic dan
direct/transfective. The former strategy cultures the somatic cells to be repro-
rgrammed in cytoplasmic extracts (cytoplast is the term used to describe the matte
that composes an enucleated cell. It therefore acts on the cell’s environment (the cul-
ture material) and activates genetic expression mechanisms on the basis of factors
that are extrinsic to the genome itself but that occur in the cytoplast. As the history
of biology and medicine shows, this is a very important f ield of research: if these
factors can be identified, it will be possible to produce them both naturally (from
oocytes belonging to other species: rabbit, bovine, swine, amphibian) and artif icial-
ly (biochemical synthesis). Just consider the production of pharmacological mole-
cules (e.g. certain hormones) from matter that is no longer biological (corpses,
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organic liquids such as urine), but that is actually biotechnological (bioreactors with
microorganisms engineered by implantation of the synthesis genes from the
rrequired molecules). To get a wide view on the genes already identified as maste
stemness genes and the way they interact, the reader can benefit from several sem-
inal papers: Boiani and Scholer [21], Li [22] and Hemberger et al. [23]. In particu-
lar, Figure 1 of Li’s paper, which depicts the signaling interaction and core tran-
scription regulation network that governs the pluripotency state, clearly demon-
strates that Oct4, Sox2 and Nanog are master transcription factors for the mainte-
nance of the undifferentiated state and self-renewal while Sox17 [24] is (one of) the
dES key transcriptional regulator(s) of differentiation: when Sox17 is represse
pluripotency-associated transcription factors Oct4, Nanog and Sox2 are active while
its expression downregulates those three genes and activates genes controlling
extraembryonic endoderm cytodifferentiation. In fact, our understanding of the
gene’s network controlling ES pluripotency is becoming clearer with respect to the
vague idea we had until few years ago. What we have learned is that the same
dgene(s) can act simultaneously in contrasting directions, both promoting an
repressing pluripotency and/or differentiation; this is achieved thanks to the action
of ante- and retro-grade mechanisms active in a conceptual model of cross-antago-
nisms in binary lineage decisions r(see below). In other words, there is a circula
relationship between extrinsic signaling and epigenetic modifiers remodeling chro-
matin conformation which leads to transcriptional and post-transcriptional regula-
ftion of pluripotency factors. Among the players of this remarkable phenomenon o
crosstalk regulating self-renewal are microRNAs (miRNAs) that control, by repress-
ing the translation of selected mRNAs, self-renewal and differentiation [25]. Figure
1 of the paper by Gangaraju and Lin [26] highlights this, and Table 1 of the same
aper lists t e m RNAs  n all cell types an  lineage ates ot  n SC anp h i involved i d f b h i d
ES cells. The crucial role played by miR-21 and miR-296 in promoting differentia-
tion (i.e. repressing self-renewal) and of miR-22 and miR-290-296 cluster in pro-
moting self-renewal (i.e. blocking differentiation) is quite clear. More than words,
the information depicted in Figures 3 and 4 of Hemberger et al [23] will teach the
reader of this crosstalk between genetic – epigenetic networks, molecular executors
– pluripotency – gene expression / silencing – stemness.
9.5
Induction of Pluripotency
The proof that the identity of differentiated cells can be fully reversed comes from
several lines of evidence beginning in the 1980s with Weintraub’s group, which
showed that the forced expression of MyoD in fibroblasts induces myotube forma-
tion (see [27] for a review). The author’s team [16] used the environmental/cytoplas-
tic strategy to reprogram fibroblasts into ES-like cells by growing them in cytoplas-
ts of mouse oocytes. The other research strategy uses a direct route by genetic engi-
neering techniques to insert stem cells directly into somatic cells and thus to acti-
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vate intrinsic factors of the genome. Both Yamanaka’s (Kyoto University) and
Thomson’s (Wisconsin University) teams successfully used [14] retroviral transfec-
tion to insert four genes responsible for stemness (Oct4, Sox2, c-myc,Klf4). At ≈
0.001 - 0.1% efficiency and stemness yields are still very low for both these strate-
gies. However, the path has been cleared, and over the next few years we will dis-
cover how to isolate reprogrammed ES cells (cytoplastic strategy) and how to clean
up the retroviruses used (transfective strategy).
We already have proof that thanks to a true epigenetic virus-free transfection
approach, that of inserting the same four factors into human cells using DNA trans-
posons (i.e. piggyBac, from the cabbage looper moth), reprogramming factors can
be inserted into differentiated cells to create clean iPS [28, 29]. In fact, DNA trans-
osons can easily e comp ete  remove  rom t e enome t us avoidi  t e r  op b l ly d f h g h ng h isk f
insertional mutagenesis occurring with the use of retroviruses, lentiviruses, aden-
oviruses and plasmids carriers. However, all of the reprogramming techniques still
had very low efficiencies, which may be due to several reasons as Shinya Yamanaka
tried to explain [14].
These kinds of experiments have also allowed the conceptual derivation of the
principle of transcription factor cross-antagonisms in binary lineage decisions
ddeveloped by Thomas Graf‘s group [27] to explain cell transdetermination an
ftransdifferentiation in development and experimental biology. A great merit o
fGraf ’s group is the additional effort to framework these concepts in the context o
dWaddington’s epigenetic landscape models [27; refer to Figs. 1, 3, 5] as di
Hemberger et al. (see above) reflecting on the epigenetic dynamics of SC biology
[23]. Another great paper by Zhou and Melton [30] clearly explains the conversion
of one cell into another, as did Wernig’s group [31] showing the “direct conversion
dof fibroblasts to functional neurons in vitro by only three factors (Ascl1, Brn2 an
Myt1l)”. The piggyBac transposon system has been developed to avoid permanent-
ly altering the genome, e.g. non-integrating adenoviruses and transient plasmids.
However, all these approaches involve introducing foreign DNA, while the ideal is
to induce pluripotency for cellular reprogramming just using chemicals or biophys-
dical stimuli. Sheng Ding (Scripps Research Institute, La Jolla, California) manage
dto do so [32] using a mix of purified proteins (from the four Yamanaka genes) an
valproic acid (a histone deacetylase inhibitor). Along the route of the protein only
technique, Shen Ding’s team also contributed a detailed analysis [33] on selected
chemical compounds that regulate cell fate: synthetic small molecules and natural
ro ucts t at bi  to nuc ear receptors, histone- an  DNA-modifyi  enz mes anp d h nd l d ng y d
protein kinases and signaling molecules (see Fig. 2 and 3 in [33]). The great advan-
ftage of this promising chemical approach is that it is open to the development o
therapeutic strategies by stimulating endogenous cells to regenerate in vivo (see the
special insight on regenerative medicine [34]), thus likely targeting the patients’
own cells. This means that the world of iPS (índuced pluripotent stem cells) is a step
closer to the clinic with personalized medicine.
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9.6 
Stem Cells in Regenerative Medicine
Over the last decade, stem-cell-based therapy for cellular diseases has literally
transformed medicine (and will undoubtedly continue to do so), as traditional tissue
repair techniques have been complemented by regenerative medicine. Diseases that
already benefit of SC therapies include myeloproliferative disorders (bone marrow
transplantation), certain types of blood cancer, severe burns (artif icial skin) and
cornea damages. New treatments, which are still at an experimental stage, but which
we could reasonably expect to be ready in as little as five years, will target for heart
attacks, Parkinson’s disease and diabetes. To complete the experimental scenario, it
ris important to note that several SC applications are already being developed fo
regenerative medicine. The conceptual paradigm underlying this innovative research
dis the understanding that biological reagents, namely SCs, are now available, an
that they are the means by which tissues can be regenerated. Some approaches to
regenerative medicine (e.g. for defects in bone growth) use SCs from the patients
themselves (autologous cells) and induce either circulating SCs or SCs from certain
histological niches to move towards the area in need of repair. Other approaches use
the current ability to produce large quantities of differentiated cells in vitro: SCs are
cultured in solutions of varying composition containing molecules which can trig-
ger differentiation into all the cell types that make up tissues (renal epithelium,
lung, liver cells, cardiomyocytes, dopaminergic neurons, motor neurons, bone cells,
detc.). In tissue engineering, these large quantities of differentiated cells can be use
to obtain three-dimensional, transplantable constructs. The process  uses biopoly-
mer skeletons to produce the organ required. Research and experiments are testing
this technique on animal models in the pursuit of ambitious goals. For example,
nude mice (deprived of their immune system) are used to produce human germinal
cells, spermatozoids and oocytes; with pliable biomaterials serving as a skeleton on
which to grow transplant organs, SCs are triggered to differentiate into the cell types
that will form the organ in question. To date, success in the cultivation of trans-
lantable organs is limited to the bladder (Anthony Atala, Winston-Salem, Nortp h
Carolina). Attempts to grow teeth and the heart are in the early stages of develop-
ment. Research into organ cultivation is underway in several countries, and covers
the whole spectrum of systems that are prone to organ and tissue diseases: the nerv-
rous system (spinal injuries and neurodegenerative disorders), the cardiovascula
system (repair of necrotic area after heart failure, blood vessels), muscle and bone
(muscles, articular cartilage, production of collagen type I for skeletal diseases, ten-
dons, ligaments), endocrine (diabetes type I). It is worth recalling a few examples
of the therapeutic use of SC, while the reader is referred to other sections of this
volume for a detailed analysis. The recovery from adenosine deaminase deficiency
(resulting in severe combined immunodeficiency, ADA – SCID) in young patients
[35, 36] by stem cell gene therapy is a good example of the potential use of the pow-
erful technique of genetic modification of somatic SC [37]. The ongoing successful
trials today cover a wide range of diseases that already find therapeutic ameliora-
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tion thanks to SC treatments, i.e. the necrotic heart, Parkinson’s loss of dopaminer-
gic neurons and diabetes I. The latter has seen a great advancement, from islet trans-
plantation strategy to in vivo reprogramming of differentiated pancreatic exocrine
cells in adults (mice) into ß-cells [38] thanks to the re-expression of three key devel-
opmental regulators (Neurog3, Pdx1 and Mafa).
The first methodic clinical trial treatment based on human ES has also been
given the green light although the study is currently deadlocked (February 2010) by
the Food and Drug Administration (FDA). Geron Corporation (Menlo Park,
California) received approval to treat eleven patients (in a phase 1 multicenter trial)
who had suffered a complete thoracic-level spinal cord injury with the “GRNOPC1
ro uct”. This s a suspens on o  uman ES cell er  oligo en rocyte progen top d i i f h d ived d d i r
cells that already showed in preclinical studies an amazing capacity to remyelinate
and to stimulate nerve growth. This is the first time that the FDA has testif ied the
acceptance of all the procedures used to grow and characterize a SC population.
rBefore this approval there were only anecdotal cases of treatment, the most popula
being the study by Prof. Evan Y. Snyder, who implanted SC harvested from placen-
tas or derived from a variety of tissue types into patients with multiple sclerosis,
muscular dystrophy and several other neurological diseases. Interestingly enough,
the meta-analysis of more than sixty preclinical studies carried out by Janowski et
al. [39] on the employment of intravenous cell delivery for treatment of neurologi-
cal disorders showed that the indisputable positive effects of the therapy on brain
functioning are due to the molecular inhibition of several apoptosis pathways.
A good example of how fast and furious the advancement of knowledge has been
is given by the discovery by Songtao Shi of SC in dental pulp ten years ago: in such
a short time period we are already at the first translational medicine clinical trials
for regenerative medicine with autologous treatments (for which a full FDA
approval is not required). One of these studies was carried out by an Italian team
[40] that used dental SC to reconstruct the bone surrounding the site from which the
dental pulp was extracted. In addition, since these SC originate from the neural crest
they have the potential to treat neurodegenerative diseases as shown by the success-
ful neuronal growth detected after their grafting into the hippocampus of immuno-
suppressed mice [41].
Scientific development apart, the legal and ethical issues must undoubtedly be
resolved before these experimental models can be applied clinically, whether to treat
patients, or to relieve the transplant crisis, or to use SC to perform dpersonalize
medicine.
9.7
International Legal Framework: Stem Cell Biopolitics 
and Scientific Citizenship
SC technology challenges many of the principles of modern culture, such as free-
rdom, progress, democracy and justice; it affects all aspects of our life and ou
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health. Internationally,  we note the conspicuous absence of a politico-cultural
stance such as might identify the points of contact between advances in scientific
research and the autonomy of individuals over bio-existential choices. This absence
is partly due to the fact that in recent years knowledge has progressed tumultuous-
ly. More generally, however, the relationship between citizens and the state on bio-
political issues has not been redefined, and the same may be said of the relationship
between democracy and rights. The scientific community needs political decision-
fmakers to develop valid policy guidelines upon which to base the management o
the wide-ranging issues generated by the biotechnological revolution and by SC
research. Of extreme importance and urgency is the governance of biotechnology
research, a process to which all citizens should be able to contribute. To do so, cit-
izens will have to expand their understanding of the intrinsic opportunities and lim-
itations inherent in biotechnology, and particularly in SC biology and techniques.
fIdeally, each individual should be able to constantly re-delineate the boundaries o
his relationship with the world, and thus to stay abreast of the changes wrought in
boundaries, as well as in the deeper meaning of life and its forms, by our era’s con-
stant advances in knowledge: the biopolitics of the body and its transformations,
birth, end-of-life decisions, biomedical experimentation and control of personal
decisions, are all at issue. Only through the development of reflective attitudes will
citizens avoid the easy routes din debate, e.g. the opinion that the research describe
here “will lead to technology taking control over humans” would be (horribly) easy.
A perfect example of the impediment of the unreflective, easy route thinking is to
be found in the story of cloning.
The story highlights other limits of knowledge-based Western societies: ideolog-
ical preconceptions and prejudices. On an international scale, with more or less
emphasis, political decision-makers tend to discuss the nature of the embryo with-
out paying attention to what researchers or scientists have to say. Typically, there is
a reluctance both to make scientific information readily available, and to allow cit-
izens to express themselves freely on constraints and limitations, or even on those
possible applications that are deemed lawful. The general public is manipulated with
poor information and scaremongering about what the mad scientists would like to
do. The result is a huge delay in possible therapeutic applications for Parkinson’s,
dystrophy and juvenile diabetes, to name but a few afflictions. The most dramatic
example of this is how some countries fail to deal with cryopreserved embryos,
when the simple application of a scientific method could help bring the complicat-
ed debate on bioethics to an end. There are three ways to deal with frozen embryos
(adoption is excluded from the list because it is impractical and unrealistic: In Italy
only two or three embryos a year are implanted into adoptive mothers):
1) leave them frozen indefinitely. This decision is synonymous with death, albeit
slow;
2) defrost and discard them, thus accelerating their death;
3) use them for research into cell differentiation. This option also implies death,
but by  providing humanity with important scientific knowledge on how to use
fcells in reconstructive cell therapy, it would arguably be an attenuated form o
death. And indeed reconstruction also implies a living embryo, albeit in an
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extended sense, because the embryo’s cells would be disseminated to other liv-
ing individuals.
Looking beyond ideological, religious and ethical standpoints, it is clear that
only the third option ensures the embryo’s life. The decision should be based on
what to do instead of considering what they are. It is important to stress once again
how the application of a scientific method could help decide what to do with hun-
dreds of thousands of frozen embryos, instead of inappropriately referring to ethi-
cal principles or to the concept of person. This concept does not belong to biology
or to factual science, and is only valid in philosophy, law and theology: the charac-
ter mask in Greco-Roman theatre, and the Holy Trinity and Christ as a person. Many
religions consider animals and hurricanes to be people with souls, just like human
beings. One suggestion might be to find an operational definition of ethics, the the-
ory and practice of the conduct aimed at f inding happiness through being good.
Aristotle thought that happiness and good were virtues, whereas Kant thought they
meant having the autonomy to behave according to universal laws. But it is not easy
to determine the factual nature of being good. Indeed, it is clear that the alleged eth-
ical consensus of humanity continues to be a beguiling hypothesis: man’s exploita-
tion of man, the just war and human history in its entirety, suggest that the hypoth-
esis is probably false. Ethics are determined by religion and ideology. Religion
entails adhesion to a view of the world in which life is constrained (relegated) to the
notion of fundamental choice, to the extent that you would even give your life in
support of this choice. Ideology is a vision and assessment of the world marked by
social transcendence (political ethics in Aristotle). Therefore, we cannot expect a
Hindu, a Christian and a dialectical materialist to follow the same ethics. In today’s
complex world, only responsibility can assist decision-making, since the basic ele-
ment of ethics is responsible conduct (conscious and voluntary), and therefore, mak-
ing a choice. These embryos exist and demand a better fate than being kept frozen
indefinitely or being discarded: now that they have been created, they petition us to
play a part in the matter-energy process that we call life. Scientific method could
clearly be of assistance if we were to re-collocate our own legitimate principles
within an awareness of ongoing advances in scientific knowledge. Keeping abreast
of such advances is an integral part of our culture; it requires patient dedication to
acquire the conceptual instruments needed to assess technical applications.
Today, in the age of knowledge-based societies, those instruments are necessary,
especially for society’s leaders, such as political decision makers, magistrates and
journalists. The generation gap that affects attitudes towards the technical repro-
dducibility of certain phases of embryo development is once again paradigmatic, an
it is hindering all SC research in Italy, Austria, Germany and Ireland. As already
stated, this hindrance certainly derives from the refusal of a scientific approach to
the problem. It is clear that differences of opinion about the embryo derives from
disagreement on exactly when in the development process the cells become a new
individual. An individual is composed of about one million billion cells and origi-
nates from a development process that is programmed in the first copy of the new
individual’s DNA, the zygote genome. This affirmation has been ascertained as fact:
biological knowledge allows us to clearly establish that the beginning of the devel-
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opment process coincides with the formation of the first functional copy of its
dgenome. All forms of animal and plant reproduction, both natural (fertilization an
parthenogenesis) and artif icial (assisted reproduction and cloning), share this prin-
ciple; the principle accordingly assumes a universal validity that shelters it from all
fdoubt whatsoever, and scatters all other propositions as to the ontogenetic origin o
a living being. In mammals, this originating moment does not coincide with the
appearance of the unicellular embryo, the zygote. It varies on the basis of the
species in question: in mice, it occurs when there are two cells, in humans, when
there are four. Acknowledgement of this factual datum would allow advocates of all
religious and ideological standpoints both to defend their principles and to realign
their positions to a setting within the boundaries of current scientific knowledge. At
least two positions collapse as fallacy (i.e. as lacking universality): the gradualist
view (whereby the human individual begins to exist when the nervous system
appears, around either day 14 of gestation, or days 6-7 in the case of uterine implan-
tation); and the view that considers fertilization (the fusion of sperm and oocyte
membranes) as the beginning of a human life. Indeed, not all living creatures form
a nervous system, become implanted in the uterus, or exist through fertilization (e.g.
babies born following ICSI treatment never passed through fertilization in the nat-
ural way, i.e. through the sperm and egg membranes fusion). The four-cell embryo
occurs between the 40th and 50th rhour of development in humans, so the docto
would have time to produce the number of embryos needed, to perform pre-implan-
tation diagnoses, and to derive SCs, without having to enter into philosophical
debates on the nature of existence, or play semantic games on the meaning of the
word embryo.
Developments in life sciences raise wide-ranging collateral issues (social, legal,
political, economic, religious and philosophic), and the breadth of these issues is
central to any analysis of the transformation of Western societies. Of particular
importance is the role of politics and the extent to which the political system: (a)
recognizes alternative policies as valid within a democratic framework and (b)
invests in projects that promote shared values. Such values are an invaluable asset
in a multicultural society, and science can contribute to their development. For a
society to be democratic and based on justice and equity, its citizens need to be sci-
entifically literate and knowledgeable. Only citizens who have the conceptual tools
to critically evaluate the new frontiers of scientific knowledge can ensure a demo-
hcratic system, because they are able to influence society in an effective way wit
their own independent opinions.
The organization of new knowledge and the development of  new models of rep-
resentation are the basis for a new and necessary form of democracy, in which new
dknowledge is not seen as a threat but as an opportunity. Instead of being considere
a source of inequality, knowledge should actually serve to promote the welfare of all
humanity, as Francis Bacon proposed four hundred years ago. In order for this to
happen, the biosciences need to develop new analytical tools, both for the assess-
ment of science-driven revolution and for the delivery of clear explanations of the
hsame to the general public, the lay-people; well-informed citizens guarantee bot
tstrong support for investing in scientific research, and the formation of independen
Biotechnology in Surgery146
9
opinions that are reflected in democratic decisions about what should or should not
be done. A good example of procedural correctness is to be found in the UK gov-
ernment’s recently published “White Paper on Genetics in the NHS”; addressed to
all citizens, it establishes democratic monitoring, and ensures respect for the elabo-
ration of principles and ethical norms that permit multiple values.
fThe biological knowledge available to us today puts many of the principles o
modern culture to the test: freedom (e.g. the opportunities that genetic databanks
offer medical research or criminal investigation), progress (opportunities in finance
and in medical diagnosis), and even democracy and distributive justice; it intervenes
in all areas of individual and social life. Biology’s manipulation of living organisms
(think of the substantial opportunities offered by GM technologies) has effectively
rought a out a sc entific revo ut on whi  as a most exc us  e n considereb b i l i ch h l l ively b e d
in terms of technological progress. Accordingly, the impact of such manipulation  on
modern culture has not yet been sufficiently debated and assessed. This leads us to
ask a philosophical and political question; should we refuse scientific progress
r(which would lead to a genetic class system, as any new advances in medicine, fo
instance, would only be available to the people who could afford them), or should
we speed up the processes of social awareness and management of the new relation-
ship between science and society, which the new biological revolution has instigat-
ed? The true nature of scientific endeavor is democracy: advancement of scientific
knowledge can mitigate or eliminate the inequalities that have historically charac-
terized the life of all human beings. It could enable a new conception of citizenship
which goes beyond that of Jefferson’s American Revolution, or of the French
Revolution: in the era of globalization and scientific knowledge-based societies
(knowledge has evidently become the real economic and social driving force), citi-
zens will all have equal access to SC therapies, and any other medical care they
need, regardless of where they come from or how wealthy they are.
Well-informed, healthy citizens can guarantee a democratic, fair society.
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10.1 
Origin and Evolution of the Cancer Stem Cell Paradigm
Far from being a new concept, the belief that cancer might originate from stem cells
dates back to the mid-19th century when Rudolf Virchow proposed that cancer aris-
es from embryo-like cells, based on the histologic similarity between embryonic
and cancer tissues. This hypothesis was later extended by Cohnheim and Durante,
who postulated that adult tissues contain embryonic remnants that usually lie dor-
mant, but can be activated to give rise to a tumor. This original view, formerly
referred to as the embryonic rest theory, has been updated with the cancer stem cell
hypothesis, according to which a vicious stem cell-like subpopulation generates a
tumor through the deregulation of the self-renewal process. However, the proof-of-
concept was provided more than a century later with the identification of leukemia-
initiating stem cells in the peripheral blood of acute myeloid leukemia patients [1].
Ever since, the cancer stem cell theory has gained identity and different tissue-spe-
cific cancer stem cells (CSCs) have been isolated from both big killers, and rare
cancers. These studies were based on a similar experimental approach, which com-
bined fluorescence-activated cell sorting (FACS analysis) of primary tumor cells
with antibodies against specific cell-surface markers and serial orthotropic trans-
plantation into immunocompromised mice. Although different operational defini-
tions of CSCs have been proposed, four properties are in general adopted to define
them: (i) expression of a distinctive repertoire of cell surface markers for isolation
and purification; (ii) formation of tumorspheres in suspension culture; (iii) tumori-
genic capacity in immunocompromised mice, as opposed to all other cellular sub-
sets; and (iv) generation of a heterogeneous cancer tissue closely resembling the
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original tumor. A further technique for isolation of CSCs relies on their ability to
actively exclude the dye HOECHST 33342, which defines them as side population
(SP).
10.2
Functional Genomics of CSCs
Given the complexity and heterogeneity of genetic derangements, cancer is canoni-
cally defined as a genetic disease. In the last ten years, the introduction of whole
genome profiling technologies has expanded our knowledge of the genetic pathways
associated with the development and progression of cancer and, more recently,
microarray analysis of gene expression profiles has provided a way to improve diag-
nosis and risk stratif ication of cancer patients. Two prognostic signatures, for exam-
ple, the MammaPrint® and the Oncotype DX® r, have been validated in breast cance
and represent the basis for large ongoing clinical trials named MINDACT
(Microarray In Node negative Disease may Avoid ChemoTherapy) and TAILORx
(Trial Assigning Individualized Options for Treatment). Since the major implication
of the cancer stem cell theory is that key pathways controlling normal stem cells are
deregulated in their malignant counterpart, gene expression profiling of CSC-asso-
ciated genes might provide a more exhaustive picture of deregulated stemness-asso-
ciated genes. The identification and validation of CSC-based signatures might have
different implications including a more accurate individual risk assessment, the
identification of new druggable pathways and the discovery of more specific mark-
ers for CSC isolation and purification. In a proof-of-principle study, a global gene
expression profiling led to the identification of an invasiveness gene signature
(IGS), consisting of 186 differentially expressed genes in breast cancer stem cells
compared with normal breast epithelium [2]. The IGS was significantly associated
with overall and metastasis-free survival in a large cohort of breast cancer patients.
Using a similar approach, genes involved in maintenance of stemness and tumor-
stroma crosstalk, such as hedgehog signaling and transforming growth factor-β
(TGF-β) pathways, have been found selectively deregulated in breast CSCs, while
nontumorigenic cancer cells express differentiation-related genes. Notably, TGF-β
is a well-known mediator of the epithelial-to-mesenchymal transition (EMT) pro-
gram which, in turn, is associated with the acquisition of stemness traits. With
fregard to anticancer therapy, a stem-cell-resembling expression profile consisting o
an 11-gene signature has emerged as a powerful predictor of a short interval to dis-
ease recurrence and death after therapy in distinct types of cancer patients [3].
Finally, microarray analysis of SP versus non-SP thyroid cancer cells revealed a dis-
tinctive pattern of expression of stem-cell-associated genes, thus suggesting a




Molecular Biology of CSCs
dA normal stem cell is defined as a low-frequency cell type able to renew itself an
to differentiate into one or more specialized cells. In general, self-renewal, exten-
sive proliferation and capability to differentiate into multiple lineages are the hall-
marks of stem cells, which make them unique. The self-renewal program, fluctuat-
ring from symmetric to asymmetric divisions, is the most important variable fo
stemness maintenance in both physiology and pathobiology. The symmetric division
implies the generation of two daughter stem (or two more differentiated) cells,
whereas during the asymmetric division the progeny consists in a cell retaining a
stem cell phenotype and a more differentiated cell. Two major classes of normal
stem cells are to be distinguished: embryonic stem cells (ESCs) and somatic stem
cells (SSCs). The first are pluripotent progenitors derived from early embryos able
to generate the three germ layers and then, under a strict differentiation pattern, all
differentiated cell types. SSCs have a much more restricted potential, representing
a dedicated pool of undifferentiated and slowly cycling cells located in various
organs of the body. This cellular subset maintains tissue homeostasis by replacing
senescent, dying or damaged cells through a high capability of both self-renewal
and asymmetric division. Thus, SSCs play a critical role in sustaining the lifelong
functionality of organs. In adults, the functional triad of SSCs is spatially and tem-
porally regulated into specialized microenvironments, named niches, in which stem
dcells reside. These highly organized micro-architectonic entities, mainly constitute
by mesenchymal cells, provide physical anchorage and govern the stem cell fate by
dcontrolling both their number and the replication kinetic. To date, the most advance
studies in stem cell niche research have been carried out in the hematopoietic sys-
tem [5]. Within the bone marrow two different niches have been described and char-
acterized. The osteoblastic niche controls hematopoietic stem-cell cycling and pro-
dmotes quiescence, whereas the vascular niche mainly regulates proliferation an
egress to the circulation. The shuttling of hematopoietic precursor cells between the
two niches is probably dependent on the oxygen level. Under hypoxic condition,
hematopoietic stem cells move from the osteoblastic to the vascular niche, thus pro-
viding the necessary supply of mature cells in the peripheral blood stream. The
opposite path takes place with the re-establishment of a normoxic state. Since CSCs
probably share various properties with their normal counterpart, it is currently
believed that these tumor-initiating cells act by hijacking physiologic stem cell sig-
nalings and require a niche-like supportive microenvironment. From a functional
nt o   his not on mplies t at opmenta  re ator  mo ecu es and/poi f view, t i i h devel l gul y l l or
pathways orchestrating the self-renewal program in adult tissue stem cell compart-
ments, such as wingless-type-β-catenin, notch-jagged, hedgehog-patched-
fsmoothened and bone morphogenetic proteins, represent the major controllers o
CSCs. For example, the hedgehog signaling pathway has been found to be reactivat-
ded in some skin and central nervous system cancers, like basal-cell tumor [6] an
medulloblastoma [7], in consequence of loss- or gain-of-function mutations in the
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negative (patched homologue 1, PTCH1) or positive (smoothened homologue,
SMO) regulator of the pathway, respectively. These mutations result in constitutive
activation of the hedgehog signaling, leading to unrestrained proliferation of early
progenitor cells of the skin and cerebellum. Similarly, activating mutations in the
Wnt-β f-catenin axis result in colonic polyps in consequence of hyperproliferation o
dintestinal crypt progenitor cells [8]. Considering the similarities between CSCs an
their normal counterpart, it is also likely that CSCs rely on a tumor-promoting
microenvironment that maintains CSCs able to self-renew, differentiate and prolif-
erate. A paradigmatic example has been observed in AML, in which leukemic stem




dCarcinogenesis is defined as a multi-step process in which both exogenous an
endogenous factors concur in determining the accumulation of DNA mutations. The
progressive acquisition of random, non-lethal transforming mutations finally turn a
normal cell into a malignant cell. Historically, the stochastic or clonal evolution
model of cancer has been widely accepted for decades. According to this model, dif-
ferent dominant mutant clones able to self-renew themselves acquire a survival
advantage over other populations cohabitating within the tumor mass. Since differ-
ent malignant cells maintain and propagate the tumor, the heterogeneity seen in can-
cer mirrors the natural competition between various dominant clones for vital
resources, according to Darwinian principles. Even if the accumulation of genetic
lesions underpins this model, also epigenetic changes and microenvironmental fac-
tors cooperate to finally generate a malignant phenotype. On the other hand, the
concept that a CSC represents the seed of tumors implies that a stem cell is the ini-
tial target of the oncogenic process and, although CSCs constitute a minority of the
cells within a tumor, this subpopulation is critical for tumor propagation. In gener-
dal, the higher proliferative potential and the longer life-span of stem cells, compare
with their differentiated progeny, make these cells more likely to undergo and accu-
mulate genetic alterations. In recent years, the identification of these tumor-initiat-
ing cells led to the paradigm of cancer as a heterogeneous, organ-like micro-ecosys-
tems in which the CSC is positioned at the apex of the tissue hierarchy, thus close-
ly resembling the functional architecture of normal tissues. As a result, the histolog-
ic, genetic and molecular heterogeneity of tumors, as well as the interindividual
variability in the natural course of neoplastic diseases, could be explained with the
intrinsic plasticity of a CSC which retains, albeit aberrantly, many features of its
normal counterpart. Although this hierarchical model with a small pool of stem cell-
like tumor-initiating cells at the top of the pyramid has largely replaced the lclona
evolution model, both models are not mutually exclusive, but probably coexist, since




CSCs and Tumor Recurrence
The  widespread adoption of screening programs and the refinement of radiologic
techniques have led to a dramatic increase in patients diagnosed with early-stage
disease, thus suitable for treatment with a curative intent. If radical surgery is the
mainstay of treatment for these patients, perioperative radiotherapy and/or systemic
therapy are often administered in order to decrease the likelihood of loco-regional
and distant recurrence, respectively. Despite these efforts, the global mortality rate
for many tumors remains quite stable. This is, at least in part, attributable to distant
recurrence. The pattern and the time of recurrence of many tumors, often in the
order of years after the primary treatment, imposes three major biologic considera-
tions: (i) the acquisition of malignant traits that enable cancer cells to colonize dis-
rtant sites is an early event, as corroborated by the detection of circulating tumo
rcells and/or disseminated tumor cells in the bone marrow of early-stage cance
patients (minimal residual disease); (ii) early-disseminated cancer cells can remain
in a quiescent status for years, a condition known as tumor dormancy, which
explains tumor relapse after a long period of remission; (iii) residual cancer cells,
or at least a fraction, are intrinsically resistant to radiotherapy- and chemotherapy-
induced cell death, thus impairing (neo)adjuvant therapy. There are many biologic
clues supporting CSCs as the ideal candidate for explaining the failure of this inte-
grated therapeutic approach. First, increasing evidence is connecting CSC biology
to the EMT, which is thought to be one of the major determinants in cancer invasion
and metastasis. The EMT is a genetic program consisting in a drastic cytoskeletal
rearrangement through which cancer cells at the leading invasive edge acquire a
high motile, mesenchymal-like phenotype. It has been demonstrated that the induc-
tion of EMT results in the acquisition of stem-cell like properties, such as an
fincreased ability to form spheres in suspension culture [9]. Moreover, the ability o
normal stem cells, and probably of CSC, to remain in a quiescent state within a pro-
tective niche provides the conceptual framework of tumor dormancy. In light of this,
the observation that breast cancer-derived bone marrow micrometastases contain a
higher percentage of cancer cells expressing stemness markers compared with the
primary tumor site further enforces this assumption [10]. Other properties of CSCs,
such as the constitutive activation of the DNA repair checkpoint and a strong
expression of radical scavenger genes, can be linked to local and locoregional recur-
rence following adjuvant or salvage radiotherapy. Moreover, the failure of systemic
adjuvant chemotherapy and the progressive acquisition of a chemorefractory pheno-
type suggest that adaptive mechanisms are brought into play by CSCs in order to
circumvent chemotherapy-induced cytotoxicity. Schematically, it is possible to dis-
tinguish at least four independent mechanisms of chemoresistance [11]: (i) an
fincreased expression of multidrug-resistance proteins; (ii) an efficient system o
DNA repair; (iii) strategies to avoid apoptosis; and (iv) capability to remain in a qui-
escent state. CSCs express high level of drug pumps such as adenosine triphosphate
(ATP)-binding cassette transporters (ABC transporters), which provide the rationale
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or t e HOECHST 33342 e ux assay. Thi ogenet cally conserve  system f h ffl s phyl i d for
drug efflux extrudes a broad range of amphiphilic compounds, also including a wide
range of chemotherapeutic agents of natural origin such as mitotic-spindle poisons.
This phenomenon is known as multi-drug resistance (MDR). An enhanced capabil-
ity to repair DNA damage can confer resistance to alkylating agents. It is well
known that the overexpression of proteins playing a critical role in the nucleotide
excision repair (NER) pathway, such as ERCC1 (enzyme repair cross-complemen-
tation group 1), makes cancer cells more proficient in removing platinum-DNA
dadducts. Next, harmful damaged cells are physiologically removed by programme
cell death, or apoptosis. Conversely, the imbalance in the apoptotic machinery is
associated with chemoresistance. CSCs express high levels of anti-apoptotic pro-
teins such as BCL-2, BCL-XL and IAP family members, which confer a proclivity
towards an anti-apoptotic state. Moreover, quiescent or dormant CSCs might be
intrinsically resistant to chemotherapy since such agents are exclusively effective
against active cycling cells. Finally, an enrichment of the CSC pool has been docu-
mented following exposure to different chemotherapeutic agents. This latter phe-
nomenon has a dual, biologic and clinical, implication since, on the one hand, it rep-
resents a crossroad between the clonal evolution model and the lhierarchical mode
and, on the other hand, it might explain the progressive chemorefractory state that
finally leads to patient death. Figure 10.1 shows the natural course of tumors
according to the CSCs theory.
10.6
CSC and Metastases
Once metastasized, a tumor becomes incurable and palliative systemic therapy is the
ronly therapeutic option which provides some benefits in terms of delay in tumo
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Fig. 10.1 The clinical course of tumors which relapse at distant sites years after surgical treatment
and which progressively become unresponsive to chemotherapy can be explain by the biological
properties of CSCs
progression and relief from tumor-related symptoms. For many years, a passive
metastatization model based on the escape of cancer cells from the primary tumor,
the subsequent access to systemic circulation and the final entrapment in the
microvascular bed (mechanical trapping theory) has been accepted. However, this
model does not explain the organ-specific metastatic pattern of many cancers, as
well as the unusual involvement of some organs such as heart or kidney. Although
the site-specific spreading of tumors was guessed since 1889 by Stephen Paget, it
was only during the 21st century that the seed and soil theory has taken more con-
crete shape. According to a modern view, the metastatic cascade occurs in a step-
wise, nonrandom fashion and requires a series of coordinate events ranging from the
generation of new blood vessels to adaptation to growth in a foreign soil. Metastasis
formation is far from being an efficient process since only a limited number of cells,
once having left the primary tumor, can successfully complete all steps required to
re-grow in a distant site. In such a scenario, therefore, the discovery of CSCs has
added a further level of complexity about mechanisms orchestrating cancer metas-
tasis. Based on the assumption that a plastic CSC is the tumor-initiating cell, it is
reasonable that a solitary CSC can initiate a metastatic lesion and then thrive in a
tumor-hostile microenvironment. To reach a distant site, however, cancer cells have
to accomplish early phases of the metastatic cascade, which enable them to enter the
systemic circulation and, afterwards, to migrate toward the future site of metastasis.
The generation of new blood vessels, a process known as neoangiogenesis, repre-
dsents a rate-limiting process in growth and survival of both primary tumor an
metastasis. In fact, a tumor cannot grow beyond 2 mm in the absence of an adequate
vascular supply. Through neoangiogenesis cancer cells not only gain access to oxy-
gen and nutrients, but also can enter the systemic blood circulation. This complex
rand dynamic process is mainly sustained by vascular endothelial growth facto
(VEGF) family members and their cognate receptors (VEGFR family members),
which trigger a multitude of proangiogenic activities. Evidence on how CSCs influ-
ence neoangiogenesis comes from studies on high-grade primary nervous system
tumors. Under both normoxic and hypoxic conditions, stem-cell-like glioma cells
produce higher levels of VEGF than the non-CSC population, thus suggesting a
potential role of CSCs in the angiogenic switch [12]. It is, however, likely that with-
in a heterogeneous tumor mass some clones do not rely on angiogenic programs, but
adopt alternative strategies to recreate a vascular bed including vasculogenesis (de
rnovo generation of vessels from pluripotent stem cells) or vascular mimicry (tumo
cells mimicking endothelial cell functions). It has been demonstrated, for example,
that under specific tissue conditions ovarian CSCs differentiate into endothelial-like
cells [13]. Thus, CSCs actively contribute to tumor vascularization by serving, ulti-
mately, as vascular progenitors. Although it is not clear to what extent CSCs are
dependent on a protective microenvironment (the vascular niche), brain tumor-initi-
ating cells localize near the capillaries [14]. In these areas endothelial cells proba-
bly maintain CSCs in an undifferentiated state via the regulation of the self-renew-
al program. Once within the blood stream, cancer cells migrate in a nonrandom
manner, probably driven by a complex network of chemoattractant cytokines that
physiologically control leukocyte trafficking and stem cell movements within the
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bone marrow niches. Ample evidence suggests that the chemokine receptor CXCR4
ddictates the migratory itinerary of cancer cells once engaged by its exclusive ligan
CXCL12. This migratory response probably exploits a chemokine gradient since
CXCL12 is constitutively produced in the most common sites of cancer metastasis
such as bone, lymph nodes, liver and lung. Notably, CXCR4 has been found to be
expressed by several cancer cells and has been proposed as CSCs marker [15]. It is,
therefore, likely that CSCs adopt CXCR4 to selectively migrate toward, and then
colonize, distant organs expressing a high amount of CXCL12. The role of EMT in
cancer metastasis is discussed in Section 10.5.
10.7
In Vivo Imaging of CSCs
In clinical practice the extension of a tumor and the response following systemic
dtherapy are assessed by morphologic imaging technologies, such as compute
tomography (CT) and magnetic resonance imaging (MRI), or metabolic techniques
like positron emission tomography (PET). Given that CSCs represent a rare subpop-
ulation within a tumor, the CSC model raises the question of a single-cell or single
compartment resolution. Albeit with a certain degree of variability, in fact, CSCs are
rin the order of 0.1% in primary tumors and commercial cell lines. However, thei
biologic relevance imposes the development of new imaging techniques and/or the
adaption of preexisting high-resolution radiologic technologies to detect and moni-
tor them. Even though ex vivo imaging of cancer cells at a single-cell level was
made possible a number of years ago, in vivo imaging of CSCs is a more complex
challenge. In particular, the critical point is the choice of the optical signal.
Although bioluminescence is widely used to define tumor growth and  metastasis in
vivo, bioluminescence imaging has intrinsic limitations. This technique is far from
a single-cell resolution since it needs approximately 2,500 luciferase-expressing
cells for a proper visualization [16]. Moreover, both the need to inject animals with
the luciferin and the biodistribution of the substrate should be considered as poten-
tial limiting factors. Fluorescent signals represent the gold standard for tracking a
poorly represented population of cells [17]. The detection of fluorescence offers
fthree major advantages: high intensity and stability of the signal, high sensitivity o
the optical imaging devices for fluorescence readout and the possibility to concomi-
tantly employ two or more fluorophores, thus allowing the concomitantly visualiza-
tion of different populations within a tumor mass. Furthermore, the surgical creation
tof a skin flap allows internal organs to be imaged by avoiding skin-related ligh
scatter. Beside fluorescent and bioluminescent signals, different probes are available
rto detect microenvironmental changes, such as neoangiogenesis or extracellula
matrix degradation, thus providing an overview of the whole tumor-stroma compart-
dment. However, given the long experience gained with the development of MRI an
PET, these technologies have more possibility to be adopted in the clinic with the
gspecific aim of monitorin  the CSCs pool. This has become a more concrete option
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through the evolution of contrast agents for MRI, which have given the opportunity
to image at a cellular resolution [18].
10.8
CSCs and Colon Cancer
dColorectal cancer (CRC) is a major public health problem, representing the secon
most prevalent malignant disease in industrialized countries. Despite radical sur-
gery, approximately 40-50% of patients who undergo curative resection will experi-
ence distant recurrence. In addition, 20-25% of patients present with metastatic dis-
ease at the time of diagnosis. Although third-generation regimens incorporating tar-
geted agents into the chemotherapy backbone are able to produce tumor response in
nearly half of metastatic patients, the progressive development of a chemorefracto-
ry disease ultimately leads to patient death. In order to provide a more comprehen-
sive picture on how colon CSCs (CCSCs) impact on the course of the disease, a
rief examination of the functional organization of colonic stem cells in the contexb t
of their microenvironment is required. The normal histology of colonic epithelium
consists of tube-shaped units, called crypts of Lieberkühn. Stem cells are located at
the bottom of the crypt and through self-renewal generate a transit-amplifying pop-
ulation that, during migration up the crypt, terminally differentiate into colonocytes,
rgoblet cells or enteroendocrine cells. Moving toward CRC pathobiology, the pionee
study of colorectal carcinogenesis came from Vogelstein who two decades ago
described the adenoma-carcinoma sequence. This model was based on sequential
mutations occurring in oncogenes and tumor suppressor genes that, through a pro-
gressive acquisition of neoplastic features, f inally turn a normal epithelium into an
invasive tumor. Within this framework it can therefore be assumed that it is a tissue
stem cell located in the depths of the intestinal crypt that undergoes neoplastic
transformation and progressively acquires pro-metastatic properties. This is consis-
tent with histologic evidence showing multiple differentiated cell types in CRC
rsamples. CCSCs have been identified by the expression of the cell-surface marke
CD133 [19], also known as prominin-1. Although this molecule seems to act as
organizer of plasma membrane topology, its functional role is still debated.
However, according to the operational definition of CSCs, only the CD133+ popu-
lation (accounting for approximately 2.5% of all tumor cells) is able to recapitulate
the parental tumor in immunocompromised mice, thus giving rise a tumor with a
ratio of CD133+ and CD133- cells similar to the tumor of origin. A further cell sur-
face marker repertoire, consisting of CD44+/EpCAMhigh , identified a cellular pop-
ulation that displays the common features of CSCs [20]. More recently, beside these
two protocols, aldehyde dehydrogenase 1 (ALDH1) has emerged as a promising
CCSC marker [21]. Since all the above-mentioned protocols allow a cellular sub-
population with features of CSCs to be isolated, it is reasonable to assume that a
combination of these markers could improve the isolation rate or, alternatively,
could help distinguish CSCs with distinct biologic behavior. However, whether a
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multiple-marker approach translates into a more efficient isolation of CCSCs has
yet to be defined.
In order to shed light on CRC metastases, a migrating CSC model has been pro-
posed. Consistent with this theory, it is currently believed that a mobilized CSC arises
from a stationary CSC via the persistent activation of self-renewal-associated pathways
and/or of the EMT program. This idea is corroborated by the fact that metastases from
many tumors recapitulate the polarized pattern seen in the primary tumor, in which dif-
ferentiated and undifferentiated cells reside in distinct areas of the tumor. Finally, while
CSCs have been defined as the dark seed of cancer, this is mainly because of they are
insensitive to treatment. Cytotoxic agents, in fact, are active against actively prolifer-
rating cells, representing the bulk of tumor mass, without affecting slowly-cycling (o
quiescent) CSCs. As a result, chemotherapy kills differentiated, non-tumorigenic cells,
leaving behind the CSC pool, or even its enrichment.
10.9
Breast Cancer and CSCs
Despite advances in early diagnosis and treatment, breast cancer (BC) remains a sig-
nificant public health concern, with more than a million new cases diagnosed annu-
ally. To date, prognosis and treatment of early-stage BC are largely dependent on
well-known clinical and pathologic features including age, menopausal status,
tumor size, grade, nodal involvement, hormonal receptors expression and HER-2
status. Despite major advances in the characterization of the biologic aggressiveness
of the disease, survival data reveal a wide variability in BC course within each pre-
diction category, thus indicating that as yet uncharacterized molecular differences
are responsible for such heterogeneity. In recent years, whole genome profiling
technologies offered a working model for a BC molecular taxonomy. The original
classification proposed by Perou, named the molecular portrait of BC, led to the
identification of five subgroups (luminal A, luminal B, basal-like, HER2, and nor-
mal breast-like), according to the resemblance between the genetic profiles of nor-
mal and neoplastic breast epithelial and mioepithelial cells. Each group mainly dif-
fers by the presence or the absence of the estrogen receptor (ER), the progesterone
receptor (PgR) and the amplification/overexpression of the protoncogene Her2-neu.
Moreover, the presence of germline BRCA1 mutations, which predispose women to
a lifetime risk of developing BC of up to 80%, make the picture even more complex
since such mutations identify a further clinical and molecular entity. BRCA1-
rmutant BC are characterized by early onset, extremely aggressive biologic behavio
and, probably, a different spectrum of sensitivity to chemotherapeutic agents, com-
pared with all other subtypes. Taking into account this heterogeneity, the prevailing
concept is that a different cell of origin is the seed of distinct subtypes. In the mam-
mary gland, tissue stem cells able to undergo multilineage differentiation give rise
to all three lineages (ductal epithelial cells, alveolar epithelial cells and myoepithe-
lial cells) via lineage-restricted intermediates. This normal epithelial hierarchy
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might explain, although in a merely correlative manner, the molecular and clinical
heterogeneity of BC. Breast CSCs (BCSCs) have been characterized by the expres-
sion of cell-surface markers CD44+/CD24low/lin–, comprising 1% to 10% of the total
population [22]. Consistent with the hallmarks of CSCs, this subpopulation recapit-
ulated the phenotypic heterogeneity of the parental tumor when injected into
NOD/SCID mice. BCSCs can be also isolated by the expression of ALDH1.
Considering a partial overlap between the CD44+/CD24low/lin– and the ALDH1-pos-
itive population, it has been found that as few as 20 cells CD44+/CD24low/lin–
/ALDH1-positive are able to form a tumor [23]. If uncertainty exists about tumor-
enhancing properties of other CSCs markers, CD44 is known to be involved in cell-
fmatrix adhesion by binding hyaluronic acid, whilst CD24 is a negative regulator o
CXCR4. With regard to ALDH1, it is interesting to note that this enzyme is able to
metabolize chemotherapeutic agents, such as cyclophosphamide. Given the general
principles of CSCs, it is reasonable to assume that the elucidation of stemness-asso-
ciated pathways underlying breast carcinogenesis is the keystone to killing them.
The Her2-neu, for example, is overexpressed in approximately 20-25% of human
BC. If, on the one hand, Her-2 positive BC is associated with an aggressive clinical
course, the development of Her-2 inhibitors such as trastuzumab and lapatinib have
significantly improved clinical outcome. Since a direct relationship between Her-2
and ALDH1 has been documented, it is likely that Her2 plays a role in breast car-
tcinogenesis and, at the same time, that anti-Her-2 therapy may be effective agains
BCSCs. In line with this, neoadjuvant anti-Her-2 therapy results in reduction of the
BCSCs pool and an increase in the pathologic complete response rate [24].
Conversely, neoadjuvant chemotherapy-only regimens, which often achieve dramat-
ic tumor debulking, result in an increased proportion of CD44+/CD24low/lin– cells,
as analogously reported for other tumors. Bearing in mind that BCSCs share the
general properties conferring chemoresistance treated in Section 10.5, it is worth
noting that the multi-drug resistant protein ABCG2, also known as breast cancer-
resistant protein, was initially described in BC. Beside the Her-2, other pathways
involved in mammary organogenesis, such as Notch and Hedgehog, are thought to
e the major determinants of BCSCs behavior and specific inhibitors (i.e. gammb a
secretase inhibitors blocking Notch signaling) are currently undergoing clinical tri-
als. Beyond a therapeutic approach, the evaluation of the BCSCs pool could provide
prognostic information. For example, the increased expression of ALDH1 seems to
didentify a subset of patients with inflammatory breast carcinoma with an increase
risk of recurrence. The prognostic value of the 186-gene signatures is discussed in
Section 10.2.
10.10 
CSCs and Ovarian Cancer
Ovarian cancer (OC) is the most lethal malignancy of the female reproductive sys-
tem. The high mortality rate of OC is due to the inability to detect the disease at
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early stages, the high rate of disease recurrence and the development of a chemore-
fractory form. More than 90% of OC arise from the surface epithelium in conse-
quence of ovulation-associated wound repair which, in turn, leads to abnormal
expansion of the stem cell compartment. Epithelial ovarian cancers (EOC) is the
most common type and includes various histologic subtypes mainly resembling the
epithelial component of the lower genital tract. Each of these histotypes is charac-
rterized by a different genetic background. Thus, the existence of ovarian cance
stem cells (OCSCs) capable of unlimited self-renewal and multilineage differentia-
tion may account for the histologic heterogeneity of OC. The first evidence connect-
ing OCSCs to the aggressiveness of OC arose from the isolation of a single tumori-
genic clone among a variegate population harvested from a patient suffering from
ascitic effusion [25]. This clone was able to grow in an anchorage-independent man-
ner (tumorspheres) and to establish, in animal model, a tumor having the histopatho-
logic architecture of the human disease. Furthermore, the isolation of putative
mouse ovarian CSC capitalized on the observation that stem cells defend themselves
through MDR pumps, able to extrude harmful chemicals. As a result, the HOECHST
33342 efflux assay made possible the isolation of a SP representative of putative
OC-initiating cells [26]. More recently, human OCSCs have been isolated by the
expression of the cell-surface marker CD133 [27]. This CD133+ population pos-
sessed the operational criteria to define CSCs.
10.11 
CSCs and Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide in both men
and women. Approximately two thirds of patients present with advanced-stage dis-
ease, and a considerable percentage of patients with resected early-stage disease
will experience distant recurrence. Non-small cell lung cancer (NSCLC) accounts
for approximately 85% of all cases of lung cancer, while the even more aggressive
small cell lung cancer (SCLC) makes up the remaining 15-20%. Regarding NSCLC,
over the past two decades an epidemiologic shift has been observed and, to date,
lung adenocarcinoma (LAC) has replaced squamous cell carcinoma (SCC) as the
most common subtype of NSCLC. It is worth noting that while SCC is exclusively
related to tobacco smoking, LAC and its variants (such as bronchiole-alveolar car-
cinoma) represent the most common histologic type in never and former smokers.
Given the different etiology of LAC and SCC, as well as their differential molecu-
lar portrait and a partially different spectrum of sensitivity to some antineoplastic
agents, the dual face of NSCLC has become evident. Thus, to date, LAC and SCC
are considered two different clinical entities. As for other solid tumors, one of the
most promising approaches to improving long-term outcome of patients is to define
the source which maintains and propagates the tumor. According to the CSCs theo-
ry, in fact, such cells might exhibit vulnerability to targeted agents blocking stem-
ness-associated pathways. The conceptual framework for targeting lung cancer stem
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cells (LCSCs) is an exhaustive knowledge of the hierarchical organization of the
normal airway system. Although in this context normal stem cells have not been
identified yet, the topographic and functional organization of the respiratory tree
support the existence of regional precursors such as bronchoalveolar progenitor
cells, basal/mucous secretory bronchiolar progenitor cells and neuroendocrine pro-
genitors, which maintain tissue homeostasis. Consistent with the CSCs model,
tumorigenic hits occurring either in unidentified stem cells or in a more restricted
precursor cells trigger the region-specific neoplastic transformation, thus providing
a plausible explanation for the clinical heterogeneity of lung cancer. However, due
to the lack of a representative repertoire of markers for the normal stem cell com-
partments, the identification of lung cancer tumor-initiating cells is far from being
widely reproducible. Initially, a side-population identified by the Hoechst 33342
efflux displayed more tumorigenic proclivity in vivo and higher resistance to
chemotherapy compared with the non-SP cells [28]. In spite of this, further attempts
to identify phenotypic markers for this population have been disappointing. Only
recently a rare CD133+ population isolated from both NSCLC and SCLC has been
found to generate long-term tumorspheres in vitro and capacity to recapitulate
tumor heterogeneity in vivo [29]. Probably, however, additional markers are needed
for dissecting lung cancer heterogeneity. If phenotypic characterization of LCSCs is
still challenging, understanding the functional forces driving them is even more
complex. Since preclinical evidence suggests that both Notch and Hedgehog path-
ways play a role in determining the fate of LCSCs, the  most promising mechanism
of disease-based therapy is oriented to disarm CSCs by pharmacologically blocking
CSC pathways.
10.12 
CSCs and Pancreatic Adenocarcinoma
rPancreatic cancer is a highly lethal disease with an annual death rate almost simila
dto the annual incidence. The late diagnosis and chemo-radioresistance, combine
with the intrinsic aggressiveness of the tumor all contribute to the dismal prognosis
of pancreatic cancer patients. The median survival for patients undergone patholog-
nically margin-negative resection is approximately 2 years with a 5-year survival i
the range of 15%-20%. In the metastatic setting standard of care gemcitabine
robtains a very modest benefit. Although debated, pancreatic acinar or centroacina
cells are the most suspected as the origin of pancreatic adenocarcinoma. Pancreatic
CSCs (PCSCs) are def ined by the expression of the cell surface markers
CD44+CD24+/epithelial-specific antigen+(ESA+), accounting for approximately
r0.2-0.8% of all pancreatic cancer cells [30]. According to the general criteria fo
defining CSCs, these cells are highly tumorigenic and possess the ability to both
fself-renew and produce differentiated progeny, thus mirroring the heterogeneity o
the primary tumor. However, in human pancreatic ductal adenocarcinoma samples
also a subpopulation of CD133+ expressing cells seems to embrace all the proper-
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ties that define CSCs, with only modest overlap with the CD44+CD24+ESA+ phe-
notype. Among the CD133+ population, cells at the invading front coexpress
CD133+ and CXCR4. Notably, whilst both CD133+CXCR4+ and CD133+CXCR4-
cells are tumorigenic, only the CD133+CXCR4+ fraction displays metastatic pro-
clivity. Taken together, these observations raise the question on whether different
PCSCs populations, endowed with differential biologic aggressiveness, coexist
within pancreatic adenocarcinoma. As expected, PCSC are resistant to conventional
chemotherapeutic agents. Their treatment in vitro with therapeutic doses of gemc-
itabine results in morphologic and biochemical changes attributable to the activation
of the EMT program, as well as in an increased expression of PCSCs markers [31].
Moreover, an enrichment of the CSCs pool following  chemotherapy or exposure to
fionizing radiation has been documented. Similar to other CSCs, the activation o
developmental signaling pathways involved in the control of the self-renewal pro-
fgram are the major determinants of PCSCs fate. In line with this, the activation o
the hedgehog pathway has been correlated with the development of cancer precur-
rsor lesions, while SMO inhibition by cyclopamine results in the arrest of cance
rgrowth [32]. In conclusion, evidence is growing to support an important role fo
CSCs in pancreatic adenocarcinoma and novel targeted therapies blocking CSCs
pathways are needed to really improve patient outcomes.
10.13 
CSCs and Prostate Cancer
Prostate cancer (PC) is the most commonly diagnosed male cancer in Western coun-
tries. The increase in incidence is largely due to the combination of an aging male
population and the use of screening tests based on the measurement of serum levels
for prostate-specific antigen. PC can be efficiently treated by surgery if localized,
but once metastasized it becomes fatal. Although PC initially responds to androgen
deprivation therapy, the development of a castration-resistant disease is almost
inevitable and the time to death is approximately 18 months, despite the improve-
ment achieved with taxotere-containing regimens. The conventional model of PC
implies that androgen receptor-(AR) expressing cells gain ability to spread and then
re-grow in a distant site. This theory arose from the observation that the bulk popu-
lation of tumor cells co-expresses AR and luminal cell-specific markers. In recent
years, however, both the elucidation of the functional architecture of the normal
rostate and the discover  of prostate tumor-initiatin  cells have radicall  chanp y g y ged
this view. The prostate epithelium is a two-layered structure consisting of terminal-
ly differentiated luminal cells (the exocrine compartment) which rest upon an undif-
ferentiated layer of basal cells. While luminal cells, representing the major cell type,
express AR and are dependent on androgen stimulation for their survival, the basal
compartment does not express AR and is independent of androgens. In their midst,
a transit-amplifying population probably mirrors a continuum in the differentiation
program. Because the basal stem cell is a long-lived cell, thus having more oppor-
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tunity to acquire transforming mutations, it was not surprising that PC stem cells
(PCSCs) have been identified through the same antigenic profile characterizing
their normal counterpart (CD44+/α2β1hi/CD133+) [33]. These cells are likewise AR–
and express several stemness genes, including OCT3/4, BMI1, β d-CATENIN an
SMO. Such preclinical f indings could provide a ready explanation for the minimal
residual disease following androgen deprivation therapy. Although the hormonal-
resistant disease has been largely associated, in fact, with AR amplification, activat-
ring mutations in the AR gene and/or alteration in the AR corepressor-coactivato
activity [34], the intrinsic insensitivity of PCSCs to the androgen milieu might dras-
tically change the future course of hormonal manipulations. By combining the
notion that PCSCs do not rely on androgens with the observation that CSCs retain
the protective mechanisms of normal stem cells (expression of ABC transporters,
ability to stay protected by their niches, highly efficiency in repairing DNA dam-
ages) the discovery of innovative therapeutic approaches has become a priority to
really improve the continuum of care concept of PC patients.
10.14 
CSCs and Glioblastoma Multiforme
rGlioblastoma multiforme (GBM) is the most common and aggressive primary tumo
of the central nervous system. Despite surgical resection and adjuvant
radiochemotherapy, the median survival is approximately 15 months. Mounting evi-
dence suggests that GBM arises from a rare cellular population which shares func-
tional properties with neural stem cells (NSCs). Microarray analysis, in fact,
revealed considerable similarity in gene-expression profiles between GBM and nor-
mal progenitor cells of the developing forebrain. Although little is known about the
hierarchal organization of the brain, the evidence that NSCs are located in privi-
leged areas, such as the subventricular zone (SVZ), makes plausible that these
regions may represent the major source of GBM-initiating cells. GBM-initiating
cells have been isolated from fresh specimens based on the expression of CD133
[35], a marker initially identified for NSCs. Like their normal counterpart, GBM-
initiating cells possess, in vitro, the general characteristics of  stem cells including
extensive self-renewal and capability of multilineage differentiation. Most impor-
tantly, CD133+ cells are able to initiate a tumor in vivo after orthotopic transplan-
tation in immunocompromised mice. However, a less clear distinction in the tumori-
genic properties of CD133+ and CD133- cells has recently emerged [36]. In fact,
since also cells that are devoid of CD133 can initiate a tumor, the presence of a yet
uncharacterized, tumorigenic CD133- population is not so unlikely. The identifica-
tion of tumorigenic GBM cells provided new insights into the mechanisms of resist-
ance responsible for the failure of a multimodal treatment. CD133+ cells are not
only resistant to radiation therapy but, moreover, their number increase after irradi-
ation [37]. In fact, although CD133+ cells undergo DNA damage, these cells have a
better ability to repair strand breaks via a more efficient activation of DNA-damage
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checkpoints. Similarly, GBM-initiating cells are resistant to standard-of-care temo-
zolomide. In this bleak landscape, however, innovative anticancer therapies are
emerging. In a proof-of-principle experiment, for example, the pharmacologic inhi-
bition of DNA-repair mechanisms, obtained by blocking Chk1 and Chk2 kinases,
frestored the sensitivity of CD133+ cells to ionizing radiation. Also the disruption o
the vascular niche supporting GBM-initiating cells has emerged as a promising
approach, as demonstrated by the growing number of clinical trials with the anti-




CSCs are responsible not only for tumor propagation, but are also the main actors
in determining treatment failure. Thus, to eradicate a tumor, the priority is to exact-
ly identify the target population. As discussed above, different cellular populations
that share the hallmarks of CSCs often coexist in many tumors. In such a scenario,
high-throughput genomic and proteomic technologies could provide powerful tools
to capture a snapshot of key deregulated pathways in CSCs. If, in many cases,
purification of CSCs is still limited by the lack of reliable markers, their detection
and monitoring in vivo is an even more complex challenge. Far from being applica-
ble in clinical practice, the development of new imaging techniques with single-cell
or single compartment resolution, however, has made considerable breakthroughs in
rrecent years. Thus, the measurement of the CSC compartment in cancer patients, fo
example by combining high-resolution imaging and CSC-specific probes, would
allow the detection of early disseminated cancer cells, as well as a more accurate
assessment of the radiologic response. Although resistant to current treatments, new
insights into CSC biology have allowed a first wave of development of innovative
drugs. As a result, different therapeutic strategies are on the horizon and include: (i)
small molecules or monoclonal antibodies inhibiting stemness-associated pathways.
Notably, some of these compounds are currently undergoing early phases of clinical
development; (ii) agents able to restore sensitivity to chemotherapy and radiothera-
py, such as those blocking ABC-transporters and DNA-repair mechanisms; (iii)
pharmacologic strategies depriving CSCs of the necessary microenvironmental sup-
port, such as antiangiogenic agents and vascular disrupting agents, which impair the
CSC-niche crosstalk; and (iv) differentiation-inducing agents. By way of summary,
dthe acquisition of a more complete picture of pathways governing CSCs, combine
with the progressive refinement of imaging techniques and the development of inno-
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Appendix
The Impact on Surgical Practice of Recent Advances in
Biotechnology. Interactions Between Inherited and
Environmental Factors in the Occurrence 
- and Biological Behavior - of Diseases of Surgical Interest
F. Cetta
The recent advances in biotechnology (molecular biology, genome-wide association
studies, proteomics) and in biomedical technology (CT scan, PET, radioimmunogu-
ided procedures, minimally invasive surgery, robot assisted surgery) has dramati-
cally affected the surgeon’s decisions, involving both early diagnosis of diseases,
multidisciplinary approach, multimodal treatment and also surgical technique and
timing of surgical treatment.
Genetics, in addition to provide a precise diagnosis on the basis of the germ-line
and somatic mutation, is also useful: (1) to improve our pathophysiologic knowl-
edge; (2) to help us to select the proper treatment and the timing for treatment. This
is of paramount importance in inherited multitumoral syndromes.
Lesson from Inherited Multitumoral Syndromes
In inherited multitumoral syndromes [1-19], in the presence of an individual with
multiple different neoplasms – or at least bound to develop them in the near future
– it is crucial to provide a list of the possible neoplasms which are typical of the
syndrome and then potentially occurring during the subject’s life, along with a
scheduled list of treatments, and to select which is the most adequate treatment for
that particular subject or when is the best time to do which.
In particular, it must be outlined that within the siblings belonging to a kindred
with a given multitumoral syndrome, some neoplasms are obliged, i.e. they are
bound to occur invariably in all siblings affected by the mutated gene, whereas
other neoplasms show variable expression, i.e. they are organic to the syndrome,
F. Cetta ()
Department of Surgery, University of Siena, Siena, Italy and Geriatric Institute Pio Albergo
Trivulzio, Milano, Italy
but their actual occurrence depends on interactions between the common germ-line
mutation affecting the various siblings and epigenetic changes, which are usually
induced by environmental factors [1].
The former group, i.e. obliged tumors, includes colonic polyps and colorectal
cancers in patients with familial adenomatous polyposis (FAP) and germ-line muta-
tion of the APC gene, mapped at chromosome 5 q 21, or medullary thyroid carcino-
ma, occurring invariably before age 5 in subjects with MEN 2A or 2B and germ line
mutation in the RET gene, mapped at chromosome 10q 11. In particular, the precise
site of the mutation in the RET gene (codon 619, 620, etc.) will dictate the biolog-
ical behavior of the tumor.
dAmong the latter, i.e. those occurring only in some of the affected siblings an
with a combination varying from individual to individual, we could include, in
patients with FAP, papillary carcinoma of the thyroid [3-11] or brain tumors [15-18]
such as medulloblastoma, but also desmoids tumors and other extracolonic manifes-
tations, including hepatoblastoma and hepatocellular carcinoma [12-14,] ampullo-
ma or pancreatic and bile tract tumors.
In particular, concerning both thyroid carcinoma and brain tumors, a striking
ffemale prevalence has been observed in FAP associated tumors, i.e. a F:M ratio o
f50:1 in FAP associated papillary thyroid tumors, during the last 20 years, instead o
3:1 as occurs in sporadic tumors, or 18:0 as in the personal series of FAP PTC
reported in Table 1, or a F:M ratio of 4:0, brain tumors (Tab. 2), instead of 1:2 with
male prevalence as usually occurs in sporadic medulloblastomas.
Whereas colonic polyps and cancers occur homogenously in males and females
[1, 19], this striking female prevalence in some extracolonic manifestations strong-
ly suggests that the germ-line APC mutation plays a facilitating or predisposing
role, but other factors, namely environmental factors, and likely factors associated
with female sex, could also play an important role.
FAP associated PTCs and brain tumors are neoplasms which are integral to this
multitumoral syndrome, because they occur only in patients with the specific APC
germ-line mutation (and are more frequently associated with one germ-line muta-
rtion instead of another). However, additional factors are required for them to occu
(environmental, dietary etc.). In addition they can be considered a typical example
of interaction between genetic predisposition and environmental factors. In particu-
lar, since FAP-associated PTCs showed an increased incidence 5-10 years after the
Chernobyl accident, it is possible that nuclear accidents could also determine long-
term consequences, even in subjects living at long distance (thousands of km), in
frail or genetically predisposed subjects [11].
Tumors integral to multitumoral syndromes are also likely to have a better bio-
logical behavior than their sporadic counterpart.
In particular, duodenal and/or pancreatic endocrine neoplasms associated with
MEN1 showed a better survival and a reduced incidence of liver metastases than
dsimilar sporadic tumors, whereas breast cancers in subjects with BRAC1 an
BRAC2 germ-line mutations were more frequently of the medullary histotypes,
which is associated with a better prognosis. It has been suggested that patients with
inherited germ-line mutations, facilitating the occurrence of multiple primary
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Table 1 A personal series of cases comprising patients with FAP-associated papillary thyroid carci-
noma (PTC)
Patient Sex Age Codon Exon CHRPE LOH APC Ret/PTC BT
number number number gene activation
1 F 30 140 3 - np np -
2 F 19 593 14 + np np -
3 F 22 778 15 + - + +
4 F 31 937 15 + - + -
5 F 18 976 15 + np np -
6 F 27 993 15 + np np -
7 F 39 1105 15 + np np -
8 F 34 1105 15 + np np -
9 F 25 1068 15 + - + -
10 F 26 1061 15 + - + -
11b F 22 1061 15 + - + -
12b F 20 1061 15 + - + -
13b F 36 1061 15 + - - +
14 F 24 1061 15 + - - -
15 F 20 1309 15 + - + -
16 F 27 1309 15 na np np -
17 F 22 na 15 na np np -
18 F 20 na na na np np -
APC, adenomatous polyposis coli; BT, brain tumor; CHRP, congenital hypertrophy of retinal pig-
ment epithelium; FAP, familial adenomatous polyposis; LOH, loss of heterozygosity; np, not per-
formed; na, not available
aIn two patients, also with brain tumors
bHepatoblastoma and hepatocellular carcinoma in a member of this kindred
Table 2 Brain tumors associated with PTC in the same patients or FAP kindred
Study Sex Agea APC Brain tumor histotype Patient PTC CHRPE
mutation age
Crail (1994) M 24 1061 Medulloblastoma 24 +b nr
Lynch (2001) F 29 1061 Medulloblastoma 30 +c nr
Fenton (2001) F 29 1061 Medulloblastoma 6 +b +
Plawski (2004)nr 35 608 Cerebral flax tumor na +c nr
nr 10 608 Brain fibromatosis 10 +c nr
Gadish (2006) F 21 1061 Pinealoblastoma 18 +c nr
Present series F 22 778 Craniopharyngioma 16 +b +
F 36 1061 Medulloblastoma 32 +c +
F 20 1061 - - +c +
F 22 1061 - - +c +
APC, adenomatous polyposis coli; CHRP, congenital hypertrophy of retinal pigment epithelium;
FAP, familial adenomatous polyposis; na, not available; nr, not reported; PTC, papillary thyroid
carcinoma
aAge (years) of first diagnosis of colonic polyps
bIn the same patient   
cIn another member of the same kindred
tumors in different organs or districts stimulate a stronger immunological response
(lymphocytic tumoral infiltration) which could be responsible for this more favor-
able biological behavior.
At any rate, it is noteworthy that even within the same kindred with the same
germ-line mutation or within the same individual with an inherited multitumoral
fsyndrome, environmental factors are of importance, both due to the occurrence o
supplementary tumors, in addition to those obliged, i.e. occurring in all the subjects
affected by the syndrome, and their aggressiveness.
Surgeons should become familiar with genetics and molecular biology of multi-
tumoral syndromes, either for proper screening and early diagnosis of the various
neoplasms occurring in each individual, or his/her siblings, or for the proper treat-
ment and timing of treatment, which usually depend on the type of mutation and the
biological behavior of these peculiar tumors.
Lesson from Inherited Multitumoral Syndromes Including Early Aging
It is likely that surgeons in the future will with increasing frequency be faced with
individuals showing multiple primary solid tumors in diverse and not related organs
and districts, even in the absence of inherited multitumoral syndromes. This is a
consequence of the increased life expectancy and prolonged survival after diagnosis
and treatment of the first malignancy [1, 11, 20-29].
Immunology and genetics suggest that the occurrence and progression of clini-
fcally evident malignancies is strictly related to aging and changes in mechanisms o
the immune defense. In particular, some inherited syndromes, such as Werner’s
Syndrome and Rothmund-Thomson Syndrome, Bloom Syndrome and similar syn-
dromes are characterized by early aging and greater predisposition to the occurrence
of malignancies at an earlier age, in comparison with the rest of the population.
fInterestingly, it has been suggested that in subjects with germ-line mutations o
the genes responsible for these syndromes, environmental factors (air pollution,
dietary factors) could determine a greater damage, with more severe complications
in these frail predisposed individuals [1, 2, 11, 20-28].
In addition, it is well known that tumors occur or progress more rapidly or have
da more severe behavior in immunodeficient or frail subjects. Their occurrence an
development points to the break of the balance among noxious agents and host
defenses. Subjects become predisposed, and it is more frequent and probable that a
new tumor occurs in an individual who has previously been affected by other malig-
nancies (Tab. 3).
Both multitumoral syndromes and multiple tumors in the absence of an evident
finherited syndrome must be taken into account and could help proper detection o
fthe new tumor. This is of basic importance, because early diagnosis is still one o















































































































































































































































































































































































































































































































































































































































































Lesson from Hepatobiliary and Pancreatic Malignancies
rFocusing on some hepatobiliary pancreatic tumors, it is well known that the 5-yea
dsurvival after radical treatment of ductal carcinoma of the pancreas is only 10% an
that in some patients with ductal adenocarcinoma disease free survival could also be
greater than 10 years, i.e. the tumor can be considered clinically cured, as in some
of our personal cases with pancreatic ductal carcinoma (or hilar cholangiocarcino-
ma) (See Tab. 3). In contrast, the remaining 90% of pancreatic cancers have a homo-
rgeneously dismal prognosis, with an average survival of 10-15 months, howeve
daggressive and potentially radical the treatment. Extended lymphadenectomy an
parenchymal resection have been invoked, but overall prognosis has little changed,
despite the improvement of clinical skills and technology.
It is likely that among the apparently homogeneous group of subjects with duc-
tal adenocarcinoma there is a great majority of subjects who will have a dismal
prognosis, whatever treatment we provide. In contrast, there is a smaller minority
that we are not yet able to identify in advance – because the tumor appear histolog-
ically similar – who will have long survival after radical treatment (Tab. 3).
The recently extended use of neoadjuvant chemotherapy in the multimodal treat-
fment of pancreatic cancer facilitates the exclusion from radical surgical treatment o
subjects with no response to preoperative chemotherapy. Even if we do not yet know
why these patients do not respond, this preselection actually goes in the right direc-
tion of restricting aggressive and demanding surgical treatment only to those sub-
jects with a more favorable biological behavior of the malignancy.
However, we have honestly to admit our current ignorance concerning a crucial
issue, i.e. the timely detection of which is which, in order to reserve radical treat-
ment and even extended and aggressive procedures to those subjects with more
favorable tumors, and to select for palliative or low-risk treatments those with
invariably dismal prognosis.
Lesson from Liver Regeneration
A better knowledge of pathophysiologic changes after liver resection has dramati-
cally improved our approach to major liver surgery, in particular in patients with
hilar cholangiocarcinoma. These subjects, usually severely jaundiced and septic
because of previous endoscopic retrograde cholangiopancreatography (ERCP) [11,
r23-26], are extremely frail and with reduced potential for liver regeneration afte
major liver resection, including more than 60% of liver parenchyma (trisegmentec-
tomy, left or right, always including caudate lobe resection i.e. removal of segments
I-VI- or IV-VIII plus I).
dTherefore, in addition to procedures aimed at improving biliary stasis an
cholangitis [25, 26], preoperative chemoembolization is usually performed of the
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dliver segments which are planned to be removed. This determines hypertrophy an
improved function or residual segments, which could facilitate patient survival dur-
ing the immediate postoperative period. In fact, after portal chemoembolization,
liver volume of residual lobes increases of about 30%, usually within 4-5 weeks
[27].
Pathophysiologic and oncological data show that:
- the strongest and most adequate stimulus facilitating liver regeneration and pro-
duction of cytokines and growth factors is parenchymal trauma to the liver, in
particular liver resection;
- liver regeneration, which usually occurs within 30-45 days after resection,
involves all residual liver, with a normal regenerative response from normal
parenchyma, but with tremendous hyperproliferative reaction from residual neo-
plastic tissue.
Therefore, removal of a single neoplastic nodule or multiple liver metastases,
leaving in situ residual neoplastic nodules, must be considered with great caution in
the absence of a planned multimodal treatment (e.g. removal of a small liver nodule
to perform a correct diagnosis, when the primary tumor is still undetected).
In fact, in the presence of multiple liver nodules, these peculiar pathophysiolog-
ic consequences must be adequately taken into account, before planning liver resec-
tion, even using minimally invasive surgical procedures, if the possible side-effects
of the procedure might include the explosive growth of residual tumors.
rThis is a typical example of how recent advances in biotechnology (molecula
biology, genetics, a better knowledge of the role of growth factors in liver regener-
ation) should cope with advances in biomedical technologies (laparoscopic surgery
or use of new therapeutic and diagnostic devices) in order to avoid severe side-
effects and complications of the incorrect application of new technologies and pro-
vide the best therapeutic options for each individual.
Recent advancements in genetics and nanotechnology, in addition to being pos-
sible tools for therapeutic purposes, are also useful for a better knowledge of patho-
logic mechanisms and biological behavior of malignant (and non malignant) dis-
eases.
In particular, in the near future it will be easier to distinguish between subjects
with more favorable biological behavior and therefore susceptible to more aggres-
sive and demanding surgical treatment and those who, regardless of an apparent rad-
ical surgical treatment, will have a dismal prognosis (e.g. 80-90% of subjects with
ductal pancreatic carcinoma) [27].
Better therapeutic results are expected using an integrated multidisciplinary
rapproach, combining both recent advances in biomedical technologies and a bette
knowledge of basic disciplines, including pathogenetic mechanisms and pathophys-
iologic linkages.
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Lesson from Genetics and Genetic Engineering or Advances in Biotechnology:
Surgical Implications
New drugs with molecular target (monoclonal antibodies against EGFR, VEGFR,
anti c-kit drugs) are considered with increased interest and have shown to provide
significant improvement in the treatment of patients with malignancies. However,
even though we are still waiting for the silver bullet, i.e. a drug or device which is
able to invert a pathologic pathway, and destroy or tackle selectively malignant cells
with a low to nil impact on normal cells, it is self-evident that in the present context
there is no chance for a single gene therapy, i.e. the possibility that the re-introduc-
dtion of a wild-type gene in a subject with a mutated gene can switch the damage
pattern on again and enable complete tumor regression. In fact, before a clinically
evident tumor occurs, not a single genetic mutation, but a long train of different
genetic and biological alterations must develop, usually occurring during a long
time lapse. It is therefore not realistic that a single drug or the reintroduction of a
normal gene, instead of a previously altered one, or a new product of genetic engi-
neering will be able to invert a long-term altered and chronically impaired mecha-
nism responsible for a clinically evident malignancy.
In contrast, on the one hand while it is likely that new drugs, devices or treat-
dments will be able to co-operate or be used together for a better multitumoral an
multidisciplinary treatment of a single patient with single or multiple tumors, on the
other improved biotechnology and the development of new devices and instruments
for new technological advancements will also improve our present knowledge o
basic pathophysiologic pathways and mechanisms which are responsible for the
occurrence of malignancies and/or determine their severity or biological behavior.
In fact, thanks to further development in new technologies such as genome-wide
arrays, proteomics and metabolomics, it is likely that in the near future we will be
able to detect which is which, among various tumors affecting the same organ or dis-
trict, and showing apparently the same histotype, but having a dramatically differ-
ent prognosis. In other words, it may become possible to detect in advance which
tumors have the best biological behavior, i.e. are less aggressive, more responsive to
dtreatment, and therefore are going to have a better prognosis and yield an increase
survival. This knowledge will dramatically affect the surgical approach, indications
for surgery, technical procedures and the extension of planned resection, including
the selection of a mini-invasive approach or, in contrast, justify an aggressive
approach and extended resection, including major vessel resection and reconstruc-
tion, because of a known favorable biology and biological behavior of the tumor. Or,
fin case of unfavorable biological behavior, exclude surgical treatment in favor o
palliative treatments.
Biotechnology in Surgery176
Lesson from Pollution Related Diseases
Air pollution consists of tiny ambient particles measuring < 10–15 micron (PM10)
rand arising from dust, smoke, or aerosol liquids produced by vehicles, factories, o
burning wood. In vitro studies have shown that exposure to diesel soot and other
PM10 particles activates pro-inflammatory genes in a process mediated by free rad-
ical/oxidative stress mechanisms. These, in turn, induce pro-inflammatory tran-
scription factors, such as nuclear factors-B (NFRB) and activator protein 1 (AP-1),
which promote increased histone acetyl transferase activity, histone acetylation,
release of interleukin 6 (IL-6) and interleukin-8 (IL-8), markers of inflammation,
and, f inally, expression of inflammatory genes [28-37].
The adverse health effects of air pollution are difficult to dissect since the
atmosphere contains about 18,000 different substances, each of which is present at
dvery low concentrations. Despite the well-known in vitro toxicity, mutagenicity, an
carcinogenicity of many pollutants documented by experiments in animal models, it
must be stressed that in most of these in vitro studies, the exposure level to each pol-
rlutant, e.g. polycyclic aromatic hydrocarbons (PAHs) and TCDD (dioxin), is highe
than that occurring under actual conditions, in which PAHs are present at 10 parts
per million (ppm), ozone at ppb (parts per billion), and TCDD at ppt (parts per tril-
lion). Therefore the health damage caused by a single pollutant, even after long-term
exposure, is likely to be very low.
In particular, airborne pollutants are currently considered weak pollutants. These
are responsible for health effects which occur as a no-threshold phenomenon, name-
ly that is no threshold above which all humans are affected and no threshold below
which no effect is observable [31-33]. In other words, even very low concentrations
of airborne pollutants (PM) can be responsible for health effects in particularly sus-
ceptible individuals [31-33].
Although this behavior has been confirmed both by epidemiological and exper-
imental data, a linear dose-effect relation is still considered the main medianistinal
linkage between concentration of pollutants and health effects. In other words, the
greater the concentration of pollutant, the greater the number of hospital admis-
sions.
In January 2008, a municipal fee (ECOPASS) was introduced in Milan to reduce
the entrance of pollutant vehicles within the city. As a result, there has been an evi-
dent reduction in the vehicular traffic by up to 30-35% of private vehicles.
A scientific project called Prolife, involving all major local Universities, was
started in January 2007, i.e. 1 year before the introduction of Ecopass. The project
aimed at analyzing at 360° all the possible implications of health effects of air pol-
lution, with particular reference to host-particle interactions in humans. The first
step involved reproducing the same cross-sectional and longitudinal studies in
Milan that have been performed in the United States and other countries. 
In particular, during 2007-2009 we performed a comparison between the con-
centration of various pollutants and hospital admissions (53,514 hospital admissions
because of cardiovascular and respiratory symptoms), and also longitudinal studies
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in small cohorts of children attending primary schools (close to or far from main
crossroads) and of old patients living in nursing homes, also comparing those living
in hospices close to or far from main crossroads.
In particular, we performed 2 two-week campaigns per year, with mobile moni-
tors placed either indoors and outdoors at the schools and nursing homes (corridors
and gardens, respectively) and compared these direct f ield measurements with clin-
ical f indings, in particular in children, who all had a unique referral hospital. This
made it possible to analyze any pollution related hospital admission and complica-
tions in children enrolled for longitudinal studies [33].
Lastly, the filters obtained during these first-hand seasonal campaigns, during
which we measured both qualitative and quantitative parameters and for which we
had the comparison with clinical f indings, were used for in vitro studies.
Obviously, at the beginning, we reproduced previous in vitro studies using pul-
monary alveolar cell lines (A549) or bronchial epithelial cell lines (BEAS-2B).
However, after these preliminary studies, we also tried to make the same in vitro
studies, with the same types of particles and the same variable concentrations,
focusing on 2 distant districts, which on the basis of clinical and epidemiological
findings could be affected by air pollution, namely sperm cells and synoviocytes
[33-35].
In fact, it has been frequently reported that fertility is decreasing in males living
in metropolitan areas, whereas rheumatoid arthritis is increasing, at least in females
exposed to increased pollutant concentration, namely to traffic related pollutants.
The main reason for our choice was that both rheumatoid arthritis and male
infertility – in particular in patients with varicocele – are two diseases in the occur-
rence of which autoinflammation plays a crucial role. In particular, the damage to
sperm cells can be measured by semiquantitative methods, including both morpho-
logic and functional parameters. This feature enabled us to make a quantitative com-
parison of the functional effects, not only varying the type and concentration of pol-
lutants, but also varying the type of the host. In fact, we performed 3 different stud-
ies, using as host the rabbit, the normal human, and men affected by varicocele [33-
35]. Data obtained suggested that, at least for some diseases, the variation of the
host could be more important in terms of functional loss than the variation of the
concentration or of the type of pollutants.
Lesson from In Vitro Studies of Airborne Pollutants on
Synoviocytes and Sperm Cells
Oxidative stress is a working hypothesis that has been suggested as a common
mechanistic linkage between particulate material and adverse health effects. But it
is not unique. In particular, in a recent in vitro study in which different types of par-
ticles were used (PM < 2.5 or ≤ 10 μm/m3 in aerodynamic diameter, tire debris), the
same concentration of different particles with the same exposure time elicited dif-
ferent effects on sperm cell function (motility, viability, rate of apoptosis).
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However, variability of the observed effects was less than that elicited by chang-
ing the host, with lower adverse effects in New Zealand rabbit sperm [34], more evi-
dent effects in human sperm, and very severe effects in humans with previous
dimpaired sperm function (e.g. varicocele) [28]. In particular, sperm function coul
be reduced by up to 80% of the initial values in sperm cells from some humans with
varicocele (unpublished data). Sperm cell function is easy to quantify and compare
not only among different pollutants but also among different host species or sub-
groups [33, 34]. These findings are also in accordance with recent epidemiologic
data showing more pronounced respiratory and cardiovascular effects in patients
with previous respiratory and cardiovascular impairment or specific susceptibility,
respectively [38].
Daily levels of PM10, PM2.5 and PM1 fwere sampled and various concentration o
PM (10μg/cm2, 50μg/cm2, 70μg/cm2) were incubated at 37°C for 24, 48, 72 hours
with synoviocytes from 5 patients with rheumatoid arthritis (RA) and 5 patients
with osteoarthrosis (OA).
Synoviocyte-like fibroblasts (SLF) are cells of mesodermal origin that line the
synovial cavity and are considered of importance in the pathogenesis of RA.
In particular: (1) PM was engulfed within synoviocytes; (2) after entering the
fcell, it determined an increased cytokine production (up to 9-fold the basal level o
IL6) p( <0.001); (3) this increased inflammatory reaction was more pronounced in
synoviocytes from subjects with RA than in those from subjects with OA; (4) this 9-
fold increase in IL-6 produced by cells which are distant from the portal of entrance
of PM – and this is crucial for the occurrence of RA in humans – was greater than
similar increases in cytokines, which had previously been observed by our group
incubating PM, with cells from front-line districts (alveolar macrophages, A549
alveolar epithelial cell line; bronchial epithelial cell-line BEAS-1B [36].
These data show that SLF are able to determine an autonomous inflammatory
response, which greatly also depends on the intrinsic properties and genetic
imprinting of synoviocytes. Namely, those deriving from subjects with RA seem to
be more inflammogenic than SLF from the control group (subjects with OA), thus
dsuggesting that individual susceptibility, i.e. inherited predisposition associate
with previous patient history and acquired susceptibility, plays a role greater than
intrinsic toxicity of PM in the occurrence of RA [36].
Lesson from Asbestos Exposure and Mesothelioma in Humans
Data in accordance with these observations were also found in couples with the hus-
band, who was occupationally exposed to asbestos for more than 30 years and who
dhad not developed either asbestosis or mesothelioma, and the wife, who was expose
to asbestos only through her husband’s clothes, who developed pleural mesothelioma.
This lesson from asbestos exposure, together with recent results in patients with
fmesothelioma from Cappadocia [39, 40], suggests that individual susceptibility is o
major important in the occurrence of asbestos related diseases [31-33].
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In particular, a genome-wide analysis performed in a small subset of these couples
(husband occupationally exposed, but unaffected, and wife unexposed but affected)
showed a panel of differently expressed genes which were partly different from cou-
ple to couple, and partly common. Interestingly, common genes with diverse copy
numbers included major histocompatibility genes, genes involved in the metabolism
of xenobiotics and genes involved in the inflammatory response (Tab. 4).
Therefore, a great bulk of clinical and laboratory data suggests that the occur-
frence of clinically evident diseases is not simply related to the intrinsic toxicity o
fvarious pollutants. In fact, if intrinsic toxicity of pollutants were the main cause o
health effects, diseases should be similar and homogeneously distributed in the var-
hious hosts. On the contrary, it seems that host-particle interactions generate healt
end-points, which greatly depend not only on individual susceptibility, but also on
the type of the response and on the severity of the reaction, which are strictly relat-
ed to previous patient history or immune habitus (RA vs OA) and also to tissue
specificity [33-36].
dIn particular, we hypothesize that PM-related diseases are not simply determine
y an flammatory mec an sm ue to ntr ns c tox ty o  pollutants an  mediateb in h i d i i i ici f d d
by oxidative stress as unique common mechanism, but more complex responses are
generated, namely those typical of autoinflammatory and/or autoimmune diseases,
which are more pronounced or clinically evident in predisposed subjects. And the
degree of magnitude of the final clinical outcome can depend – at least for some
diseases such as RA – more on host susceptibility and reactivity (host immune
nresponse) than on intrinsic toxicity or concentration of PM [33-36]. This will ope
new avenues for a basic role of autoimmunity in most PM related diseases. In par-
rticular, if PM actually reaches the synovial cavity, if autoinflammation is crucial fo
RA occurrence, and RA is part of the pollution related syndrome, then even low
local concentration of PM could be sufficient to trigger pathologic events in predis-
posed individuals.
On the basis of the overall amount of available data we estimate that about 15-
20% of the general population can be affected by a whatever disease linked with air
pollution, even if susceptibility for each disease may be as low as 1%, whereas some
individuals may be susceptible to multiple diseases in different organs or districts.
Clinical experience shows that a greater proportion of susceptible children have
non-susceptible parents. Therefore, in addition to inherited susceptibility, acquired
susceptibility linked to environmental factors, including air pollution, plays an
important role in the occurrence of this greater proportion of susceptible individu-
als. It has been proposed that, in particular for the respiratory tract, which reaches
its f inal development after adolescence, exposure to air pollutants during the peri-
natal susceptibility window could be of major importance [36, 37].
There is increased evidence that children whose mothers have been exposed to
increased concentrations of air pollutants during the third trimester of gestation or
who have been exposed personally during the first months of life have a greater inci-
dence of asthma at age 4 [37], i.e. there is a delayed effect, in comparison with the
time of actual exposure. It is presumed that, during this high susceptibility window,














































































































































































































































































































































































































































































































































































































































































this perinatal exposure can be amplified by one or more degrees of magnitude in
comparison with later exposure of the same subject. Experimental studies also seem
to support this view. In addition, since damage from xenobiotics during the perina-
tal period affects epigenetic mechanisms, previously unsusceptible subjects may
become susceptible, and this acquired susceptibility may also be transmitted to
future generations [37].
dThis mechanism, together with other mechanisms on pathogenic linkages, coul
be relevant for a better knowledge of how inherited factors (such as genetic alter-
ations or germ-line mutations) may interact with environmental factors (diet, pollu-
tion, radiation), generating effects which could be restricted to the subject of inter-
est, but which could also determine a permanent change in the genome or
repigenome which is transmissible to offspring and which could be responsible fo
the occurrence of chronic or malignant diseases.
In particular, during the perinatal susceptible window weak pollutants or dietary
toxicants which usually do not elicit severe or permanent alterations because of their
very low concentrations could determine effects similar to those of in vitro studies
that are usually performed with pathologically relevant concentrations, which are
dsome degrees of magnitude greater than real world exposure. These mechanisms an
these interactions should be better known not only by epidemiologists, statisticians
and scientists involved in correlation studies, but also by surgeons, to be used in
their everyday clinical practice.
dIn other words, a large proportion of the most critical effects in humans coul
occur because of exposure to increased pollution during perinatal life. The effects
of this exposure may become evident many years later, as asthma at age 4, or in
adult life as COPD or as tumors or cardiovascular diseases (or rheumatoid arthritis)
in the elderly. Therefore, there will be an asynchronism between the time of expo-
sure and the occurrence of clinically evident effects [36].
It may be possible, although this requires further documentation, that the
greater bulk of future long-term effects (i.e. those related with acquired suscepti-
bility) is actually due to exposure to pollutants during the f irst years of life.
According to this hypothesis, even pollution related lung cancer (there are differ-
ent types of lung cancers differently linked with smoke and/or air pollution) could
be mainly determined during these f irst years, i.e. the exposure during these cru-
cial years could play a greater role for the occurrence of future diseases than future
exposure during later life.
These observations and inferences based on different pathophysiologic mecha-
nisms greatly affect the results of epidemiologic studies comparing pollutant con-
centrations and concomitant hospital admissions. In fact, the latter are going to
completely miss the health effects in newborns, which could be comparatively the
most important [30-36].
Our working hypothesis [32, 33, 35, 36] is the following: usual concentrations
of pollutants in most Western countries is responsible for very few and non-severe
health effects in healthy humans. In contrast, the same pollutant concentrations
could determine significant and severe effects in the elderly, or in children, or in
frail predisposed individuals. Even among children and old people, clinical out-
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comes will be evident only in a minority of the subpopulation. At the moment we
are unable to distinguish which is which. A critical exposure will be possible in the
er nata  per , ur  hi  e e ect o  pollutants could e amplifi , anp i l iod d ing w ch th ff f b ed d
effects could be determined either in previously susceptible or in previously unsus-
ceptible individuals, which will turn into susceptible because of this perinatal expo-
dsure. This is a crucial aspect of our hypothesis, which could explain the increase
incidence of susceptible people during the last decades including those affected by
nonmalignant diseases such as asthma, BPCO, cardiovascular diseases or male
infertility, but also pollution associated malignancies [35, 36] (Figs. 1, 2).
Appendix 183
INTRINSIC TOXICITY OF POLLUTANTS
EMISSION  SOURCES OF EMISSION  SOURCE APPORTIONMENT








structure of each pollutant
surface reactivity
inflammogenicity
Each pollutant has its own peculiar features; they are harmful all together with







 acquired (perinatal susceptibility window)
 previous personal history (systemic diseases, diabetes,
  obesity, infection, chronic inflammation)
 previous loss of function
INDIVIDUAL REACTIVITY
  antioxidant systems
  detoxifying enzymes
 immune defense mechanisms
 
                              cellular
innate                   acquired
                                                                                           humoral
Fig. 1 Host-particle interaction depends on the particle side (concentration, composition, structure,




Since individual susceptibility (or resistance) is crucial for the future occurrence
of clinically evident diseases or symptoms, it is presumed that not a pure toxic
mechanism will be responsible for clinical outcomes, i.e. a causative mechanism
determining severe effects which are homogenously distributed in all individuals on
the basis of the concentration of pollutants (linear dose-effect relation), but a differ-
ent mechanism, involving more host related factors will be responsible for most
final health effects (Fig. 3).
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Fig. 2 Clinically relevant outcomes of host – particle interactions do not depend only on intrinsic
toxicity of pollutants, but also on host- reactivity and repair ability of the host, which includes
gene repair and cell function repair, but also tissue repair and functional recovery. Accordingly,
biomarkers will include: markers of oxidative stress (reversible), intermediate effects (persistent)
and of permanent tissue damage (irreversible). Only the last markers of irreversible effect are
strictly related to final outcomes. The absence of reliable markers of persistent effect of PM is one
possible factor of the lack of correlation between pollutant concentration and diseases responsi-
ble for hospital admission
Host-pollutant interactions
Accumulation of the harmful insult; host-capacity of repairing or healing
Duration of the harmful insult (hours, days, weeks, seasons)*
Pattern of the harmful insult constant and progressive*
intermittent or reversible*
Biomarkers
Reversible effect Intermediate effects Persistent effect
(Oxidative Stress) Persistent, but not irreversible (Tissutal permanent damage)
Effects usually not always evident Clinically evident effects
not clinically evident
DNA adduct formation - tissutal repair mechanisms*
- biological effect - tissue or district functional recovery*
(Antioxidant effects and anti-oxidant systems
[GSTM1, GSMTT, Cys-P450] DNA repair systems
[mismatch repair genes] cellular repair pathways)
Different time lapse for functional recovery
- wound healing (7 days)
- blood red cells recovery after hemorrhage (120 days)
- sperm cells maturation (75 days)
- liver tissue regeneration (30-45 days)
- recovery after bone fracture (45 days)
* For each of these pathways and processes an adequate variable should be included in the model,
in order to obtain a more realistic risk evaluation for each individual.
Suggestions to Policy Makers to Tackle Health Effects from Air Pollution
fIf most pollution-related clinically evident diseases occur because of a major role o
inherited or acquired factors (because of previous personal history or previous
exposure), it may be more logical and more affordable as an objective to allocate
resources into early recognition of susceptible at-risk individuals than to try to abate
further PM concentration. The latter in densely populated metropolitan areas may
appear as a non realistic goal, and also extremely expensive in terms of cost-bene-
fits for human health.
Therefore, if the main goal of antipollution measures is not the simple reduction
of measured air parameters, but a better treatment and/or a proper prevention of pol-
lution related clinically evident diseases in humans, instead of fixing anachronistic
fand often difficult to reach objectives in metropolitan areas, where presence o
humans and related activities (population density) are the most relevant causes of air
pollution, a sound objective to reach could be the early detection of individuals at
greater risk because of increased susceptibility, in order to electively address prop-
er therapeutic and prophylactic measures for this subpopulation of at-risk subjects.
Lesson from Epidemiologic and Genome-wide Association Studies
Recently proper attention has been drawn to the rhetoric of false-positive results
concerning environmental determinants and human health outcomes. In particular,
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A) High concentration of strong pollutants
Concentration of pollutants health effect severity
Linear relationship
on the basis of intrinsic toxicity
B) Low concentration of weak pollutants
Host-related inflammatory response health effect severity
(Autoimmunity)
Regardless of pollutants concentration
(no threshold phenomenon)*
Fig. 3 Current paradigms to explain health effects of air pollution are mainly based on a linear dose
and effect relationship (the greater the concentration of pollutant the greater the effect ). An alter-
native pathogenic mechanism suggests that, at low concentration of weak pollutants, health
effects could be due to host-related autoimmune mechanisms, relatively independent of pollutant
concentration
Boffetta et al. [41, 42] suggested that “users of epidemiological results outside the
rscientific community ... should be aware of the fact that statistically significant o
positive results are often false” and that “epidemiology is particularly prone to the
dgeneration of false-positive results.” In particular, in a review of 39 highly cite
(citation index >1.000) randomized controlled trials that reported an original claim
of an effect [43], only the results of 19 trials were replicated by subsequent studies.
Therefore, caution should be applied in the communication of results to the media
and the general public, because both tend to consider numbers and percentages as
the truth and make their own speculations on data that are often based on inferences
and weak associations [41].
However, the question of non-reproducibility of scientific results cannot be
reduced to a mere controversy among epidemiologists – a controversy that should be
limited strictly to them and treated only by improving statistical methods. It actual-
ly affects the basis of empirical knowledge, in particular when it involves biological
and medical questions. When sensational new discoveries are counter to empirical
observation, caution is mandatory. Biases may be detectable by epidemiologists, but
there are other possible sources of basic errors concerning pathophysiologic mech-
anisms that are peculiar to each disease and that are unknown to statisticians, who
apply the same methods to a wide variety of different conditions [2].
Biological plausibility is not enough. Individual susceptibility plays a role
greater than previously supposed in the occurrence of clinical outcomes in the host
ddue to environmental factors. The importance of susceptibility reflects a decrease
drelative role of pollutant concentration (i.e. intrinsic toxicity of xenobiotics [inhale
dor ingested]), and reduces the applicability of certain models – based on dose an
effect linearity – to no-threshold phenomena [2, 31-34] (Fig. 3).
dProper selection of subgroups, which should be homogeneous not only for age an
sex but also for pathophysiologic relevance, is not only an epidemiologist’s task but
should be directed also by clinicians and pathologists. For example, lung cancer is still
considered by epidemiologists as a single entity, but clinicians are aware that, in addi-
tion to cancer occurring in an anthracotic lung, pulmonary cancers may also occur in
non-anthracotic lungs; this is a different disease less likely to be dependent on air pol-
lution [2]. The knowledge of this fact will greatly affect population selection.
In particular, a senior clinician (surgeon, internist, clinical specialist) having
long-term experience with the disease of concern should always be involved in the
fdesign of the study and in reporting study results. Interdisciplinary control o
research is not only a desirable option, but a necessary measure to mitigate the sen-
sational effect of new discoveries. This is true in particular when, despite statistical
significance of observed differences, f indings are counter to everyday clinical expe-
rience, or they are not clearly adherent to – or a logical consequence of – strict cri-
teria such as Koch’s postulates [1, 2]. Clinicians could also suggest the proper tim-
ding for large and expensive epidemiological trials, which should be performe
exclusively when adequate metrics and reliable pathophysiologic causative mecha-
nisms between determinants and outcomes have been established. Our view is that
clinicians should be involved both in study design and timing, so that interdiscipli-
nary control of the study can be guaranteed from the beginning [2].
Biotechnology in Surgery186
Conclusions
The recent advance in biotechnology has dramatically changed not only the sur-
geon‘s approach to diagnosis and treatment of diseases of interest, but also his role
in multidisciplinary research.
Concerning malignant diseases, the increased life expectancy that has been
achieved with dramatic improvements in the diagnosis and treatment of primary
tumors has been accompanied by the occurrence of second or third solid tumors in
some cancer patients. These multiple tumors are apparently not related to germline
mutations of tumor suppressor genes [1].
Increased exposure to traffic-related air pollution in densely populated metro-
politan areas and to a wide variety of genotoxic xenobiotics introduced either by
diet or by inhalation, together with spontaneous mutations related to aging are like-
ly responsible not only for the observed incidence of chronic inflammatory diseases
but also of malignant tumors. Future research will better elucidate the mutual, high-
ly complex interconnections between inherited and environmental factors in the
occurrence of malignancies. The phenotypic manifestations of the same germline
mutation of a tumor suppressor gene are highly variable, even when patients belong
to the same kindred. This is mainly due to superimposed epigenetic factors, which
could be sex-based or environmentally related [1]. Likewise, health damage from
occupational exposure to known carcinogens such as PAHs or even asbestos greatly
varies among individuals with the same exposure level and/or belonging to the same
dfamily because of individual susceptibility [32-37, 44-46]. This includes inherite
predisposition due to ethnic or individual differences not only in genetic polymor-
phisms for the genes encoding enzymes involved in xenobiotic metabolism, but also
in acquired predisposition r, related to the effects of aging, concomitant chronic o
metabolic disease, such as infections, immunodepression or diabetes, and variable
exposure to environmental agents, beginning from fetal development and/or the first
weeks of life.
rOn the one hand, surgeons should be more prone to learning lessons from othe
disciplines, namely oncology, genetics, molecular biology, biotechnology and bio-
fengineering in order to use these new technologies not only for better knowledge o
the biological behavior of the various diseases, but also for the proper treatment and
a multidisciplinary approach to new complex phenomena (for instance, multitu-
moral syndromes, or multiple primary tumors or metachronous tumors). On the
other hand, surgeons, as well as all clinicians belonging to various subspecialties,
should be involved from the beginning in the design of epidemiologic or correlation
studies, which up to now have been considered the exclusive realm of geneticians,
biologists, molecular biologists, epidemiologists, statisticians, concerning the
degree of association between congenital factors or environmental factors (air pol-
lution, dietary habits) and clinically evident diseases, including a better knowledge
of mechanistic linkages and causative mechanisms. In fact, the latter should not
only be biologically plausible on the basis of in vitro studies and studies in experi-
mental animals, but should also be relevant, from a pathophysiologic point of view,
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rto clinical pictures and diseases observable in the real world. Otherwise, imprope
inferences can be made by epidemiologists or statisticians or biologists, who try to
make uncorrected extrapolations from their data [41-43].
Therefore the surgeons and clinicians of the future, on the one hand should be
more specialized in a smaller subset of their own discipline to guarantee state of the
art treatment to their patients, while on the other they should be open to cooperate
fwith other specialists, and play a primary role from the beginning in the design o
epidemiological studies concerning the health effects or clinical outcomes of inher-
ited germ-line mutations or environmental factors (such as air pollution, dietary
dhabits), or aging or age related alterations, in order to avoid biased results an
improper inferences, which otherwise are very frequent (up to 85%) [41-43] in the
absence of deep involvement of clinicians in multidisciplinary studies.
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